{"docstore/metadata": {"17c56752-6519-446f-9e97-720e092e952c": {"doc_hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28"}, "19e61bd9-9ada-4585-92ba-ea7057a3177d": {"doc_hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17"}, "0888d018-d0e7-4ed5-8c8f-28c076377ab6": {"doc_hash": "2e3dd18bdc597ac0638bd8c5ee5a5c6b60680b8ac419e6b868c641a921fae5a1", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "efb691c9-779f-4807-a721-cc931c505f5b": {"doc_hash": "9b5f784a828f1bb123aaff8b9e8f2748a8a91fb752d3799c4b85efe2468e2783", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "0f4fda4c-ab13-453a-972a-0d14a8d392a5": {"doc_hash": "557fccba342e9004c229b82a72ad3c78c24664cfa78bcc4fb68aa0b463eb9ba0", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "7a5ac78f-37ef-4829-afe5-3883d481d5d1": {"doc_hash": "a5c22f828d0a8976ec5b51abd5e0844fe6ad7e484129268e4ddbb6c85171bd27", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "c9ed2c61-04fb-4557-be06-6234f82afc29": {"doc_hash": "24b9d7752094612a83223c3c80d290ae2daa5dbdc0cb90e683eb8115567682f5", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "3f0f839f-8ab9-4b74-9310-1d05cc786cb2": {"doc_hash": "76b21e37b12be875e04216afa1be15b906ee1d0f8a29a4c8a33482546731ed33", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "e2b050bf-55aa-4c83-93bf-1c7209a1fd02": {"doc_hash": "fca5571e6f22b03f3b0ddd5742b8ff50a64490a01a6e13399e74f15b37d22e91", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "c5fa6f9b-b53d-49bb-8539-279fefd22f0a": {"doc_hash": "eb38eb1f468ffd6f1db03d4efa5e42e57563decfed67be9317a537e20909bd4d", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "b49c2c4c-226a-4e90-bc6e-f1608677c5c9": {"doc_hash": "23c301c4eda2868cfe27ad004472c99023af7bd294d1c878461126fa125889e1", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "c619477d-f580-44b2-b4b0-f00d854e2a41": {"doc_hash": "49aa450578d25f398e13deb9d940eeea705caeb10e7d46a3b10f8668c90d2943", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "5097f51b-0021-4c17-9ed9-614c982ec1f3": {"doc_hash": "426ae157d6e590344a7a55a4ee2bc0a0216fd546017a8264a64cc89c4d1104b2", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "139a813e-f9bd-4ecd-b9f1-237d2c178cb0": {"doc_hash": "00c27f048180ac8313831d76db161bf85a947a03b5bd88d77f205ed6d3284efe", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "2a5492a4-51b8-4c07-9ced-6a3f2914e018": {"doc_hash": "1844faf86ceceb84cb2eaa3ac40e46bed39602c51a40b1dd076ff9f8cb57277e", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "99270021-4efe-42fd-9198-c29546e41971": {"doc_hash": "d095276131e72da04ab1647c41fcbae00376cece26aa6e35b39e5b6ca007b9b5", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb": {"doc_hash": "84599b8f2f9a677597cb11669b12de79b169655b1ea3742abe59077762a3d3db", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "4dc0d2e9-75ac-4e53-bad0-6486d04930fd": {"doc_hash": "f17cf592e85d42d8d537f6c623ad6f741237491d2bc12400e0f3ef56acfaafe7", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "57943517-b07b-44b9-89ed-1744fc90e8c6": {"doc_hash": "364844eb2caec2bd9353476e1a304b1b6c96cac7fb734d6edbb5f9ff4410aba7", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5": {"doc_hash": "d71082fbfb56fe53dfa4685d189da2fd01c54e57f78f982b46a31042bb6e718b", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "56ff8e6b-6789-4f9d-ba01-ac8238c65d95": {"doc_hash": "78cc2e3b6153620833a4d0380d108665038d14093eedc32d74dabc9778e23c22", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "5bd23122-a402-4b2c-ba33-cce5bbec1ed9": {"doc_hash": "4e8a8a1eeef5a01a131f09d8a6ccb971fc6f8ea6c06c226b3e0dbe459e28431a", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "369af8e5-326a-4397-84dc-77719cdbc4cc": {"doc_hash": "8ca23549f6a37eb537ff5b2014f4b78c3007e3c94f6f9dc18de06e9c2bb3478e", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9": {"doc_hash": "25e84ecb724e81c61350d48c7365e48fb6ed6b919069f898ab65f1d01cd6368a", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "24953b70-dd6d-497d-bd0f-e6abe76c2779": {"doc_hash": "f11c55353475ade43d570bf75502f4c461a613ed903ec54df2a4da53ec502026", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "509f0931-9b11-4161-add4-a872838696af": {"doc_hash": "c6272a6c416d9b0bd85519610454bf1fef5762df2035faebd7f2a66339c93bef", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "a02c0572-a450-497b-ba93-50dfbf326a9b": {"doc_hash": "ec9ac138a2a9c34d54d081ec9f9226968c6300d00ed0b17021bc551b03daca4b", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f": {"doc_hash": "beeffe5e1a5c207efa37e686f64d24f83adad7f6734fff4e342b503c7458b7aa", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "9689eb5f-06fd-4abc-b35c-6fe438aef1a0": {"doc_hash": "a19e57054c8f17227d506c267ae7981e2a877fedbd23954ddb418938e92b08ba", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "ac272538-d0bd-4b46-8f44-c6b46de700a3": {"doc_hash": "896eeca0bfce00722c09841262072167fe0f4204865eb3774412492b80e9c257", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "85327feb-7c9c-411c-abaf-59bc82db2369": {"doc_hash": "9637df86278144bab7dad3ae72988fada3de0fa085f695745c26519f9642cbf9", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2": {"doc_hash": "257812803f8ecfe989921d53f8c3108026f76a3d59aaee0ae51846b128e2ce46", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba": {"doc_hash": "cb5666ce488418ff8c48a07ece3cb4ea165b7e29df882af4f4a21ea821818278", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66": {"doc_hash": "4c89c9edba09b0c169318708c05e3eb09691b129981e7b3be677c8543ae187de", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "4b68bc1d-e0a4-4244-9550-766bee3d69b4": {"doc_hash": "1b3490e42a9b169932ce75717cb1b53cc03959de1f65530fd4b90a2bc89a554f", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "01483c06-0398-4f52-8dfe-59afe118a6f8": {"doc_hash": "d15cb4a14241b77875433a37b2803edf1ffdcfa89d3bf34de1ea12028c433343", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "b48f408c-12e3-4277-b226-58db609fe7b5": {"doc_hash": "5e5b92142fce370e05c08668f5c677fa31119b9b297c8d1cca6c176bf9cf5a11", "ref_doc_id": "17c56752-6519-446f-9e97-720e092e952c"}, "590deeb7-0acf-400b-82a5-514377ada131": {"doc_hash": "d4b3d23b6aedf415149697fc181a90f9c106dc2401ee252522354a72c3d766d7", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "71d6854e-62c7-458b-ab13-0a05c8479f25": {"doc_hash": "e4a66be1b202e8d7b01897231d902d5b1c943faa9a39ef01681d4ec73bd2806b", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "d6798a5a-b6b7-4110-bf80-579549521320": {"doc_hash": "3e2e7e865c08d4218ad3507bb2f9f6db47e1eb0f75ded0f1de62c6722226c6cc", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba": {"doc_hash": "0b931fcd654c1e1d44e51609b893395fc8e8ec0c1a2c1708075be8dce1b02f9f", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "5e4431a1-9c10-481e-80c5-4416fe248958": {"doc_hash": "c5c692f76291d853f85861aa8ee508357b14382624479b85e1c5007036e7ab69", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "318c2bc6-844d-4b03-b7ff-9da9a3920d78": {"doc_hash": "423021629d936687af37ef8de9e51c08cdcab73caf351702f870be224a112e06", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff": {"doc_hash": "a6893fb0a304678d68403d5b25b6ed336fb27b0640a3d60ce7d966b39b611268", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1": {"doc_hash": "b54988023dc512e604152774ca8a904e5cbf178fc9a74789dd91d9c39e67fc66", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "7bbbf578-4489-452b-9efe-3361b95034ec": {"doc_hash": "544be8ba373a7e837c479b30adac24de59a0d184f08272b9d54515609948dbdf", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "cfe2b049-c05a-4433-aa7b-5efb24283018": {"doc_hash": "54c33c9a984e2f2dc88127426cecdb7ccbf48c6ef17894c9b07fa8b851c3dd5a", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "7d22d03f-d41d-462e-9739-dcdd6733a071": {"doc_hash": "29244e9f40e128452c23e034c5ebb38ec46b5bc166f610aedf49650b64fde7ee", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91": {"doc_hash": "733a5bd56eb284e272ada6118db9788260209c8244ec72cb9a49e4487a5519eb", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "5237f296-7c75-445c-96a7-b6d718c7eee6": {"doc_hash": "c8893945d6bee6123a85d00b639a6fe1f647a3566c4b2cf08787debecfed8c36", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd": {"doc_hash": "eea1023689722ffba1fae15d83dc555f7dd2992bbb4c0c096830587506f284a9", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad": {"doc_hash": "cbef49d547dfe528ba5482ea0059c218dd20a418b7b3bc2cc272c902a92190a6", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "7b03ed8e-0d46-411f-852f-160572c0feff": {"doc_hash": "3cef5278d015e812fa31d227e3c863cdcd26681585b41f6517b2dd229ec45514", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "e3514730-c98a-4e1b-93e9-e9d37fb768b5": {"doc_hash": "cc38ff71d412f8c3fa8c9f672dc3fd8a04769f5d476622f0f3e4578cbdcd834e", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f": {"doc_hash": "dc21b902e57ff24e5a1b1e3ddd3a7899dd5d72b75be3b6b94a191b0f3d53396b", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "5b3a183c-4bfa-4f68-9df2-bd4a908e273f": {"doc_hash": "74f4cdbaeff1e3b02122c96ea4552b29eb2e415d8a3fef6f90c1690f54adce10", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "395ae58a-093d-44d1-83fc-c87bffa547ad": {"doc_hash": "373bae676365989f64f8d979d245530b7f51d248b3602417bbbc9391c51a8702", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "3fe8fe5e-e8f8-47dd-b75a-46469c361c47": {"doc_hash": "953fc9343c27ca2d4b78b837fcb3361b931c0240bb5f42be7b741c7f2f065f1e", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "af20ba09-5d3d-4b95-9195-4dbf3954ad39": {"doc_hash": "2860a6adf3fce1582930051af0d06f30336253acb17042dd6d6ac9d66ce7a1b2", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "cbb24da0-d3a7-428e-8790-6481c542a5f5": {"doc_hash": "877585a1b4de7ab861504a1a741f581b1cb04b1b7d4add18b0617cc852c0a00d", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "123e9725-4ccd-4122-900d-71d141b2d346": {"doc_hash": "fcf09b0e135badaefee62c0f6d84fe00f50256e05352b22ae2f43b4975f090a7", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "ce2633fb-05e6-4b10-b363-b8441b2742d7": {"doc_hash": "c18e4cc81ba9a3909a1897414309aa0d43ea33f1f7bbd82f2737e458b3132fae", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "bce24f24-3e71-4dd4-b6e0-20f07028ab68": {"doc_hash": "d380fbd3428e66a3c50922b4091d4ee9471bc7e21a7a8385c33c55a37630a689", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "386aca1d-221f-4bed-8f0b-a93bfd4bde2b": {"doc_hash": "d7b795f04b572a2a46f3683029676bba78e533f677698ac18b4d87dc353a8dd6", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "3ad2ca9f-da1b-4f66-9c77-4263a95aca32": {"doc_hash": "b78424b2f7d4dad9e22f1984146951afccf42ffaf4712a70b8c5aa8bc7ee55c8", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "78d39aa9-54e6-4103-b06a-385cb429b7f9": {"doc_hash": "d8858ebc939363076d77b0fd6e86663476f36307315788b84639f789d48a03d0", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "53ef186b-e83c-45e8-9df8-27b4f9aab5e7": {"doc_hash": "6af0c804d71815f8553e07b17056ba1258ef5d55266281f8e258ce9e17327df2", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "32bf73e7-7816-409a-97b9-6f60f27777f0": {"doc_hash": "db58d01a0145bf3627c49d6b55535c92c5d4d1dbc57cb56a4780c237531b68ec", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "8dee1374-936f-4ec9-b3cf-8724a44390dc": {"doc_hash": "603d27339b80d8c7883447a4e4eea4d655b50b689b6b2b622607bf8eec3dc311", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "b7fdd3cd-2f66-42c1-8e39-e49927043022": {"doc_hash": "ac28c511de5e91fb6897567d2fea13d734e4634689358c9eb64ad4d8be97f03a", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "7b793a20-f7e0-4f35-b5fe-c7167e69c66b": {"doc_hash": "8ea573abce901a71ae803a7040883494c87ac29706663374f1f45dfa8ac94b0f", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20": {"doc_hash": "178a0967c84b7e23de33a27bf1373e37c4b49019e32ccc5724846d05ddd39e54", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba": {"doc_hash": "5a4667bfc32305d8db5ea9b65f723af30a09b89094d8d91083fd53b9713f8e4a", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "a23d6423-fd1f-497c-8338-05285e3980f3": {"doc_hash": "332c38dbd30fce62482cc04611c414a48601525d7fbb32337c1a527fbe55bcab", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}, "f2cb7ffa-3cf6-46a1-ab26-316a3531efc2": {"doc_hash": "e67f8395b132881bdc29c0e54a2abff2bb06169b673375cde9ace8def7644df3", "ref_doc_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d"}}, "docstore/ref_doc_info": {"17c56752-6519-446f-9e97-720e092e952c": {"node_ids": ["0888d018-d0e7-4ed5-8c8f-28c076377ab6", "efb691c9-779f-4807-a721-cc931c505f5b", "0f4fda4c-ab13-453a-972a-0d14a8d392a5", "7a5ac78f-37ef-4829-afe5-3883d481d5d1", "c9ed2c61-04fb-4557-be06-6234f82afc29", "3f0f839f-8ab9-4b74-9310-1d05cc786cb2", "e2b050bf-55aa-4c83-93bf-1c7209a1fd02", "c5fa6f9b-b53d-49bb-8539-279fefd22f0a", "b49c2c4c-226a-4e90-bc6e-f1608677c5c9", "c619477d-f580-44b2-b4b0-f00d854e2a41", "5097f51b-0021-4c17-9ed9-614c982ec1f3", "139a813e-f9bd-4ecd-b9f1-237d2c178cb0", "2a5492a4-51b8-4c07-9ced-6a3f2914e018", "99270021-4efe-42fd-9198-c29546e41971", "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb", "4dc0d2e9-75ac-4e53-bad0-6486d04930fd", "57943517-b07b-44b9-89ed-1744fc90e8c6", "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5", "56ff8e6b-6789-4f9d-ba01-ac8238c65d95", "5bd23122-a402-4b2c-ba33-cce5bbec1ed9", "369af8e5-326a-4397-84dc-77719cdbc4cc", "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9", "24953b70-dd6d-497d-bd0f-e6abe76c2779", "509f0931-9b11-4161-add4-a872838696af", "a02c0572-a450-497b-ba93-50dfbf326a9b", "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f", "9689eb5f-06fd-4abc-b35c-6fe438aef1a0", "ac272538-d0bd-4b46-8f44-c6b46de700a3", "85327feb-7c9c-411c-abaf-59bc82db2369", "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2", "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba", "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66", "4b68bc1d-e0a4-4244-9550-766bee3d69b4", "01483c06-0398-4f52-8dfe-59afe118a6f8", "b48f408c-12e3-4277-b226-58db609fe7b5"], "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}}, "19e61bd9-9ada-4585-92ba-ea7057a3177d": {"node_ids": ["590deeb7-0acf-400b-82a5-514377ada131", "71d6854e-62c7-458b-ab13-0a05c8479f25", "d6798a5a-b6b7-4110-bf80-579549521320", "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba", "5e4431a1-9c10-481e-80c5-4416fe248958", "318c2bc6-844d-4b03-b7ff-9da9a3920d78", "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff", "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1", "7bbbf578-4489-452b-9efe-3361b95034ec", "cfe2b049-c05a-4433-aa7b-5efb24283018", "7d22d03f-d41d-462e-9739-dcdd6733a071", "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91", "5237f296-7c75-445c-96a7-b6d718c7eee6", "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd", "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad", "7b03ed8e-0d46-411f-852f-160572c0feff", "e3514730-c98a-4e1b-93e9-e9d37fb768b5", "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f", "5b3a183c-4bfa-4f68-9df2-bd4a908e273f", "395ae58a-093d-44d1-83fc-c87bffa547ad", "3fe8fe5e-e8f8-47dd-b75a-46469c361c47", "af20ba09-5d3d-4b95-9195-4dbf3954ad39", "cbb24da0-d3a7-428e-8790-6481c542a5f5", "123e9725-4ccd-4122-900d-71d141b2d346", "ce2633fb-05e6-4b10-b363-b8441b2742d7", "bce24f24-3e71-4dd4-b6e0-20f07028ab68", "386aca1d-221f-4bed-8f0b-a93bfd4bde2b", "3ad2ca9f-da1b-4f66-9c77-4263a95aca32", "78d39aa9-54e6-4103-b06a-385cb429b7f9", "53ef186b-e83c-45e8-9df8-27b4f9aab5e7", "32bf73e7-7816-409a-97b9-6f60f27777f0", "8dee1374-936f-4ec9-b3cf-8724a44390dc", "b7fdd3cd-2f66-42c1-8e39-e49927043022", "7b793a20-f7e0-4f35-b5fe-c7167e69c66b", "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20", "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba", "a23d6423-fd1f-497c-8338-05285e3980f3", "f2cb7ffa-3cf6-46a1-ab26-316a3531efc2"], "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}}}, "docstore/data": {"0888d018-d0e7-4ed5-8c8f-28c076377ab6": {"__data__": {"id_": "0888d018-d0e7-4ed5-8c8f-28c076377ab6", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efb691c9-779f-4807-a721-cc931c505f5b", "node_type": "1", "metadata": {}, "hash": "04d74c4717d21c82f1e0a37cabfeeeb4c53ff9ad8037f6865ae76e95344f6ffe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 1 ---\n\nSodium Propionate 661\n6 Pereira-da-SilvaLetal.Compatibilityofcalciumandphosphateinfour 20 GeneralReferences\nparenteralnutritionsolutionsforpretermneonates.AmJHealthSyst\nPharm2003;60:1041\u20131044. Sweetman SC, ed. Martindale: The Complete Drug Reference, 36th edn.\nLondon:PharmaceuticalPress,2009;1682.\n7 Haskell LP. Hypocalcaemic tetany induced by hypertonic-phosphate\nenema[letter].Lancet1985;ii:1433.\n8 Larson JE et al. Laxative phosphate poisoning: pharmacokinetics of\nserumphosphorus.HumToxicol1986;5:45\u201349.\n21 Authors\n9 MartinRRetal.Fatalpoisoningfromsodiumphosphateenema:case\nreport and experimental study. J Am Med Assoc 1987; 257: 2190\u2013 MEQuinn,PJSheskey.\n2192.\n10 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;3274.\n22 DateofRevision\n11 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nPharmacopeia,2008;901. 7January2009.\nSodium Propionate\n1 NonproprietaryNames propionates,caprylates,orotherantifungalagents,intheformof\nointmentsorsolutionsforthetreatmentofdermatophyteinfections.\nBP:SodiumPropionate\nEye drops containing 5% w/v sodium propionate have also been\nPhEur:SodiumPropionate\nused.SeeSection18.\nUSP-NF:SodiumPropionate In food processes, particularly baking, sodium propionate is\nusedasanantifungalagent;itmayalsobeusedasaflavoringagent\n2 Synonyms infoodproducts.Inveterinarymedicine,sodiumpropionateisused\nE281; ethylformic acid, sodium salt, hydrate; methylacetic acid,\ntherapeuticallyasaglucogenicsubstanceinruminants.(1)\nsodiumsalt,hydrate;natriipropionas;sodiumpropanoatehydrate;\nsodiumpropionatehydrate. 8 Description\nSodiumpropionateoccursascolorlesstransparentcrystalsorasa\n3 ChemicalNameandCASRegistryNumber granular,free-flowing, crystallinepowder.Itisodorless,orwitha\nPropionicacid,sodiumsalt,hydrate [6700-17-0] slight characteristic odor, and is deliquescentinmoist air. Sodium\nPropionicacid,sodiumsalt,anhydrous [137-40-6] propionate has a characteristic, slightly cheeselike taste, although\nbyitselfitisunpalatable.\n4 EmpiricalFormulaandMolecularWeight\n9 PharmacopeialSpecifications\nC H NaO (cid:2)xH O 114.06(formonohydrate) S\n3 5 2 2\nSeeTableI.\nC H NaO 96.06(foranhydrous)\n3 5 2\nTableI: Pharmacopeialspecificationsforsodiumpropionate.\n5 StructuralFormula\nTest PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe\nCharacters \u00fe \u2014\nAppearanceofsolution \u00fe \u2014\nAlkalinity \u2014 \u00fe\npH 7.8\u20139.2 \u2014\nWater \u2014 41.0%\nHeavymetals 410ppm 40.001%\nRelatedsubstances \u00fe \u2014\n6 FunctionalCategory\nReadilyoxidizablesubstances \u00fe \u2014\nAntimicrobialpreservative. Iron 410ppm \u2014\nLossondrying 0.5% \u2014\nAssay(driedbasis) 99.0\u2013101.0% 99.0\u2013100.5%\n7 Applications in Pharmaceutical Formulation or\nTechnology\nAsanexcipient,sodiumpropionateisusedinoralpharmaceutical\nformulationsasanantimicrobialpreservative.Likepropionicacid, 10 TypicalProperties\nsodium propionate and other propionic acid salts are fungistatic Antimicrobial activity Sodium propionate, propionic acid, and\nand bacteriostatic against a number of Gram-positive cocci.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2971, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "efb691c9-779f-4807-a721-cc931c505f5b": {"__data__": {"id_": "efb691c9-779f-4807-a721-cc931c505f5b", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0888d018-d0e7-4ed5-8c8f-28c076377ab6", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "2e3dd18bdc597ac0638bd8c5ee5a5c6b60680b8ac419e6b868c641a921fae5a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f4fda4c-ab13-453a-972a-0d14a8d392a5", "node_type": "1", "metadata": {}, "hash": "79a832bd659ec16d73627effd490ed143cb6fc579961ad435e94d4df715015bf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Iron 410ppm \u2014\nLossondrying 0.5% \u2014\nAssay(driedbasis) 99.0\u2013101.0% 99.0\u2013100.5%\n7 Applications in Pharmaceutical Formulation or\nTechnology\nAsanexcipient,sodiumpropionateisusedinoralpharmaceutical\nformulationsasanantimicrobialpreservative.Likepropionicacid, 10 TypicalProperties\nsodium propionate and other propionic acid salts are fungistatic Antimicrobial activity Sodium propionate, propionic acid, and\nand bacteriostatic against a number of Gram-positive cocci. other propionates possess mainly antifungal activity and are\nPropionatesaremoreactiveagainstmoldsthanissodiumbenzoate, used as preservatives primarily against molds; they exhibit\nbuthaveessentiallynoactivityagainstyeasts;seeSection10. essentially no activity against yeasts. Although, in general,\nTherapeutically, sodium propionate has been used topically in propionates exhibit little activity against bacteria, sodium\nconcentrationsupto10%w/waloneorincombinationwithother propionateiseffectiveagainstBacillusmesenterium,theorgan-\n\n\n\ud83d\udcca Tables on Page 1:", "mimetype": "text/plain", "start_char_idx": 2511, "end_char_idx": 3525, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0f4fda4c-ab13-453a-972a-0d14a8d392a5": {"__data__": {"id_": "0f4fda4c-ab13-453a-972a-0d14a8d392a5", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efb691c9-779f-4807-a721-cc931c505f5b", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "9b5f784a828f1bb123aaff8b9e8f2748a8a91fb752d3799c4b85efe2468e2783", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a5ac78f-37ef-4829-afe5-3883d481d5d1", "node_type": "1", "metadata": {}, "hash": "d5f8d1297dd601dd9af021faa6adb2ff2aa3984246cd3cbfd00585bd11ba4d41", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\ud83d\udcca Tables on Page 1:\n\n\nTable 1 (21 rows \u00d7 3 columns):\n\n| Section | Title                                                        | Content                                                                                     | | |\n|---------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------|---|---|\n| 1       | Nonproprietary Names                                         | BP: Sodium Propionate                                                                        | | |\n|         |                                                              | PhEur: Sodium Propionate                                                                     | | |\n|         |                                                              | USP-NF: Sodium Propionate                                                                    | | |\n| 2       | Synonyms                                                    | E281; ethylformic acid, sodium salt, hydrate; methylacetic acid, sodium salt, hydrate;    | | |\n|         |                                                              | natrii propionas; sodium propanoate hydrate; sodium propionate hydrate.                    | | |\n| 3       | Chemical Name and CAS Registry Number                       | Propionic acid, sodium salt, hydrate [6700-17-0]                                           | | |\n|         |                                                              | Propionic acid, sodium salt, anhydrous [137-40-6]                                          | | |\n| 4       | Empirical Formula and Molecular Weight                      | C\u2083H\u2085NaO\u2082\u2102xH\u2082O       114.06 (for monohydrate)                                             | | |\n|         |                                                              | C\u2083H\u2085NaO\u2082            96.06 (for anhydrous)                                                 | | |\n| 5       | Structural Formula                                          |                                   ONa                                                      | | |\n|         |                                                              |                H3C                                                                          | | |\n| 6       | Functional Category                                          | Antimicrobial preservative.                                                                  | | |\n| 7       | Applications in Pharmaceutical Formulation or Technology    | As an excipient, sodium propionate is used in oral pharmaceutical formulations as an      | | |\n|         |                                                              | antimicrobial preservative. Like propionic acid, sodium propionate and other propionic      | | |\n|         |                                                              | acid salts are fungistatic and bacteriostatic against a number of Gram-positive cocci.     | | |\n| 8       | Description                                                  | Sodium propionate occurs as colorless transparent crystals or as a granular, free-flowing,  | | |\n|         |                                                              | crystalline powder. It is odorless, or with a slight characteristic odor, and is           | | |\n|         |                                                              | deliquescent in moist air. Sodium propionate has a characteristic, slightly cheeselike     | | |\n|         |                                                              | taste, although by itself it is unpalatable.                                               | | |\n| 9       | Pharmacopeial Specifications                                 | See Table I.                                                                                | | |\n|         |                                                              |                                                                                             | | |\n|         | Table I: Pharmacopeial specifications for sodium propionate.| Test                                | PhEur 6.0            | USP32\u2013NF27                |\n|         |                                                              | Identification                      | \u00fe                    | \u00fe                          |\n|         |                                                              | Characters                          | \u00fe                    | \u2014                          |\n|         |                                                              | Appearance of solution              | \u00fe                    | \u2014                          |\n|         |                                                              | Alkalinity                          | \u2014                    | \u00fe                          |\n|         |                                                              | pH                                  | 7.8\u20139.2              | \u2014                          |\n|         |                                                              | Water                               | \u2014                    | 41.0%                      |\n|         |                                                              | Heavy metals                        | 410 ppm              | 40.001%                    |\n|         |                                                              | Related substances                  | \u00fe                    | \u2014                          |\n|         |                                                              | Readily oxidizable substances       | \u00fe                    | \u2014                          |\n|         |                                                              | Iron                                | 410 ppm              | \u2014                          |\n|         |                                                              | Loss on drying                      | 0.5%                 | \u2014                          |\n|         |                                                              | Assay (dried basis)                 | 99.0\u2013101.0%          | 99.0\u2013100.5%                |\n| 10      | Typical Properties                                           | Antimicrobial activity              | Sodium propionate, propionic acid, and other propionates possess mainly antifungal activity and are used as preservatives primarily against molds; they exhibit essentially no activity against yeasts. Although, in general, propionates exhibit little activity against bacteria, sodium propionate is effective against Bacillus mesenterium, the organ- | |", "mimetype": "text/plain", "start_char_idx": 3506, "end_char_idx": 10132, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7a5ac78f-37ef-4829-afe5-3883d481d5d1": {"__data__": {"id_": "7a5ac78f-37ef-4829-afe5-3883d481d5d1", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f4fda4c-ab13-453a-972a-0d14a8d392a5", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "557fccba342e9004c229b82a72ad3c78c24664cfa78bcc4fb68aa0b463eb9ba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9ed2c61-04fb-4557-be06-6234f82afc29", "node_type": "1", "metadata": {}, "hash": "482cb51773384bced6a21faeb9476a49b92154456f1ce0b399d558df937c03b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 2 ---\n\n5.0 IntheUK,theworkplaceexposurelimitsforpropionicacidare\n31mg/m3 (10ppm) long-term (8-hour TWA) and 46mg/m3\n(15ppm)short-term.(5)\n16 RegulatoryStatus\nGRAS listed. Accepted for use as a food additive in Europe. In\n0.0\ncheese products, propionates are limited to 0.3% w/w concentra-\ntion;alimitof0.32%w/wisappliedinflourandwhitebreadrolls,\nwhilealimitof0.38%w/wisappliedinwholewheatproducts.\nIncluded in the FDA Inactive Ingredients Database (oral\ncapsules, powder, suspensions, and syrups). Included in nonpar-\nenteralmedicineslicensedintheUK.IncludedintheCanadianList\n\u2212 5.0\nofAcceptableNon-medicinalIngredients.\n17 RelatedSubstances\nAnhydrous sodium propionate; calcium propionate; potassium\npropionate;propionicacid;zincpropionate.\nAnhydroussodiumpropionate\nismthatcauses\u2018rope\u2019inbread.Antimicrobialactivityislargely Empiricalformula C\n3\nH\n5\nO\n2\nNa\ndependent upon the presence of the free acid and hence Molecularweight 96.06\npropionates exhibit optimum activity at acid pH, notably at CASnumber [137-40-6]\nless than pH 5. Synergistic effects occur between propionates Synonyms E281;propanoicacid,sodiumsalt,anhydrous.\nandcarbondioxideorsorbicacid.SeealsoPropionicacid. Safety\nNIRspectra seeFigure1. LD (mouse,oral):2.35g/kg(4)\n50\nSolubility Soluble1in24ofethanol(95%),1in1ofwater,and1\nLD (rat,oral):3.92g/kg\nin0.65ofboilingwater;practicallyinsolubleinchloroformand 50\nCalciumpropionate\nether.\nEmpiricalformula C H O Ca\n6 10 4\nMolecularweight 186.22\n11 StabilityandStorageConditions CASnumber [4075-81-4]\nSodiumpropionateisdeliquescentandshouldthereforebestoredin Synonyms Calciumdipropionate;E282;propanoicacid,calcium\nanairtightcontainerinacool,dryplace. salt;propionicacid,calciumsalt.\nAppearance Whitecrystallinepowder.\n12 Incompatibilities Solubility Solubleinwater;slightlysolubleinethanol(95%)and\nmethanol;practicallyinsolubleinacetoneandbenzene.\nIncompatibilitiesforsodiumpropionatearesimilartothoseofother\nMethod of manufacture Prepared by the reaction of propionic\nweakorganicacids.\nacidandcalciumhydroxide.\nComments Occursasthemonohydrateortrihydrate.\n13 MethodofManufacture\nPotassiumpropionate\nSodium propionate is prepared by the reaction of propionic acid\nEmpiricalformula C H O K\nwithsodiumcarbonateorsodiumhydroxide. 3 5 2 Molecularweight 112.17\nCASnumber [327-62-8]\n14 Safety Synonyms E283;propanoicacid,potassiumsalt;propionicacid,\nSodium propionate and other propionates are used in oral potassiumsalt.\npharmaceutical formulations, food products, and cosmetics. The Appearance Whitecrystallinepowder.\nfreeacid,propionicacid,occursnaturallyatlevelsupto1%w/win Comments Occursastheanhydrousformandthemonohydrate.\ncertaincheeses. Decomposesinmoistairtogiveoffpropionicacid.\nFollowing oral consumption, propionate is metabolized in\nZincpropionate\nmammalsinamannersimilartothatoffattyacids.Toxicitystudies\nEmpiricalformula C H O Zn\ninanimalshaveshownsodiumpropionateandotherpropionatesto 6 10 4\nberelativelynontoxicmaterials.(2,3)Inveterinarymedicine,sodium Molecularweight 211.52\npropionateisusedasatherapeuticagentforcattleandsheep.", "mimetype": "text/plain", "start_char_idx": 10136, "end_char_idx": 13201, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c9ed2c61-04fb-4557-be06-6234f82afc29": {"__data__": {"id_": "c9ed2c61-04fb-4557-be06-6234f82afc29", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a5ac78f-37ef-4829-afe5-3883d481d5d1", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "a5c22f828d0a8976ec5b51abd5e0844fe6ad7e484129268e4ddbb6c85171bd27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f0f839f-8ab9-4b74-9310-1d05cc786cb2", "node_type": "1", "metadata": {}, "hash": "501b5d2a1dad6847281ef8f7ec501a405a696e8497a431c31b4f944fcf624d58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "pharmaceutical formulations, food products, and cosmetics. The Appearance Whitecrystallinepowder.\nfreeacid,propionicacid,occursnaturallyatlevelsupto1%w/win Comments Occursastheanhydrousformandthemonohydrate.\ncertaincheeses. Decomposesinmoistairtogiveoffpropionicacid.\nFollowing oral consumption, propionate is metabolized in\nZincpropionate\nmammalsinamannersimilartothatoffattyacids.Toxicitystudies\nEmpiricalformula C H O Zn\ninanimalshaveshownsodiumpropionateandotherpropionatesto 6 10 4\nberelativelynontoxicmaterials.(2,3)Inveterinarymedicine,sodium Molecularweight 211.52\npropionateisusedasatherapeuticagentforcattleandsheep.(1) CASnumber [557-28-8]\nSynonyms Propanoicacid,zincsalt;propionicacid,zincsalt.\nIn humans, 6 g of sodium propionate has been administered\ndaily without harm.(2) However, allergic reactions to propionates Appearance Whiteplateletsorneedlelikecrystals(forthemono-\nhydrate).\ncanoccur.\nSolubility Theanhydrousformissoluble1in36ofethanol(95%)\nLD\n50\n(mouse,oral):6.33g/kg(4) at158C,1in6ofboilingethanol(95%),and1in3ofwaterat\nLD (mouse,SC):2.1g/kg 158C.\n50\nLD (rabbit,skin):1.64g/kg Method of manufacture Prepared by dissolving zinc oxide in\n50\ndilutepropionicacidsolution.\nComments Occursastheanhydrousformandthemonohydrate.\n15 HandlingPrecautions\nDecomposesinmoistairtogiveoffpropionicacid.\nObservenormalprecautionsappropriatetothecircumstancesand\nquantityofmaterialhandled.Sodiumpropionatemaybeirritantto\n18 Comments\nthe eyes and skin. Gloves, eye protection, and a dust-mask are\nrecommended.Whenheatedtodecomposition,sodiumpropionate Propionatesareusedasantimicrobialpreservativesinpreferenceto\nemitstoxicfumesofsodiummonoxide,Na O. propionicacidsincetheyarelesscorrosive.\n2\n])R/1(gol\n.vired\ndn2[\n\u00d7\n0001\n0.5\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\n)R/1(gol\n662 Sodium Propionate\n2328 2354\n2377\n1675 1707\n1183\n2291\n1691 2311 2469\n2342\n2365\nFigure1: Near-infraredspectrumofsodiumpropionatemeasuredby\nreflectance.\nS\n\n\n\ud83d\udcca Tables on Page 2:", "mimetype": "text/plain", "start_char_idx": 12575, "end_char_idx": 14552, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f0f839f-8ab9-4b74-9310-1d05cc786cb2": {"__data__": {"id_": "3f0f839f-8ab9-4b74-9310-1d05cc786cb2", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9ed2c61-04fb-4557-be06-6234f82afc29", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "24b9d7752094612a83223c3c80d290ae2daa5dbdc0cb90e683eb8115567682f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2b050bf-55aa-4c83-93bf-1c7209a1fd02", "node_type": "1", "metadata": {}, "hash": "694fcc9ad85531ab564c2590fe31af72d2ca27e76f0e30dd6b2a70db7477096e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "S\n\n\n\ud83d\udcca Tables on Page 2:\n\n\nTable 1 (33 rows \u00d7 2 columns):\n\n| **Parameter**                          | **Value**                                   |\n|----------------------------------------|---------------------------------------------|\n| **Sodium Propionate**                  |                                             |\n| **Workplace Exposure Limits**          |                                             |\n| Long-term (8-hour TWA)                | 31 mg/m\u00b3 (10 ppm)                          |\n| Short-term                              | 46 mg/m\u00b3 (15 ppm)                          |\n| **Regulatory Status**                  | GRAS listed. Accepted for use as a food additive in Europe. In cheese products, propionates are limited to 0.3% w/w concentration; a limit of 0.32% w/w is applied in flour and white bread rolls, while a limit of 0.38% w/w is applied in whole wheat products. Included in the FDA Inactive Ingredients Database (oral capsules, powder, suspensions, and syrups). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| **Related Substances**                 | Anhydrous sodium propionate; calcium propionate; potassium propionate; propionic acid; zinc propionate. |\n| **Anhydrous Sodium Propionate**        |                                             |\n| Empirical formula                      | C\u2083H\u2085O\u2082Na                                   |\n| Molecular weight                       | 96.06                                       |\n| CAS number                             | [137-40-6]                                 |\n| Synonyms                               | E281; propanoic acid, sodium salt, anhydrous. |\n| **Safety**                             |                                             |\n| LD\u2085\u2080 (mouse, oral)                    | 2.35 g/kg (4)                              |\n| LD\u2085\u2080 (rat, oral)                      | 3.92 g/kg                                   |\n| **Calcium Propionate**                 |                                             |\n| Empirical formula                      | C\u2086H\u2081\u2080O\u2084Ca                                  |\n| Molecular weight                       | 186.22                                      |\n| CAS number                             | [4075-81-4]                                 |\n| Synonyms                               | Calcium dipropionate; E282; propanoic acid, calcium salt; propionic acid, calcium salt. |\n| Appearance                             | White crystalline powder.                   |\n| Solubility                             | Soluble in water; slightly soluble in ethanol (95%) and methanol; practically insoluble in acetone and benzene. |\n| Method of manufacture                  | Prepared by the reaction of propionic acid and calcium hydroxide. |\n| Comments                               | Occurs as the monohydrate or trihydrate.  |\n| **Potassium Propionate**               |                                             |\n| Empirical formula                      | C\u2083H\u2085O\u2082K                                    |\n| Molecular weight                       | 112.17                                      |\n| CAS number                             | [327-62-8]                                 |\n| Synonyms                               | E283; propanoic acid, potassium salt; propionic acid, potassium salt. |\n| Appearance                             | White crystalline powder.                   |\n| Comments                               | Occurs as the anhydrous form and the monohydrate. Decomposes in moist air to give off propionic acid. |\n| **Zinc Propionate**                    |                                             |\n| Empirical formula                      | C\u2081H\u2086O\u2084Zn                                   |\n| Molecular weight                       | 211.52                                      |\n| CAS number                             | [557-28-8]                                 |\n| Synonyms                               | Propanoic acid, zinc salt; propionic acid, zinc salt. |\n| Appearance                             | White platelets or needlelike crystals (for the monohydrate). |\n| Solubility                             | The anhydrous form is soluble 1 in 36 of ethanol (95%) at 158\u00b0C, 1 in 6 of boiling ethanol (95%), and 1 in 3 of water at 158\u00b0C. |\n| Method of manufacture                  | Prepared by dissolving zinc oxide in dilute propionic acid solution. |\n| Comments                               | Occurs as the anhydrous form and the monohydrate. Decomposes in moist air to give off propionic acid. |\n| **Comments**                           | Propionates are used as antimicrobial preservatives in preference to propionic acid since they are less corrosive. |", "mimetype": "text/plain", "start_char_idx": 14529, "end_char_idx": 19297, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e2b050bf-55aa-4c83-93bf-1c7209a1fd02": {"__data__": {"id_": "e2b050bf-55aa-4c83-93bf-1c7209a1fd02", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f0f839f-8ab9-4b74-9310-1d05cc786cb2", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "76b21e37b12be875e04216afa1be15b906ee1d0f8a29a4c8a33482546731ed33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5fa6f9b-b53d-49bb-8539-279fefd22f0a", "node_type": "1", "metadata": {}, "hash": "259ac7e10c27ce81c832a15f7d92f6e983b0f892015ee74a3a3aefc6acda493b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 3 ---\n\nSodium Starch Glycolate 663\nThetherapeuticuseofsodiumpropionateintopicalantifungal 5 HealthandSafetyExecutive.EH40/2005:WorkplaceExposureLimits.\npreparations has largely been superseded by a new generation of Sudbury: HSE Books, 2005 (updated 2007). http://www.hse.gov.uk/\nantifungaldrugs. coshh/table1.pdf(accessed5February2009).\nAspecificationforsodiumpropionateiscontainedintheFood 6 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nChemicalsCodex(FCC).(6) Pharmacopeia,2008;906.\nTheEINECSnumberforsodiumpropionateis205-290-4.The\nPubChem Compound ID (CID) for sodium propionate is 20 GeneralReferences\n23663426. DooresS.Organicacids.BranenAL,DavidsonPM,eds.Antimicrobialsin\nFoods.NewYork:MarcelDekker,1983;85\u201387.\nFuria TE, ed. CRC Handbook of Food Additives. Cleveland, OH: CRC\n19 SpecificReferences\nPress,1972;137\u2013141.\n1 Bishop Y, ed. The Veterinary Formulary, 6th edn. London:\nPharmaceuticalPress,2005;419\u2013420.\n21 Author\n2 Heseltine WW. A note on sodium propionate. J Pharm Pharmacol\n1952;4:120\u2013122. TSakurai.\n3 GrahamWDetal.Chronictoxicityofbreadadditivestorats.JPharm\nPharmacol1954;6:534\u2013545.\n22 DateofRevision\n4 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;3276. 5February2009.\nSodium Starch Glycolate\n1 NonproprietaryNames 5 StructuralFormula\nBP:SodiumStarchGlycolate\nPhEur:SodiumStarchGlycolate\nUSP-NF:SodiumStarchGlycolate\n2 Synonyms\nCarboxymethyl starch, sodium salt; carboxymethylamylum natri-\ncum;Explosol;Explotab;Glycolys;Primojel;starchcarboxymethyl\nether,sodiumsalt;Tablo;VivastarP.\nS\n3 ChemicalNameandCASRegistryNumber 6 FunctionalCategory\nSodiumcarboxymethylstarch [9063-38-1] Tabletandcapsuledisintegrant.\n7 Applications in Pharmaceutical Formulation or\n4 EmpiricalFormulaandMolecularWeight Technology\nTheUSP32\u2013NF27describestwotypesofsodiumstarchglycolate, Sodiumstarchglycolateiswidelyusedinoralpharmaceuticalsasa\nTypeAandTypeB,andstatesthatsodiumstarchglycolateisthe disintegrant in capsule(1\u20136) and tablet formulations.(7\u201310) It is\nsodiumsaltofacarboxymethyletherofstarchorofacrosslinked commonly used in tablets prepared by either direct-compres-\ncarboxymethyletherofstarch. sion(11\u201313) or wet-granulation processes.(14\u201316) The usual concen-\nThePhEur6.0describesthreetypesofmaterial:TypeAandType trationemployedinaformulationisbetween2%and8%,withthe\nB are described as the sodium salt of a crosslinked partly O- optimumconcentrationabout4%,althoughinmanycases2%is\ncarboxymethylatedpotatostarch.TypeCisdescribedasthesodium sufficient.Disintegrationoccursbyrapiduptakeofwaterfollowed\nsalt of a partly O-carboxymethylated starch, crosslinked by byrapidandenormousswelling.(17\u201320)\nphysicaldehydration.TypesA,B,andCaredifferentiatedbytheir Although the effectiveness of many disintegrants is affected by\npH,sodium,andsodiumchloridecontent. the presence of hydrophobic excipients such as lubricants, the\nThePhEurandUSP\u2013NFmonographshavebeenharmonizedfor disintegrant efficiency of sodium starch glycolate is unimpaired.", "mimetype": "text/plain", "start_char_idx": 19301, "end_char_idx": 22305, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5fa6f9b-b53d-49bb-8539-279fefd22f0a": {"__data__": {"id_": "c5fa6f9b-b53d-49bb-8539-279fefd22f0a", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2b050bf-55aa-4c83-93bf-1c7209a1fd02", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "fca5571e6f22b03f3b0ddd5742b8ff50a64490a01a6e13399e74f15b37d22e91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49c2c4c-226a-4e90-bc6e-f1608677c5c9", "node_type": "1", "metadata": {}, "hash": "1f5cc1d316924ebd9c4d0b5955f8dfed1643c2f5a0fce0810e4dfbbb9ea0e902", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(17\u201320)\nphysicaldehydration.TypesA,B,andCaredifferentiatedbytheir Although the effectiveness of many disintegrants is affected by\npH,sodium,andsodiumchloridecontent. the presence of hydrophobic excipients such as lubricants, the\nThePhEurandUSP\u2013NFmonographshavebeenharmonizedfor disintegrant efficiency of sodium starch glycolate is unimpaired.\nTypeAandTypeBvariants. Increasingthetabletcompressionpressurealsoappearstohaveno\nSodiumstarchglycolatemaybecharacterizedbythedegreeof effectondisintegrationtime.(10\u201312)\nsubstitutionandcrosslinking.Themolecularweightistypically5(cid:3) Sodiumstarchglycolatehasalsobeeninvestigatedforuseasa\n105\u20131(cid:3)106. suspendingvehicle.(21)\n\n\n\ud83d\udcca Tables on Page 3:\n\n\nTable 2 (3 rows \u00d7 2 columns):\n\n| **1 Nonproprietary Names** | **5 Structural Formula** |\n|----------------------------|-------------------------|\n| BP: Sodium Starch Glycolate | CH2COONa |\n| PhEur: Sodium Starch Glycolate | CH2OH CH CHOH |\n| USP-NF: Sodium Starch Glycolate | OH OH OH |\n| | OH OH OH |\n| | n S |\n\n\n\nTable 3 (1 rows \u00d7 1 columns):\n\n| **2 Synonyms** | |\n|----------------|---------------------|\n| Carboxymethyl starch, sodium salt; carboxymethylamylum natri- cum; Explosol; Explotab; Glycolys; Primojel; starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. | |\n\n\n\nTable 4 (1 rows \u00d7 2 columns):\n\n| **3 Chemical Name and CAS Registry Number** | **6 Functional Category** |\n|----------------------------------------------|---------------------------|\n| Sodium carboxymethyl starch [9063-38-1] | Tablet and capsule disintegrant. |\n\n\n\nTable 5 (2 rows \u00d7 2 columns):\n\n| **4 Empirical Formula and Molecular Weight** | **7 Applications in Pharmaceutical Formulation or Technology** |\n|------------------------------------------------|-------------------------------------------------------------|\n| The USP32\u2013NF27 describes two types of sodium starch glycolate, Type A and Type B, and states that sodium starch glycolate is the sodium salt of a carboxymethyl ether of starch or of a crosslinked carboxymethyl ether of starch. | Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in capsule(1\u20136) and tablet formulations.(7\u201310) It is commonly used in tablets prepared by either direct-compression(11\u201313) or wet-granulation processes.(14\u201316) The usual concentration employed in a formulation is between 2% and 8%, with the optimum concentration about 4%, although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling.(17\u201320) |\n| The PhEur 6.0 describes three types of material: Type A and Type B are described as the sodium salt of a crosslinked partly carboxymethylated potato starch. Type C is described as the sodium salt of a partly O-carboxymethylated starch, crosslinked by physical dehydration. Types A, B, and C are differentiated by their pH, sodium, and sodium chloride content. | Although the effectiveness of many disintegrants is affected by the presence of hydrophobic excipients such as lubricants, the disintegrant efficiency of sodium starch glycolate is unimpaired. Increasing the tablet compression pressure also appears to have no effect on disintegration time.(10\u201312) Sodium starch glycolate has also been investigated for use as a suspending vehicle.(21) |", "mimetype": "text/plain", "start_char_idx": 21962, "end_char_idx": 25241, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b49c2c4c-226a-4e90-bc6e-f1608677c5c9": {"__data__": {"id_": "b49c2c4c-226a-4e90-bc6e-f1608677c5c9", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5fa6f9b-b53d-49bb-8539-279fefd22f0a", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "eb38eb1f468ffd6f1db03d4efa5e42e57563decfed67be9317a537e20909bd4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c619477d-f580-44b2-b4b0-f00d854e2a41", "node_type": "1", "metadata": {}, "hash": "457708ff43773a83a5817f68f05a7d9b1bcce24e5851c7ff34f7f8d5565c0b31", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 4 ---\n\n664 Sodium Starch Glycolate\n8 Description 0.756g/cm3forGlycolys;\nSodiumstarchglycolateisawhiteoralmostwhitefree-flowingvery 0.81g/cm3forPrimojel;\nhygroscopic powder. The PhEur 6.0 states that when examined 0.67g/cm3forTablo.\nunder a microscope it is seen to consist of: granules, irregularly Density(tapped)\nshaped, ovoid or pear-shaped, 30\u2013100 mm in size, or rounded, 0.945g/cm3forGlycolys;\n10\u201335 mm in size; compound granules consisting of 2\u20134 compo-\n0.98g/cm3forPrimojel;\nnentsoccuroccasionally;thegranuleshaveaneccentrichilumand\n0.83g/cm3forTablo.\nclearly visible concentric striations. Between crossed nicol prisms,\nDensity(true)\nthe granules show a distinct black cross intersecting at the hilum;\nsmallcrystalsarevisibleatthesurfaceofthegranules.Thegranules\n1.56g/cm3forPrimojel;\nshowconsiderableswellingincontactwithwater. 1.49g/cm3forTablo.\nMeltingpoint Doesnotmelt,butcharsatapproximately2008C.\nNIRspectra seeFigure1.\n9 PharmacopeialSpecifications\nParticle size distribution 100% of particles less than 106mm in\nSeeTableI.SeealsoSection18. size.Averageparticlesize(d )is38mmand42mmforPrimojel\n50\nbymicroscopyandsieving,respectively.\n10 TypicalProperties Solubility Practically insoluble in methylene chloride. It gives a\nAcidity/alkalinity SeeSection9. translucentsuspensioninwater.\nDensity(bulk) Specificsurfacearea\n0.24m2/gforGlycolys;\nSEM1: Excipient:sodiumstarchglycolate(Explotab);manufacturer:JRS\n0.185m2/gforPrimojel;\nPharma;magnification:300(cid:3);voltage:5kV. 0.335m2/gforTablo.\nSEM3: Excipient:sodiumstarchglycolate(Primojel);manufacturer:DMV-\nFonterraExcipients;magnification:200(cid:3);voltage:1.5kV.\nS\nSEM4: Excipient:sodiumstarchglycolate(VivastarP);manufacturer:JRS\nSEM2: Excipient:sodiumstarchglycolate(Glycolys);manufacturer: Pharma;magnification:300(cid:3);voltage:5kV.\nRoquettesFre`res.\n\n\n\ud83d\udcca Tables on Page 4:", "mimetype": "text/plain", "start_char_idx": 25245, "end_char_idx": 27098, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c619477d-f580-44b2-b4b0-f00d854e2a41": {"__data__": {"id_": "c619477d-f580-44b2-b4b0-f00d854e2a41", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49c2c4c-226a-4e90-bc6e-f1608677c5c9", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "23c301c4eda2868cfe27ad004472c99023af7bd294d1c878461126fa125889e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5097f51b-0021-4c17-9ed9-614c982ec1f3", "node_type": "1", "metadata": {}, "hash": "0f5b58e91bbc6e3deea950893a5862a7622393ca8dc4511a49b3b2f5a00fd7c1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\ud83d\udcca Tables on Page 4:\n\n\nTable 1 (11 rows \u00d7 2 columns):\n\n| Property                        | Value                                      |\n|--------------------------------|--------------------------------------------|\n| Description                    | Sodium starch glycolate is a white or almost white free-flowing very hygroscopic powder. The PhEur 6.0 states that when examined under a microscope it is seen to consist of: granules, irregularly shaped, ovoid or pear-shaped, 30\u2013100 mm in size, or rounded, 10\u201335 mm in size; compound granules consisting of 2\u20134 components occur occasionally; the granules have an eccentric hilum and clearly visible concentric striations. Between crossed nicol prisms, the granules show a distinct black cross intersecting at the hilum; small crystals are visible at the surface of the granules. The granules show considerable swelling in contact with water. |\n| Density (tapped)              | 0.756 g/cm\u00b3 for Glycolys;                  |\n|                                | 0.81 g/cm\u00b3 for Primojel;                   |\n|                                | 0.67 g/cm\u00b3 for Tablo.                      |\n| Density (true)                | 0.945 g/cm\u00b3 for Glycolys;                  |\n|                                | 0.98 g/cm\u00b3 for Primojel;                   |\n|                                | 0.83 g/cm\u00b3 for Tablo.                      |\n| Melting point                  | 1.56 g/cm\u00b3 for Primojel;                   |\n|                                | 1.49 g/cm\u00b3 for Tablo.                      |\n|                                | Does not melt, but chars at approximately 200\u00b0C. |\n| Pharmacopeial Specifications    | NIR spectra see Figure 1.                  |\n|                                | See Table I. See also Section 18.          |\n| Particle size distribution      | 100% of particles less than 106 mm in size. |\n|                                | Average particle size (d\u2085\u2080) is 38 mm and 42 mm for Primojel by microscopy and sieving, respectively. |\n| Typical Properties              | Acidity/alkalinity See Section 9.         |\n|                                | Density (bulk)                             |\n|                                | Specific surface area                       |\n|                                | 0.24 m\u00b2/g for Glycolys;                    |\n|                                | 0.185 m\u00b2/g for Primojel;                   |\n|                                | 0.335 m\u00b2/g for Tablo.                      |\n| SEM 1                          | Excipient: sodium starch glycolate (Explotab); manufacturer: JRS Pharma; magnification: 300; voltage: 5 kV. |\n| SEM 2                          | Excipient: sodium starch glycolate (Glycolys); manufacturer: Roquettes. |\n| SEM 3                          | Excipient: sodium starch glycolate (Primojel); manufacturer: DMV-Fonterra Excipients; magnification: 200; voltage: 1.5 kV. |\n| SEM 4                          | Excipient: sodium starch glycolate (Vivastar P); manufacturer: JRS Pharma; magnification: 300; voltage: 5 kV. |\n\n\n\n--- Page 5 ---\n\n3.0\nTableI: Pharmacopeialspecificationsforsodiumstarchglycolate.\nTest PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe\nCharacters \u00fe \u2014\nAppearanceofsolution \u00fe \u2014 0.0\npH \u00fe \u00fe\nTypeA 5.5\u20137.5 5.5\u20137.5\nTypeB 3.0\u20135.0 3.0\u20135.0\nTypeC 5.5\u20137.5 \u2014\nHeavymetals 420ppm 40.002%\nIron 420ppm 40.002%\nLossondrying \u00fe 410%\nTypeA 410.0% \u2014 \u22124.0\nTypeB 410.0% \u2014\nTypeC 47.0% \u2014\nMicrobiallimits \u00fe(a) \u00fe(a)\nSodiumchloride \u00fe 47.0%\nTypeA 47.0% \u2014\nTypeB 47.0% \u2014\nTypeC 41.0% \u2014\nSodiumglycolate \u00fe 42.0%\nTypeA 42.0% \u2014 15 HandlingPrecautions\nTypeB 42.0% \u2014 Observenormalprecautionsappropriatetothecircumstancesand\nTypeC 42.0% \u2014\nquantity of material handled.", "mimetype": "text/plain", "start_char_idx": 27079, "end_char_idx": 30741, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5097f51b-0021-4c17-9ed9-614c982ec1f3": {"__data__": {"id_": "5097f51b-0021-4c17-9ed9-614c982ec1f3", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c619477d-f580-44b2-b4b0-f00d854e2a41", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "49aa450578d25f398e13deb9d940eeea705caeb10e7d46a3b10f8668c90d2943", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "139a813e-f9bd-4ecd-b9f1-237d2c178cb0", "node_type": "1", "metadata": {}, "hash": "3954b3fc6546975d6b1358960ed72eff1d67030d93a80c0bb9450f3dcc0c8465", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sodium starch glycolate may be\nAssay(ofNa) \u00fe \u00fe\nirritanttotheeyes;eyeprotectionandglovesarerecommended.A\nTypeA 2.8\u20134.2% 2.8\u20134.2%\nTypeB 2.0\u20133.4% 2.0\u20133.4% dustmaskorrespiratorisrecommendedforprocessesthatgenerate\nTypeC 2.8\u20135.0% \u2014 alargequantityofdust.\n(a)ComplieswithtestsforSalmonellaandEscherichiacoli.\n16 RegulatoryAcceptance\nSwellingcapacity Inwater,sodiumstarchglycolateswellstoupto Included in the FDA Inactive Ingredients Database (oral capsules\n300timesitsvolume. and tablets). Included in nonparenteral medicines licensed in the\nViscosity(dynamic) 4200mPas(200cP)fora4%w/vaqueous UK. Included in the Canadian List of Acceptable Non-medicinal\ndispersion; viscosity is 4.26mPas for a 2% w/v aqueous Ingredients.\ndispersion(dependingonsourceandgrade).\n17 RelatedSubstances\n11 StabilityandStorageConditions\nPregelatinizedstarch;starch.\nTablets prepared with sodium starch glycolate have good storage\nproperties.(22\u201324) Sodium starch glycolate is stable although very\n18 Comments\nhygroscopic, and should be stored in a well-closed container in\norder to protect it from wide variations of humidity and Sodium starch glycolate is one of the materials that have been\ntemperature,whichmaycausecaking. selected for harmonization by the Pharmacopeial Discussion\nThe physical properties of sodium starch glycolate remain Group. For further information see the General Information\nunchangedforupto3yearsifitisstoredatmoderatetemperatures Chapter <1196> in the USP32\u2013NF27, the General Chapter 5.8\nandhumidity.\ninPhEur6.0,alongwiththe\u2018StateofWork\u2019documentonthePhEur\nEDQMwebsite,andalsotheGeneralInformationChapter8inthe\nJPXV.\n12 Incompatibilities\nThephysicalpropertiesofsodiumstarchglycolate,andhenceits\nSodiumstarchglycolateisincompatiblewithascorbicacid.(25)\neffectiveness as a disintegrant, are affected by the degree of\ncrosslinkage,extentofcarboxymethylation,andpurity.(27,28)\n13 MethodofManufacture\nSodium starch glycolate has been reported to interact with\nSodiumstarchglycolateisasubstitutedderivativeofpotatostarch. glycopeptideantibiotics,(29,30)basicdrugs,andincreasethephoto-\nTypically, commercial products are also crosslinked using either stabilityofnorfloxacin.(31)Thesolubilityoftheformulationmatrix\nsodium trimetaphosphate (Types A and B) or dehydration (Type and mode of incorporation in wet granulation can affect the\nC).(26) disintegration time; disintegration times can be slower in tablets\nStarch is carboxymethylated by reacting it with sodium containinghighlevelsofsolubleexcipients.(32)\nchloroacetate in an alkaline, nonaqueous medium, typically Commercially,sodiumstarchglycolateisavailableinanumber\ndenatured ethanol or methanol, followed by neutralization with ofspecialitygrades,e.g.lowpH(ExplotabLowpH,GlycolysLow\ncitric acid, acetic acid, or some other acid. Vivastar P is pH); low viscosity (Explotab CLV, Glycolys LV); low solvent\nmanufactured in methanolic medium, and Explotab in ethanolic (VivastarPSF);andlowmoistureGlycolysLM.\nmedium. A specification for sodium starch glycolate is included in the\nJapanesePharmaceuticalExcipients(JPE).(33)\n14 Safety\nSodium starch glycolate is widely used in oral pharmaceutical 19 SpecificReferences\nformulations and is generally regarded as a nontoxic and 1 Newton JM, Razzo FN. Interaction of formulation factors and\nnonirritant material. However, oral ingestion of large quantities dissolution fluid and the in vitro release of drug from hard gelatin\nmaybeharmful.", "mimetype": "text/plain", "start_char_idx": 30742, "end_char_idx": 34173, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "139a813e-f9bd-4ecd-b9f1-237d2c178cb0": {"__data__": {"id_": "139a813e-f9bd-4ecd-b9f1-237d2c178cb0", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5097f51b-0021-4c17-9ed9-614c982ec1f3", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "426ae157d6e590344a7a55a4ee2bc0a0216fd546017a8264a64cc89c4d1104b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a5492a4-51b8-4c07-9ced-6a3f2914e018", "node_type": "1", "metadata": {}, "hash": "9d2bb7c0bf4cab2e3cf9964aba27a92f347aca31116e7797a980fe4040c3cd4e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Vivastar P is pH); low viscosity (Explotab CLV, Glycolys LV); low solvent\nmanufactured in methanolic medium, and Explotab in ethanolic (VivastarPSF);andlowmoistureGlycolysLM.\nmedium. A specification for sodium starch glycolate is included in the\nJapanesePharmaceuticalExcipients(JPE).(33)\n14 Safety\nSodium starch glycolate is widely used in oral pharmaceutical 19 SpecificReferences\nformulations and is generally regarded as a nontoxic and 1 Newton JM, Razzo FN. Interaction of formulation factors and\nnonirritant material. However, oral ingestion of large quantities dissolution fluid and the in vitro release of drug from hard gelatin\nmaybeharmful. capsules.JPharmPharmacol1975;27:78P.\n])R/1(gol\n.vired\ndn2[\n\u00d7\n00001\n0.5\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\n)R/1(gol\nSodium Starch Glycolate 665\n1406 1888 2239\n2011 2398\n2305\n1201\n2093 2325\n1433 1923 2282\nFigure1: Near-infraredspectrumofsodiumstarchglycolatemeasured\nbyreflectance.\nS\n\n\n\ud83d\udcca Tables on Page 5:\n\n\nTable 1 (26 rows \u00d7 3 columns):\n\n| Test                              | PhEur 6.0         | USP32\u2013NF27       |\n|-----------------------------------|-------------------|------------------|\n| Identification                    | \u00fe                 | \u00fe                |\n| Characters                        | \u00fe                 | \u2014                |\n| Appearance of solution            | \u00fe                 | \u2014                |\n| pH                                | \u00fe                 | \u00fe                |\n| Type A                            | 5.5\u20137.5           | 5.5\u20137.5          |\n| Type B                            | 3.0\u20135.0           | 3.0\u20135.0          |\n| Type C                            | 5.5\u20137.5           | \u2014                |\n| Heavy metals                      | 420 ppm           | 40.002%          |\n| Iron                              | 420 ppm           | 40.002%          |\n| Loss on drying                    | \u00fe                 | 410%             |\n| Type A                            | 410.0%            | \u2014                |\n| Type B                            | 410.0%            | \u2014                |\n| Type C                            | 47.0%             | \u2014                |\n| Microbial limits                  | \u00fe(a)              | \u00fe(a)             |\n| Sodium chloride                   | \u00fe                 | 47.0%            |\n| Type A                            | 47.0%             | \u2014                |\n| Type B                            | 47.0%             | \u2014                |\n| Type C                            | 41.0%             | \u2014                |\n| Sodium glycolate                  | \u00fe                 | 42.0%            |\n| Type A                            | 42.0%             | \u2014                |\n| Type B                            | 42.0%             | \u2014                |\n| Type C                            | 42.0%             | \u2014                |\n| Assay (of Na)                    | \u00fe                 | \u00fe                |\n| Type A                            | 2.8\u20134.2%          | 2.8\u20134.2%         |\n| Type B                            | 2.0\u20133.4%          | 2.0\u20133.4%         |\n| Type C                            | 2.8\u20135.0%          | \u2014                |\n\n\n\n--- Page 6 ---\n\n666 Sodium Starch Glycolate\n2 StewartAGetal.Thereleaseofamodellow-dosedrug(riboflavine) tionofthesymptomsofcoldsandflu.III.DrugDevIndPharm1987;\nfromhardgelatincapsuleformulations.JPharmPharmacol1979;31: 13(7):1197\u20131215.\n1\u20136. 26 Bolhuis GK et al. On the similarity of sodium starch glycolate from\n3 Chowhan ZT, Chi L-H. Drug\u2013excipient interactions resulting from differentsources.DrugDevIndPharm1986;12(4):621\u2013630.", "mimetype": "text/plain", "start_char_idx": 33523, "end_char_idx": 37123, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2a5492a4-51b8-4c07-9ced-6a3f2914e018": {"__data__": {"id_": "2a5492a4-51b8-4c07-9ced-6a3f2914e018", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "139a813e-f9bd-4ecd-b9f1-237d2c178cb0", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "00c27f048180ac8313831d76db161bf85a947a03b5bd88d77f205ed6d3284efe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99270021-4efe-42fd-9198-c29546e41971", "node_type": "1", "metadata": {}, "hash": "617d1d0ba2d61b28035f9375df8950851d94a19e386c73c401655633790f5ef7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 6 ---\n\n666 Sodium Starch Glycolate\n2 StewartAGetal.Thereleaseofamodellow-dosedrug(riboflavine) tionofthesymptomsofcoldsandflu.III.DrugDevIndPharm1987;\nfromhardgelatincapsuleformulations.JPharmPharmacol1979;31: 13(7):1197\u20131215.\n1\u20136. 26 Bolhuis GK et al. On the similarity of sodium starch glycolate from\n3 Chowhan ZT, Chi L-H. Drug\u2013excipient interactions resulting from differentsources.DrugDevIndPharm1986;12(4):621\u2013630.\npowder mixing III: solid state properties and their effect on drug 27 Rudnic EM et al. Effect of molecular structure variation on the\ndissolution.JPharmSci1986;75:534\u2013541. disintegrantactionofsodiumstarchglycolate.JPharmSci1985;74:\n4 Botzolakis JE, Augsburger LL. Disintegrating agents in hard gelatin 647\u2013650.\ncapsules part 1: mechanism of action. Drug Dev Ind Pharm 1988; 28 Bolhuis GK et al. Effect of variation of degree of substitution,\n14(1):29\u201341. crosslinkingandpurityonthedisintegrantefficiencyofsodiumstarch\n5 Hannula A-M et al. Release of ibuprofen from hard gelatin capsule glycolate.ActaPharmTechnol1984;30:24\u201332.\nformulations:effectofmoderndisintegrants.ActaPharmFenn1989; 29 Claudius JS, Neau SH. Kinetic and equilibrium characterization of\n98:189\u2013196. interactions between glycopeptide antibiotics and sodium carboxy-\n6 Marvola M et al. Effect of sodium bicarbonate and sodium starch methylstarch.IntJPharm1996;144:71\u201379.\nglycolate on the in vivo disintegration of hard gelatin capsules \u2013 a 30 Claudius JS, Neau SH. The solution stability of vancomycin in the\nradiologicalstudyinthedog.ActaPharmNord1989;1:355\u2013362. presence and absence of sodium carboxymethyl starch. Int J Pharm\n7 KhanKA,RookeDJ.Effectofdisintegranttypeupontherelationship 1998;168:41\u201348.\nbetween compressional pressure and dissolution efficiency. J Pharm 31 Cordoba-Borrego M et al. Validation of a high performance liquid\nPharmacol1976;28:633\u2013636. chromatographicmethodforthedeterminationofnorfloxacinandits\n8 Rubinstein MH, Price EJ. In vivo evaluation of the effect of five applicationtostabilitystudies(photostabilitystudyofnorfloxacin).J\ndisintegrantsonthebioavailabilityoffrusemidefrom40mgtablets.J PharmBiomedAnal1999;18:919\u2013926.\nPharmPharmacol1977;29:5P. 32 GordonMSetal.Effectofthemodeofsuperdisintegrantincorporation\n9 CaramellaCetal.Theinfluenceofdisintegrantsonthecharacteristics ondissolutioninwetgranulatedtablets.JPharmSci1993;82:220\u2013\nof coated acetylsalicylic acid tablets. Farmaco(Prat) 1978; 33: 498\u2013 226.\n507. 33 JapanesePharmaceuticalExcipientsCouncil.JapanesePharmaceutical\n10 GebreMariamTetal.Evaluationofthedisintegrationefficiencyofa Excipients2004.Tokyo:YakujiNippo,2004;774.\nsodium starch glycolate prepared from enset starch in compressed\ntablets.EurJPharmBiopharm1996;42(2):124\u2013132.\n20 GeneralReferences\n11 CidE,JaminetF.[Influenceofadjuvantsonthedissolutionrateand\nstability of acetylsalicylic acid in compressed tablets.] J Pharm Belg Augsburger LL et al. Superdisintegrants: characterisation and function.\n1971;26:38\u201348[inFrench]. SwarbrickJ,ed.EncyclopediaofPharmaceuticalTechnology,3rdedn.", "mimetype": "text/plain", "start_char_idx": 36694, "end_char_idx": 39731, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "99270021-4efe-42fd-9198-c29546e41971": {"__data__": {"id_": "99270021-4efe-42fd-9198-c29546e41971", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a5492a4-51b8-4c07-9ced-6a3f2914e018", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "1844faf86ceceb84cb2eaa3ac40e46bed39602c51a40b1dd076ff9f8cb57277e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb", "node_type": "1", "metadata": {}, "hash": "eb6fb03518caaa7d3f0ec607efce01ce0b91c3834ee948101ffd4a262f06e174", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "507. 33 JapanesePharmaceuticalExcipientsCouncil.JapanesePharmaceutical\n10 GebreMariamTetal.Evaluationofthedisintegrationefficiencyofa Excipients2004.Tokyo:YakujiNippo,2004;774.\nsodium starch glycolate prepared from enset starch in compressed\ntablets.EurJPharmBiopharm1996;42(2):124\u2013132.\n20 GeneralReferences\n11 CidE,JaminetF.[Influenceofadjuvantsonthedissolutionrateand\nstability of acetylsalicylic acid in compressed tablets.] J Pharm Belg Augsburger LL et al. Superdisintegrants: characterisation and function.\n1971;26:38\u201348[inFrench]. SwarbrickJ,ed.EncyclopediaofPharmaceuticalTechnology,3rdedn.\n12 GordonMS,ChowhanZT.Effectoftabletsolubilityandhygroscopi- London:InformaHealthcare,2007;2553\u20132567.\ncityondisintegrantefficiencyindirectcompressiontabletsintermsof Blanver.Technicalliterature:Tablo,Explosol,2008.\ndissolution.JPharmSci1987;76:907\u2013909. DMV-FonterraExcipients.Technicalliterature:Primojel,2008.\n13 Cordoba-DiazMetal.Influenceofpharmacotechnicaldesignonthe European Directorate for the Quality of Medicines and Healthcare\ninteractionandavailabilityofnorfloxacinindirectlycompressedtablets (EDQM).EuropeanPharmacopoeia\u2013StateOfWorkOfInternational\nwithcertainantacids.DrugDevIndPharm2000;26:159\u2013166. Harmonisation. Pharmeuropa2009;21(1):142\u2013143.http://www.edq-\n14 Sekulovic\u00b4Detal.TheinvestigationoftheinfluenceofExplotabonthe m.eu/site/-614.html(accessed3February2009).\ndisintegrationoftablets.Pharmazie1986;41:153\u2013154. EdgeSetal.Chemicalcharacterisationofsodiumstarchglycolateparticles.\n15 BolhiusGKetal.Improvementofdissolutionofpoorlysolubledrugsby IntJPharm2002;240:67\u201378.\nsolid deposition on a super disintegrant. Part 2. Choice of super Edge S et al. Powder compaction properties of sodium starch glycolate\ndisintegrantsandeffectofgranulation.EurJPharmSci1997;5(2):63\u2013 disintegrants.DrugDevIndPharm2002;28(8):989\u2013999.\n69. JRSPharma.Technicalliterature:Explotab,VivastarP,2004.\n16 GordonMSetal.Effectofthemodeofsuperdisintegrantincorporation KhanKA,RhodesCT.Furtherstudiesoftheeffectofcompactionpressure\nondissolutioninwetgranulatedtablets.JPharmSci1993;82:220\u2013 onthedissolutionefficiencyofdirectcompressionsystems.PharmActa\n226. Helv1974;49:258\u2013261.\n17 KhanKA,RhodesCT.Disintegrationpropertiesofcalciumphosphate MantovaniFetal.Acombinationofvaporsorptionanddynamiclaserlight\ndibasicdihydratetablets.JPharmSci1975;64:166\u2013168. scatteringmethodsforthedeterminationoftheFloryparameterchiand\nS 18 KhanKA,RhodesCT.Water-sorptionpropertiesoftabletdisintegrants. thecrosslinkdensityofapowderedpolymericgel.FluidPhaseEquilib\nJPharmSci1975;64:447\u2013451. 2000;167(1):63\u201381.\n19 WanLSC,PrasadKPP.Uptakeofwaterbyexcipientsintablets.IntJ MendellE.Anevaluationofcarboxymethylstarchasatabletdisintegrant.\nPharm1989;50:147\u2013153. PharmActaHelv1974;49:248\u2013250.\n20 Thibert R, Hancock BC. Direct visualization of superdisintegrant RoquetteFre`res.Technicalliterature:Glycolys,2008.", "mimetype": "text/plain", "start_char_idx": 39133, "end_char_idx": 42006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb": {"__data__": {"id_": "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99270021-4efe-42fd-9198-c29546e41971", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d095276131e72da04ab1647c41fcbae00376cece26aa6e35b39e5b6ca007b9b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc0d2e9-75ac-4e53-bad0-6486d04930fd", "node_type": "1", "metadata": {}, "hash": "be38b4fede731340b0e1e3ff68670993c6004004a944a6e06cea718b0dd5378b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "scatteringmethodsforthedeterminationoftheFloryparameterchiand\nS 18 KhanKA,RhodesCT.Water-sorptionpropertiesoftabletdisintegrants. thecrosslinkdensityofapowderedpolymericgel.FluidPhaseEquilib\nJPharmSci1975;64:447\u2013451. 2000;167(1):63\u201381.\n19 WanLSC,PrasadKPP.Uptakeofwaterbyexcipientsintablets.IntJ MendellE.Anevaluationofcarboxymethylstarchasatabletdisintegrant.\nPharm1989;50:147\u2013153. PharmActaHelv1974;49:248\u2013250.\n20 Thibert R, Hancock BC. Direct visualization of superdisintegrant RoquetteFre`res.Technicalliterature:Glycolys,2008.\nhydrationusingenvironmentalscanningelectronmicroscopy.JPharm Shah U, Augsburger L. Multiple sources of sodium starch glycolate NF:\nSci1996;85:1255\u20131258. evaluation of functional equivalence and development of standard\n21 DanckwertsMPetal.Pharmaceuticalformulationofafixed-doseanti- performancetests.PharmDevTech2002;7(3):345\u2013359.\ntuberculosiscombination.IntJTubercLungD2003;7:289\u2013297.\nYoung PM et al. Interaction of moisture with sodium starch glycolate.\n22 Horhota ST et al. Effect of storage at specified temperature and PharmDevTech2007;12:211\u2013216.\nhumidityonpropertiesofthreedirectlycompressibletabletformula- Young PM et al. The effect of moisture on the compressibility and\ntions.JPharmSci1976;65:1746\u20131749. compactabilityofsodiumstarchglycolates.PharmDevTech2007;12:\n23 Sheen P-C, Kim S-I. Comparative study of disintegrating agents in 217\u2013222.\ntiaramide hydrochloride tablets. Drug Dev Ind Pharm 1989; 15(3):\n401\u2013414.\n21 Author\n24 Gordon MS, Chowhan ZT. The effect of aging on disintegrant\nefficiency in direct compression tablets with varied solubility and PMYoung.\nhygroscopicity, in terms of dissolution. Drug Dev Ind Pharm 1990;\n16(3):437\u2013447.\n22 DateofRevision\n25 Botha SA et al. DSC screening for drug\u2013excipient and excipient\u2013\nexcipientinteractionsinpolypharmaceuticalsintendedfortheallevia- 3February2009.\n\n\n\ud83d\udcca Tables on Page 6:\n\n\nTable 1 (16 rows \u00d7 7 columns):\n\n| No. | Authors                                      | Title                                                                                                           | Journal                          | Year | Volume | Pages         |\n|-----|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------------|------|--------|---------------|\n| 2   | Stewart AG et al.                           | The release of a model low-dose drug (riboflavine) from hard gelatin capsule formulations.                     | J Pharm Pharmacol               | 1979 | 31     | 1\u20136           |\n| 3   | Chowhan ZT, Chi L-H.                        | Drug\u2013excipient interactions resulting from powder mixing III: solid state properties and their effect on drug dissolution. | J Pharm Sci                     | 1986 | 75     | 534\u2013541       |\n| 4   | Botzolakis JE, Augsburger LL.              | Disintegrating agents in hard gelatin capsules part 1: mechanism of action.                                   | Drug Dev Ind Pharm              | 1988 | 14(1)  | 29\u201341         |\n| 5   | Hannula A-M et al.                          | Release of ibuprofen from hard gelatin capsule formulations: effect of modern disintegrants.                   | Acta Pharm Fenn                 | 1989 |        |               |\n| 26  | Bolhuis GK et al.                           | On the similarity of sodium starch glycolate from different sources.                                           | Drug Dev Ind Pharm              | 1986 | 12(4)  | 621\u2013630       |\n| 27  | Rudnic EM et al.                            | Effect of molecular structure variation on the disintegrant action of sodium starch glycolate.", "mimetype": "text/plain", "start_char_idx": 41475, "end_char_idx": 45179, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4dc0d2e9-75ac-4e53-bad0-6486d04930fd": {"__data__": {"id_": "4dc0d2e9-75ac-4e53-bad0-6486d04930fd", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cfe3ab9-bdeb-476e-82e1-c8b418129cfb", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "84599b8f2f9a677597cb11669b12de79b169655b1ea3742abe59077762a3d3db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57943517-b07b-44b9-89ed-1744fc90e8c6", "node_type": "1", "metadata": {}, "hash": "1f170c060c223c24cde2592f6ed05456c5e8c9bafa3c4e4d562d006cd24c026a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Disintegrating agents in hard gelatin capsules part 1: mechanism of action.                                   | Drug Dev Ind Pharm              | 1988 | 14(1)  | 29\u201341         |\n| 5   | Hannula A-M et al.                          | Release of ibuprofen from hard gelatin capsule formulations: effect of modern disintegrants.                   | Acta Pharm Fenn                 | 1989 |        |               |\n| 26  | Bolhuis GK et al.                           | On the similarity of sodium starch glycolate from different sources.                                           | Drug Dev Ind Pharm              | 1986 | 12(4)  | 621\u2013630       |\n| 27  | Rudnic EM et al.                            | Effect of molecular structure variation on the disintegrant action of sodium starch glycolate.                  | J Pharm Sci                     | 1985 | 74     | 647\u2013650       |\n| 28  | Bolhuis GK et al.                           | Effect of variation of degree of substitution, crosslinking and purity on the disintegrant efficiency of sodium starch glycolate. | Acta Pharm Technol              | 1984 | 30     | 24\u201332         |\n| 29  | Claudius JS, Neau SH.                       | Kinetic and equilibrium characterization of interactions between glycopeptide antibiotics and sodium carboxymethyl starch. | Int J Pharm                     | 1996 | 144    | 71\u201379         |\n| 30  | Claudius JS, Neau SH.                       | The solution stability of vancomycin in the presence and absence of sodium carboxymethyl starch.                | Int J Pharm                     | 1998 | 168    | 41\u201348         |\n| 31  | Cordoba-Borrego M et al.                    | Validation of a high performance liquid chromatographic method for the determination of norfloxacin and its application to stability studies (photostability study of norfloxacin). | J Pharm Biomed Anal             | 1999 | 18     | 919\u2013926       |\n| 32  | Gordon MS et al.                            | Effect of the mode of super disintegrant incorporation on dissolution in wet granulated tablets.                | J Pharm Sci                     | 1993 | 82     | 220\u2013226       |\n| 33  | Japanese Pharmaceutical Excipients Council. | Japanese Pharmaceutical Excipients.                                                                            |                                  | 2004 |        | 774           |\n| 11  | Cid E, Jaminet F.                           | [Influence of adjuvants on the dissolution rate and stability of acetylsalicylic acid in compressed tablets.]   | J Pharm Belg                    | 1971 | 26     | 38\u201348         |\n| 12  | Gordon MS, Chowhan ZT.                      | Effect of tablet solubility and hygroscopicity on disintegrant efficiency in direct compression tablets in terms of dissolution. | J Pharm Sci                     | 1987 | 76     | 907\u2013909       |\n| 13  | Cordoba-Diaz M et al.                       | Influence of pharmacotechnical design on the interaction and availability of norfloxacin in directly compressed tablets with certain antacids. | Drug Dev Ind Pharm              | 2000 | 26     | 159\u2013166       |\n| 14  | Sekulovic D et al.                          | The investigation of the influence of Explotab on the disintegration of tablets.                               | Pharmazie                       | 1986 | 41     | 153\u2013154       |\n| 15  | Bolhius GK et al.                           | Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. Part 2. Choice of super disintegrants and effect of granulation. | Eur J Pharm Sci                 | 1997 | 5(2)   | 63\u201369         |\n| 20  | General References                           | Superdisintegrants: characterisation and function.                                                             |                                  | 2007 |        | 2553\u20132567     |\n| 24  | Gordon MS, Chowhan ZT.                      | The effect of aging on disintegrant efficiency in direct compression tablets with varied solubility and hygroscopicity, in terms of dissolution. | Drug Dev Ind Pharm              | 1990 | 16(3)  | 437\u2013447       |\n| 25  | Botha SA et al.", "mimetype": "text/plain", "start_char_idx": 44385, "end_char_idx": 48557, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "57943517-b07b-44b9-89ed-1744fc90e8c6": {"__data__": {"id_": "57943517-b07b-44b9-89ed-1744fc90e8c6", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc0d2e9-75ac-4e53-bad0-6486d04930fd", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "f17cf592e85d42d8d537f6c623ad6f741237491d2bc12400e0f3ef56acfaafe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5", "node_type": "1", "metadata": {}, "hash": "aeb3d1051eb6f87e418cd4154760c1f027cc53155eddb1e32953098c4851d73f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. Part 2. Choice of super disintegrants and effect of granulation. | Eur J Pharm Sci                 | 1997 | 5(2)   | 63\u201369         |\n| 20  | General References                           | Superdisintegrants: characterisation and function.                                                             |                                  | 2007 |        | 2553\u20132567     |\n| 24  | Gordon MS, Chowhan ZT.                      | The effect of aging on disintegrant efficiency in direct compression tablets with varied solubility and hygroscopicity, in terms of dissolution. | Drug Dev Ind Pharm              | 1990 | 16(3)  | 437\u2013447       |\n| 25  | Botha SA et al.                             | DSC screening for drug\u2013excipient and excipient\u2013excipient interactions in polypharmaceuticals intended for the alleviation of the symptoms of colds and flu. |                                  |      |        |               |\n\n\n\n--- Page 7 ---\n\nSodium Stearyl Fumarate\n1 NonproprietaryNames SEM1: Excipient:sodiumstearylfumarate;manufacturer:JRSPharmaLP;\nlotno.:255-01;magnification:300(cid:3).\nBP:SodiumStearylFumarate\nPhEur:SodiumStearylFumarate\nUSP-NF:SodiumStearylFumarate\n2 Synonyms\nFumaricacid,octadecylester,sodiumsalt;natriistearylisfumaras;\nPruv;sodiummonostearylfumarate.\n3 ChemicalNameandCASRegistryNumber\n2-Butenedioicacimd,onooctadecylester,sodiumsalt [4070-80-8]\n4 EmpiricalFormulaandMolecularWeight\nC H NaO 390.5\n22 39 4\n5 StructuralFormula\nSEM2: Excipient:sodiumstearylfumarate;manufacturer:JRSPharmaLP;\nlotno.:255-01;magnification:500(cid:3).\n6 FunctionalCategory\nTabletandcapsulelubricant.\n7 Applications in Pharmaceutical Formulation or\nTechnology\nSodiumstearylfumarateisusedasalubricantincapsuleandtablet S\nformulationsat0.5\u20132.0%w/wconcentration.(1\u20139)Itisalsousedin\ncertainfoodapplications;seeSection16.\n8 Description\nSodiumstearylfumarateisafine,whitepowderwithagglomerates\nofflat,circular-shapedparticles.\n9 PharmacopeialSpecifications\nSeeTableI.\nTableI: Pharmacopeialspecificationsforsodiumstearylfumarate.\nTest PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe\nCharacters \u00fe \u2014\nWater 45.0% 45.0%\nLead \u2014 40.001%\nHeavymetals \u2014 40.002% 10 TypicalProperties\nRelatedsubstances 45.0% \u2014\nSodiumstearylmaleate \u2014 40.25% Acidity/alkalinity pH = 8.3 for a 5% w/v aqueous solution at\nStearylalcohol \u2014 40.5% 908C.\nSaponificationvalue \u2014 142.2\u2013146.0 Density 1.107g/cm3\n(anhydrousbasis) Density(bulk) 0.2\u20130.35g/cm3\nAssay(anhydrousbasis) 99.0\u2013101.5% 99.0\u2013101.5% Density(tapped) 0.3\u20130.5g/cm3\n667\n\n--- Page 8 ---\n\n668 Sodium Stearyl Fumarate\nSEM3: Excipient:sodiumstearylfumarate;manufacturer:JRSPharmaLP; stearyl alcohol and fumaric acid, with the stearyl alcohol further\nlotno.:255-01;magnification:1000(cid:3).\noxidized to stearic acid. In the dog, sodium stearyl fumarate that\nwas not absorbed was excreted unchanged in the feces within 24\nhours.", "mimetype": "text/plain", "start_char_idx": 47801, "end_char_idx": 50728, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5": {"__data__": {"id_": "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57943517-b07b-44b9-89ed-1744fc90e8c6", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "364844eb2caec2bd9353476e1a304b1b6c96cac7fb734d6edbb5f9ff4410aba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ff8e6b-6789-4f9d-ba01-ac8238c65d95", "node_type": "1", "metadata": {}, "hash": "212c5457bef5115b91051a234590ff8adc6bde692e718a6dbfe88c3586939f28", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Saponificationvalue \u2014 142.2\u2013146.0 Density 1.107g/cm3\n(anhydrousbasis) Density(bulk) 0.2\u20130.35g/cm3\nAssay(anhydrousbasis) 99.0\u2013101.5% 99.0\u2013101.5% Density(tapped) 0.3\u20130.5g/cm3\n667\n\n--- Page 8 ---\n\n668 Sodium Stearyl Fumarate\nSEM3: Excipient:sodiumstearylfumarate;manufacturer:JRSPharmaLP; stearyl alcohol and fumaric acid, with the stearyl alcohol further\nlotno.:255-01;magnification:1000(cid:3).\noxidized to stearic acid. In the dog, sodium stearyl fumarate that\nwas not absorbed was excreted unchanged in the feces within 24\nhours.(11)\nStearyl alcohol and stearic acid are naturally occurring\nconstituents in various food products, while fumaric acid is a\nnormalconstituentofbodytissue.Stearatesandstearylcitratehave\nbeen reviewed by the WHO and an acceptable daily intake for\nstearylcitratehasbeensetatupto50mg/kgbody-weight.(12)The\nestablishment of an acceptable daily intake for stearates(12) and\nfumaricacid(13)wasthoughtunnecessary.\nDisodium fumarate has been reported to have a toxicity not\ngreatlyexceedingthatofsodiumchloride.(14,15)\nSeeFumaricAcid,StearicAcid,andStearylAlcoholforfurther\ninformation.\n15 HandlingPrecautions\nObservenormalprecautionsappropriatetothecircumstancesand\nquantity of material handled. Sodium stearyl fumarate should be\nhandled in a well-ventilated environment; eye protection is\nrecommended.\n16 RegulatoryStatus\nGRASlisted.PermittedbytheFDAfordirectadditiontofoodfor\nhuman consumption as a conditioning or stabilizing agent in\nvarious bakery products, flour-thickened foods, dehydrated pota-\nMeltingpoint 224\u20132458C(withdecomposition) toes,andprocessedcerealsupto0.2\u20131.0%byweightofthefood.\nSolubility seeTableII. IncludedinnonparenteralmedicineslicensedintheUK.Includedin\nSpecificsurfacearea 1.2\u20132.0m2/g theFDAInactiveIngredientsDatabase(oralcapsulesandtablets).\nIncluded in the Canadian List of Acceptable Non-medicinal\nTableII: Solubilityofsodiumstearylfumarate. Ingredients.\nSolvent Solubilityat208Cunlessotherwisestated 17 RelatedSubstances\nAcetone Practicallyinsoluble \u2014\nChloroform Practicallyinsoluble\nEthanol Practicallyinsoluble\n18 Comments\nMethanol Slightlysoluble\nWater 1in20000at258C Sodiumstearylfumarateissuppliedinapureformandisoftenof\n1in10at808C\nvalue when the less pure stearate-type lubricants are unsuitable\n1in5at908C\nowingtochemicalincompatibility.Sodiumstearylfumarateisless\nhydrophobicthanmagnesiumstearateorstearicacidandhasaless\nS\nretardanteffectontabletdissolutionthanmagnesiumstearate.\n11 StabilityandStorageConditions A specification forsodium stearyl fumarate is containedinthe\nFoodChemicalsCodex(FCC).(16)\nAtambienttemperature,sodiumstearylfumarateisstableforupto\nTheEINECSnumberforsodiumstearylfumarateis223-781-1.\n3yearswhenstoredinamberglassbottleswithpolyethylenescrew\nThePubChemCompoundID(CID)forsodiumstearylfumarateis\ncaps.\n23665634.\nThebulkmaterialshouldbestoredinawell-closedcontainerina\ncool,dryplace.\n19 SpecificReferences\n12 Incompatibilities 1 Sure\u00b4nG.Evaluationoflubricantsinthedevelopmentoftabletformula.\nDanskTidsskrFarm1971;45:331\u2013338.", "mimetype": "text/plain", "start_char_idx": 50198, "end_char_idx": 53213, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "56ff8e6b-6789-4f9d-ba01-ac8238c65d95": {"__data__": {"id_": "56ff8e6b-6789-4f9d-ba01-ac8238c65d95", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63b9d5c1-4617-4d35-8beb-fc11bd0ff3f5", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d71082fbfb56fe53dfa4685d189da2fd01c54e57f78f982b46a31042bb6e718b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bd23122-a402-4b2c-ba33-cce5bbec1ed9", "node_type": "1", "metadata": {}, "hash": "11feea713a9e86d8401002e6e6b9c7d5bee658e8987833a44cc03cfc7bc709a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11 StabilityandStorageConditions A specification forsodium stearyl fumarate is containedinthe\nFoodChemicalsCodex(FCC).(16)\nAtambienttemperature,sodiumstearylfumarateisstableforupto\nTheEINECSnumberforsodiumstearylfumarateis223-781-1.\n3yearswhenstoredinamberglassbottleswithpolyethylenescrew\nThePubChemCompoundID(CID)forsodiumstearylfumarateis\ncaps.\n23665634.\nThebulkmaterialshouldbestoredinawell-closedcontainerina\ncool,dryplace.\n19 SpecificReferences\n12 Incompatibilities 1 Sure\u00b4nG.Evaluationoflubricantsinthedevelopmentoftabletformula.\nDanskTidsskrFarm1971;45:331\u2013338.\nSodium stearyl fumarate is reported to be incompatible with\n2 Ho\u00a8lzerAW,Sjo\u00a8grenJ.Evaluationofsodiumstearylfumarateasatablet\nchlorhexidineacetate.(10)\nlubricant.IntJPharm1979;2:145\u2013153.\n3 Ho\u00a8lzerAW,Sjo\u00a8grenJ.Evaluationofsomelubricantsbythecomparison\n13 MethodofManufacture offrictioncoefficientsandtabletproperties.ActaPharmSuec1981;18:\n139\u2013148.\nStearylalcoholisreactedwithmaleicanhydride.Theproductofthis\n4 SalehSIetal.Evaluationofsomewatersolublelubricantsfordirect\nreaction then undergoes an isomerization step followed by salt compression.LabPharmProbTech1984;32:588\u2013591.\nformationtoproducesodiumstearylfumarate.\n5 Chowhan ZT, Chi L-H. Drug\u2013excipient interactions resulting from\npowder mixing IV: role of lubricants and their effect on in vitro\n14 Safety dissolution.JPharmSci1986;75:542\u2013545.\n6 ShahNHetal.Evaluationoftwonewtabletlubricantssodiumstearyl\nSodium stearyl fumarate is used in oral pharmaceutical formula-\nfumarateandglycerylbehenate.Measurementofphysicalparameters\ntions and is generally regarded as a nontoxic and nonirritant\n(compaction,ejectionandresidualforces)inthetabletingprocessand\nmaterial. theeffectonthedissolutionrate.DrugDevIndPharm1986;12:1329\u2013\nMetabolicstudiesofsodiumstearylfumarateintheratanddog 1346.\nindicated that approximately 80% was absorbed and 35% was 7 DaviesPNetal.Somepitfallsinacceleratedstabilitytestingwithtablet\nrapidly metabolized. The fraction absorbed was hydrolyzed to andcapsulelubricants.JPharmPharmacol1987;39:86P.\n\n\n\ud83d\udcca Tables on Page 8:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Solvent              | Solubility at 20\u00b0C unless otherwise stated |\n|---------------------|--------------------------------------------|\n| Acetone             | Practically insoluble                      |\n| Chloroform          | Practically insoluble                      |\n| Ethanol             | Practically insoluble                      |\n| Methanol            | Slightly soluble                           |\n| Water               | 1 in 20,000 at 25\u00b0C                       |\n|                     | 1 in 10 at 80\u00b0C                           |\n|                     | 1 in 5 at 90\u00b0C                            |\n\n\n\n--- Page 9 ---\n\nSodium Sulfite 669\n8 Mu X et al. Investigations into the food effect on a polysaccharide 16 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\ndosageform.EurJPharmSci1996;4(Suppl.1):S184. Pharmacopeia,2008;912.\n9 MichoelAetal.Comparativeevaluationofco-processedlactoseand\nmicrocrystallinecellulosewiththeirphysicalmixturesintheformula-\ntionoffolicacidtablets.PharmDevTechnol2002;7(1):79\u201387.\n20 GeneralReferences\n10 PesonenTetal.Incompatibilitiesbetweenchlorhexidinediacetateand\nsometabletexcipients.DrugDevIndPharm1995;21:747\u2013752.", "mimetype": "text/plain", "start_char_idx": 52644, "end_char_idx": 55916, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5bd23122-a402-4b2c-ba33-cce5bbec1ed9": {"__data__": {"id_": "5bd23122-a402-4b2c-ba33-cce5bbec1ed9", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ff8e6b-6789-4f9d-ba01-ac8238c65d95", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "78cc2e3b6153620833a4d0380d108665038d14093eedc32d74dabc9778e23c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369af8e5-326a-4397-84dc-77719cdbc4cc", "node_type": "1", "metadata": {}, "hash": "cdcd691cbf25483bb17340296d815bc9c143ecc52e799ad0f677eaa446447e88", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 9 ---\n\nSodium Sulfite 669\n8 Mu X et al. Investigations into the food effect on a polysaccharide 16 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\ndosageform.EurJPharmSci1996;4(Suppl.1):S184. Pharmacopeia,2008;912.\n9 MichoelAetal.Comparativeevaluationofco-processedlactoseand\nmicrocrystallinecellulosewiththeirphysicalmixturesintheformula-\ntionoffolicacidtablets.PharmDevTechnol2002;7(1):79\u201387.\n20 GeneralReferences\n10 PesonenTetal.Incompatibilitiesbetweenchlorhexidinediacetateand\nsometabletexcipients.DrugDevIndPharm1995;21:747\u2013752. NicklassonM,BrodinA.Thecoatingofdisksurfacesbytabletlubricants,\n11 Figdor SK, Pinson R. The absorption and metabolism of orally determinedbyanintrinsicrateofdissolutionmethod.ActaPharmSuec\nadministered tritium labelled sodium stearyl fumarate in the rat and 1982;19:99\u2013108.\ndog.JAgricFoodChem1970;18(5):872\u2013877. Zanowiak P. Lubrication in solid dosage form design and manufacture.\n12 FAO/WHO.Toxicologicalevaluationofcertainfoodadditiveswitha SwarbrickJ,BoylanJC,eds.EncyclopediaofPharmaceuticalTechnol-\nreviewofgeneralprinciplesandofspecifications.Seventeenthreportof ogy.,vol.9: NewYork:MarcelDekker,1994;87\u2013111.\nthejointFAO/WHOexpertcommitteeonfoodadditives.WorldHealth\nOrganTechRepSer1974;No.539.\n13 FAO/WHO. Evaluation of certain food additives and contaminants.\n21 Author\nThirty-fifth report of the FAO/WHO expert committee on food\nadditives.WorldHealthOrganTechRepSer1990;No.789. PJWeller.\n14 BodanskyOetal.Thetoxicityandlaxativeactionofsodiumfumarate.\nJAmPharmAssoc(Sci)1942;31:1\u20138.\n15 Locke A et al. The comparative toxicity and cathartic efficiency of\n22 DateofRevision\ndisodium tartrate and fumarate, and magnesium fumarate, for the\nmouseandrabbit.JAmPharmAssoc(Sci)1942;31:12\u201314. 16January2009.\nSodium Sulfite\n1 NonproprietaryNames 8 Description\nBP:AnhydrousSodiumSulphite Sodium sulfite occurs as an odorless white powder or hexagonal\nJP:DriedSodiumSulfite prisms.Notethatthecommerciallyavailablesodiumsulfiteisoften\npresentedasawhitetotan-orpink-coloredpowderthatwouldnot\nPhEur:SodiumSulphite,Anhydrous\nconformtothepharmacopeialspecification.\nUSP-NF:SodiumSulfite\n9 PharmacopeialSpecifications\n2 Synonyms\nSeeTableI.\nDisodium sulfite; exsiccated sodium sulfite; E221; natrii sulfis\nanhydricus;sulfurousaciddisodiumsalt.\nTableI: Pharmacopeialspecificationsforsodiumsulfite. S\n3 ChemicalNameandCASRegistryNumber Test JPXV PhEur6.0 USP32\u2013NF27\nSodiumsulfite [7757-83-7] Characters \u00fe \u00fe \u2014\nIdentification \u00fe \u00fe \u00fe\nAppearanceof \u2014 \u00fe \u00fe\n4 EmpiricalFormulaandMolecularWeight\nsolution\nNa 2 SO 3 126.04 Heavymetals 420ppm 410ppm 410mg/g\nArsenic 44ppm \u2014 \u2014\nIron \u2014 410ppm 410mg/g\n5 StructuralFormula\nSelenium \u2014 410ppm 410mg/g\nSeeSection4. Thiosulfates \u00fe 40.1% 40.1%\nZinc \u2014 425ppm 425mg/g\nAssay 597% 95.0\u2013100.5% 95.0\u2013100.5%\n6 FunctionalCategory\nAntimicrobialpreservative;antioxidant.", "mimetype": "text/plain", "start_char_idx": 55362, "end_char_idx": 58192, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "369af8e5-326a-4397-84dc-77719cdbc4cc": {"__data__": {"id_": "369af8e5-326a-4397-84dc-77719cdbc4cc", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bd23122-a402-4b2c-ba33-cce5bbec1ed9", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "4e8a8a1eeef5a01a131f09d8a6ccb971fc6f8ea6c06c226b3e0dbe459e28431a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9", "node_type": "1", "metadata": {}, "hash": "f69536c392a1a07238972d4e301bd9cb6bb19ddfa7f6de8c7a6f5c4033d9e7bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "S\n3 ChemicalNameandCASRegistryNumber Test JPXV PhEur6.0 USP32\u2013NF27\nSodiumsulfite [7757-83-7] Characters \u00fe \u00fe \u2014\nIdentification \u00fe \u00fe \u00fe\nAppearanceof \u2014 \u00fe \u00fe\n4 EmpiricalFormulaandMolecularWeight\nsolution\nNa 2 SO 3 126.04 Heavymetals 420ppm 410ppm 410mg/g\nArsenic 44ppm \u2014 \u2014\nIron \u2014 410ppm 410mg/g\n5 StructuralFormula\nSelenium \u2014 410ppm 410mg/g\nSeeSection4. Thiosulfates \u00fe 40.1% 40.1%\nZinc \u2014 425ppm 425mg/g\nAssay 597% 95.0\u2013100.5% 95.0\u2013100.5%\n6 FunctionalCategory\nAntimicrobialpreservative;antioxidant.\n10 TypicalProperties\n7 Applications in Pharmaceutical Formulation or\nTechnology Acidity/alkalinity pH=9foranaqueoussolution.\nDensity 2.633g/cm3\nSodiumsulfite is usedasanantioxidantinapplications similarto\nthoseforsodiummetabisulfite.(1)Itisalsoaneffectiveantimicrobial Hygroscopicity Hygroscopic.\nSolubility Soluble 1 in 3.2 parts of water; soluble in glycerin;\npreservative, particularly against fungi at low pH (0.1% w/v of\npracticallyinsolubleinethanol(95%).\nsodium sulfite is used). Sodium sulfite is used in cosmetics, food\nproducts, and pharmaceutical applications such as parenteral\nformulations, inhalations, oral formulations, and topical prepara- 11 StabilityandStorageConditions\ntions. Sodiumsulfiteshouldbestoredinawell-closedcontainerinacool,\nSeealsoSodiumMetabisulfite. dry,place.Insolution,sodiumsulfiteisslowlyoxidizedtosulfateby\n\n\n\ud83d\udcca Tables on Page 9:\n\n\nTable 1 (1 rows \u00d7 2 columns):\n\n| **Sodium Sulfite** | 66 9 |\n|--------------------|------|\n| **1 Nonproprietary Names** | BP: Anhydrous Sodium Sulphite\n\n\n\n--- Page 10 ---\n\n670 Sodium Sulfite\ndissolvedoxygen;strongacidsleadtoformationofsulfurousacid/ Sodiumsulfiteheptahydrate\nsulfur dioxide. On heating, sodium sulfite decomposes liberating Synonyms Natriisulfisheptahydricus\nsulfuroxides. CASnumber [7785-83-7]\nMolecularweight 252.15\n12 Incompatibilities Description Colorlesscrystals.\nDensity 1.56g/cm3\nSodium sulfite is incompatible with acids, oxidizing agents, many\nSolubility 1in1.6ofwater;1in30ofglycerin;sparinglysoluble\nproteins,andvitaminB .\n1 inethanol(95%).\nSeealsoSodiumMetabisulfite.\nComments SodiumsulfiteheptahydrateisincludedinthePhEur\n6.0. The heptahydrate is unstable, oxidizing in the air to the\n13 MethodofManufacture\nsulfate.\nSodium bisulfite is prepared by reacting sulfur dioxide gas with\nsodium hydroxide solution. The solid material is obtained by 18 Comments\nevaporationofwater.Furtherneutralizationwithsodiumhydroxide\nwhilekeepingthetemperatureabove33.68Cleadstocrystallization A specification for sodium sulfite is contained in the Food\nChemicalsCodex(FCC).(8)\nof the anhydrous sodium sulfite (below this temperature the\nheptahydrateformisobtained). The EINECS number for sodium sulfite is 231-821-4. The\nPubChemCompoundID(CID)forsodiumsulfiteis24437.\n14 Safety\n19 SpecificReferences\nSodium sulfite is widely used in food and pharmaceutical\napplicationsasanantioxidant.Itisgenerallyregardedasrelatively 1 IslamMSetal.Photoprotectionofdaunorubicinhydrochloridewith\nnontoxicandnonirritantwhenusedasanexcipient.", "mimetype": "text/plain", "start_char_idx": 57703, "end_char_idx": 60700, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9": {"__data__": {"id_": "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369af8e5-326a-4397-84dc-77719cdbc4cc", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "8ca23549f6a37eb537ff5b2014f4b78c3007e3c94f6f9dc18de06e9c2bb3478e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24953b70-dd6d-497d-bd0f-e6abe76c2779", "node_type": "1", "metadata": {}, "hash": "8cf3b45d64ee33425f52d4a0e4eb9ae94f98eae8c95f1e3372aad0e3ba9b109e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The solid material is obtained by 18 Comments\nevaporationofwater.Furtherneutralizationwithsodiumhydroxide\nwhilekeepingthetemperatureabove33.68Cleadstocrystallization A specification for sodium sulfite is contained in the Food\nChemicalsCodex(FCC).(8)\nof the anhydrous sodium sulfite (below this temperature the\nheptahydrateformisobtained). The EINECS number for sodium sulfite is 231-821-4. The\nPubChemCompoundID(CID)forsodiumsulfiteis24437.\n14 Safety\n19 SpecificReferences\nSodium sulfite is widely used in food and pharmaceutical\napplicationsasanantioxidant.Itisgenerallyregardedasrelatively 1 IslamMSetal.Photoprotectionofdaunorubicinhydrochloridewith\nnontoxicandnonirritantwhenusedasanexcipient.(2,3)However,\nsodiumsulfite.PDAJPharmSciTechnol1995;49:122\u2013126.\n2 NairB,ElmoreAR.Finalreportonthesafetyassessmentofsodium\ncontact dermatitis and hypersensitivity reactions have been\nreported.(4,5) The acceptable daily intake for sodium sulfite has sulfite,potassiumsulfite,ammoniumsulfite,sodiumbisulfite,ammo-\nniumbisulfite,sodiummetabisulfiteandpotassiummetabisulfite.IntJ\nbeensetatupto350mg/kgbody-weightdaily.(6)\nToxicol2003;22(2):63\u201388.\nLD (mouse,IP):0.950g/kg(7) 3 GunnissonAF.Sulphitetoxicity:acriticalreviewofinvitroandinvivo\n50 data.FoodCosmetToxicol1981;19:667\u2013682.\nLD (mouse,IV):0.130g/kg\n50 4 Vissers-Croughs KJ et al. Allergic contact dermatitis from sodium\nLD\n50\n(mouse,oral):0.820g/kg sulfite.ContactDermatitis1988;18(4):252\u2013253.\nLD (rabbit,IV):0.065g/kg 5 GunnissonAF,JacobsenDW.Sulphitehypersensitivity:acriticalreview.\n50\nLD (rabbit,oral):1.181g/kg\nCRCCritReviewToxicol1987;17(3):185\u2013214.\n50 6 FAO/WHO. Evaluation of certain food additives and contaminants.\nLD (rat,IV):0.115g/kg\n50 Thirtieth report of the joint FAO/WHO expert committee on food\nadditives.WorldHealthOrganTechRepSer 1987:No.751.\n15 HandlingPrecautions 7 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;3281\u20133282.\nObservenormalprecautionsappropriatetothecircumstancesand\n8 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nquantityofmaterialhandled.\nPharmacopeia,2008;913.\n16 RegulatoryStatus\n20 GeneralReferences\nGRAS listed. Accepted for use as a food additive in Europe.\n\u2014\nIncluded in FDA Inactive Ingredients Database (epidural, IM, IV,\nS and SC injections; inhalation solution; ophthalmic solutions; oral\n21 Author\nsyrups and suspensions; otic solutions; topical creams and emul-\nsions).IncludedinnonparenteralmedicineslicensedintheUK. HJdeJong.\n17 RelatedSubstances 22 DateofRevision\nSodiumsulfiteheptahydrate;sodiummetabisulfite. 14January2009.\n\n\n\ud83d\udcca Tables on Page 10:\n\n\nTable 1 (11 rows \u00d7 2 columns):\n\n| Section | Content                                                                                                           |\n|---------|-------------------------------------------------------------------------------------------------------------------|\n| 12      | Incompatibilities                                                                                                 |\n|         | Sodium sulfite is incompatible with acids, oxidizing agents, many proteins, and vitamin B\u2081.                      |\n|         | See also Sodium Metabisulfite.                                                                                   |\n| 13      | Method of Manufacture                                                                                             |\n|         | Sodium bisulfite is prepared by reacting sulfur dioxide gas with sodium hydroxide solution. The solid material is obtained by evaporation of water.", "mimetype": "text/plain", "start_char_idx": 60003, "end_char_idx": 63565, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "24953b70-dd6d-497d-bd0f-e6abe76c2779": {"__data__": {"id_": "24953b70-dd6d-497d-bd0f-e6abe76c2779", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8825cdb3-c6ba-47d1-bb81-0d2cb96497b9", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "25e84ecb724e81c61350d48c7365e48fb6ed6b919069f898ab65f1d01cd6368a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "509f0931-9b11-4161-add4-a872838696af", "node_type": "1", "metadata": {}, "hash": "fbe6163534cb55738e1bc522508836d51aa1e0ace51e1a9cd60b3da0ea559e00", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HJdeJong.\n17 RelatedSubstances 22 DateofRevision\nSodiumsulfiteheptahydrate;sodiummetabisulfite. 14January2009.\n\n\n\ud83d\udcca Tables on Page 10:\n\n\nTable 1 (11 rows \u00d7 2 columns):\n\n| Section | Content                                                                                                           |\n|---------|-------------------------------------------------------------------------------------------------------------------|\n| 12      | Incompatibilities                                                                                                 |\n|         | Sodium sulfite is incompatible with acids, oxidizing agents, many proteins, and vitamin B\u2081.                      |\n|         | See also Sodium Metabisulfite.                                                                                   |\n| 13      | Method of Manufacture                                                                                             |\n|         | Sodium bisulfite is prepared by reacting sulfur dioxide gas with sodium hydroxide solution. The solid material is obtained by evaporation of water. Further neutralization with sodium hydroxide while keeping the temperature above 33.68C leads to crystallization of the anhydrous sodium sulfite (below this temperature the heptahydrate form is obtained). |\n|         | Sodium sulfite heptahydrate                                                                                      |\n|         | Synonyms: Natrii sulfis heptahydricus                                                                             |\n|         | CAS number: [7785-83-7]                                                                                          |\n|         | Molecular weight: 252.15                                                                                         |\n|         | Description: Colorless crystals.                                                                                  |\n|         | Density: 1.56 g/cm\u00b3                                                                                               |\n|         | Solubility: 1 in 1.6 of water; 1 in 30 of glycerin; sparingly soluble in ethanol (95%).                          |\n|         | Comments: Sodium sulfite heptahydrate is included in the PhEur 6.0. The heptahydrate is unstable, oxidizing in the air to the sulfate. |\n| 18      | Comments                                                                                                          |\n|         | A specification for sodium sulfite is contained in the Food Chemicals Codex (FCC).(8)                           |\n|         | The EINECS number for sodium sulfite is 231-821-4. The PubChem Compound ID (CID) for sodium sulfite is 24437.    |\n| 14      | Safety                                                                                                           |\n|         | Sodium sulfite is widely used in food and pharmaceutical applications as an antioxidant. It is generally regarded as relatively nontoxic and nonirritant when used as an excipient.(2,3) However, contact dermatitis and hypersensitivity reactions have been reported.(4,5) The acceptable daily intake for sodium sulfite has been set at up to 350 mg/kg body-weight daily.(6) |\n|         | LD\u2085\u2080 (mouse, IP): 0.950 g/kg(7)                                                                                  |\n|         | LD\u2085\u2080 (mouse, IV): 0.130 g/kg                                                                                     |\n|         | LD\u2085\u2080 (mouse, oral): 0.820 g/kg                                                                                   |\n|         | LD\u2085\u2080 (rabbit, IV): 0.065 g/kg                                                                                    |\n|         | LD\u2085\u2080 (rabbit, oral): 1.181 g/kg                                                                                  |\n|         | LD\u2085\u2080 (rat, IV): 0.115 g/kg                                                                                       |\n| 15      | Handling Precautions                                                                                              |\n|         | Observe normal precautions appropriate to the circumstances and quantity of material handled.                     |\n| 16      | Regulatory Status                                                                                                |\n|         | GRAS listed. Accepted for use as a food additive in Europe.                                                      |\n|         | Included in FDA Inactive Ingredients Database (epidural, IM, IV, and SC injections; inhalation solution; ophthalmic solutions; oral syrups and suspensions; otic solutions; topical creams and emulsions). Included in nonparenteral medicines licensed in the UK. |\n| 17      | Related Substances                                                                                                 |\n|         | Sodium sulfite heptahydrate; sodium metabisulfite.                                                               |\n| 19      | Specific References                                                                                               |\n|         | 1. Islam MS et al. Photoprotection of daunorubicin hydrochloride with sodium sulfite. PDA J Pharm Sci Technol 1995; 49: 122\u2013126. |\n|         | 2. Nair B, Elmore AR.", "mimetype": "text/plain", "start_char_idx": 62472, "end_char_idx": 67811, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "509f0931-9b11-4161-add4-a872838696af": {"__data__": {"id_": "509f0931-9b11-4161-add4-a872838696af", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24953b70-dd6d-497d-bd0f-e6abe76c2779", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "f11c55353475ade43d570bf75502f4c461a613ed903ec54df2a4da53ec502026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a02c0572-a450-497b-ba93-50dfbf326a9b", "node_type": "1", "metadata": {}, "hash": "3957bbc142371048bce2e9e9f1fe9e3706312520177b01b9802a3b4e03f7d3fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Accepted for use as a food additive in Europe.                                                      |\n|         | Included in FDA Inactive Ingredients Database (epidural, IM, IV, and SC injections; inhalation solution; ophthalmic solutions; oral syrups and suspensions; otic solutions; topical creams and emulsions). Included in nonparenteral medicines licensed in the UK. |\n| 17      | Related Substances                                                                                                 |\n|         | Sodium sulfite heptahydrate; sodium metabisulfite.                                                               |\n| 19      | Specific References                                                                                               |\n|         | 1. Islam MS et al. Photoprotection of daunorubicin hydrochloride with sodium sulfite. PDA J Pharm Sci Technol 1995; 49: 122\u2013126. |\n|         | 2. Nair B, Elmore AR. Final report on the safety assessment of sodium sulfite, potassium sulfite, ammonium sulfite, sodium bisulfite, ammonium bisulfite, sodium metabisulfite and potassium metabisulfite. Int J Toxicol 2003; 22(2): 63\u201388. |\n|         | 3. Gunnisson AF. Sulphite toxicity: a critical review of in vitro and in vivo data. Food Cosmet Toxicol 1981; 19: 667\u2013682. |\n|         | 4. Vissers-Croughs KJ et al. Allergic contact dermatitis from sodium sulfite. Contact Dermatitis 1988; 18(4): 252\u2013253. |\n|         | 5. Gunnisson AF, Jacobsen DW. Sulphite hypersensitivity: a critical review. CRC Crit Review Toxicol 1987; 17(3): 185\u2013214. |\n|         | 6. FAO/WHO. Evaluation of certain food additives and contaminants. Thirtieth report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep Ser 1987: No. 751. |\n|         | 7. Lewis RJ, ed. Sax\u2019s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004; 3281\u20133282. |\n|         | 8. Food Chemicals Codex, 6th edn. Bethesda, MD: United States Pharmacopeia, 2008; 913. |\n| 20      | General References                                                                                                 |\n|         | \u2014                                                                                                                |\n| 21      | Author                                                                                                           |\n|         | HJ de Jong.                                                                                                      |\n| 22      | Date of Revision                                                                                                  |\n|         | 14 January 2009.                                                                                                 |", "mimetype": "text/plain", "start_char_idx": 66876, "end_char_idx": 69630, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a02c0572-a450-497b-ba93-50dfbf326a9b": {"__data__": {"id_": "a02c0572-a450-497b-ba93-50dfbf326a9b", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "509f0931-9b11-4161-add4-a872838696af", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "c6272a6c416d9b0bd85519610454bf1fef5762df2035faebd7f2a66339c93bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f", "node_type": "1", "metadata": {}, "hash": "27f44c92bd9abc120a7908109183305cd6464f7476cee65f80779a6c39a5c81b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|\n| 22      | Date of Revision                                                                                                  |\n|         | 14 January 2009.                                                                                                 |\n\n\n\n--- Page 11 ---\n\nSodium Thiosulfate\n1 NonproprietaryNames SEM1: Excipient:sodiumthiosulfate;magnification:100(cid:3);voltage:\n10kV.\nBP:SodiumThiosulphate\nJP:SodiumThiosulfateHydrate\nPhEur:SodiumThiosulfate\nUSP-NF:SodiumThiosulfate\n2 Synonyms\nAmetox; disodium thiosulfate; disodium thiosulfate pentahydrate;\nnatrii thiosulfas; natrium thiosulfuricum; sodium hyposulfite;\nsodium subsulfite; Sodothiol; Sulfothiorine; thiosulfuric acid\ndisodiumsalt.\n3 ChemicalNameandCASRegistryNumber\nSodiumthiosulfateanhydrous [7772-98-7]\nSodiumthiosulfatepentahydrate [10102-17-7]\n4 EmpiricalFormulaandMolecularWeight\nNa S O 158.11(foranhydrous)\n2 2 3\nNa S O (cid:2)5H O 248.2(forpentahydrate)\n2 2 3 2\nTableI: Pharmacopeialspecificationsforsodiumthiosulfate.\n5 StructuralFormula Test JPXV PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe \u00fe\nCharacters \u2014 \u00fe \u2014\npH 6.0\u20138.0 6.0\u20138.4 \u2014\nAppearanceofsolution \u00fe \u00fe \u2014\nWater \u2014 \u2014 32.0\u201337%\nCalcium \u00fe \u2014 \u00fe\nHeavymetals 420ppm 410ppm 40.002%\nArsenic 45ppm \u2014 \u2014\nLossondrying \u00fe \u2014 \u2014\n6 FunctionalCategory Sulfides \u2014 \u00fe \u2014\nSulfatesandsulfites \u2014 40.2% \u2014\nAntioxidant.\nAssay(driedbasis) 99.0\u2013101.0% 99.0\u2013101.0% 99.0\u2013100.5%\nS\n7 Applications in Pharmaceutical Formulation or\nTechnology\nSodium thiosulfate is used as an antioxidant in pharmaceuticals 11 StabilityandStorageConditions\n(ophthalmic,intravenous,andoralpreparations).Ithasalsobeen Sodium thiosulfate decomposes on heating. The bulk powder\nused for its antifungal properties(1) and as a reagent in analytical shouldbestoredinacoolplace,andthecontainershouldbekept\nchemistry. tightly closed in a dry and well-ventilated place. It should not be\nstorednearacids.\n8 Description\n12 Incompatibilities\nSodium thiosulfate occurs as odorless and colorless crystals, a\nSodiumthiosulfateisincompatiblewithiodine,withacids,andwith\ncrystalline powder or granules. It is efflorescent in dry air and\nlead, mercury, and silver salts. It may reduce the activity of some\ndeliquescentinmoistair.\npreservatives, including bronopol, phenylmercuric salts, and\nthimerosal.(1)\n9 PharmacopeialSpecifications\nSeeTableI. 13 MethodofManufacture\nOnanindustrialscale,sodiumthiosulfateisproducedchieflyfrom\n10 TypicalProperties liquidwasteproductsofsodiumsulfideorsulfurdyemanufacture.\nSmall-scale synthesis is done by boiling an aqueous solution of\nAcidity/alkalinity Aqueous solution practically neutral at pH\nsodiumsulfitewithsulfur.(2,3)\n6.5\u20138.0(pentahydrate).\nDensity 1.69g/cm3(pentahydrate)\nHygroscopicity Slightlydeliquescesinmoistair(pentahydrate). 14 Safety\nMeltingpoint 488C(pentahydrate) Sodium thiosulfate is used in ophthalmic, intravenous, and oral\nSolubility Soluble in water; practically insoluble in ethanol pharmaceutical preparations. Apart from osmotic disturbances,\n(95%). sodiumthiosulfateisrelativelynontoxic.Itismoderatelytoxicby\n671\n\n\n\ud83d\udcca Tables on Page 11:", "mimetype": "text/plain", "start_char_idx": 69374, "end_char_idx": 72433, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f": {"__data__": {"id_": "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a02c0572-a450-497b-ba93-50dfbf326a9b", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "ec9ac138a2a9c34d54d081ec9f9226968c6300d00ed0b17021bc551b03daca4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9689eb5f-06fd-4abc-b35c-6fe438aef1a0", "node_type": "1", "metadata": {}, "hash": "9b99e6afba3afb3657685bfff6b1ea4afd198f7d566551d8eedc692228100619", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\ud83d\udcca Tables on Page 11:\n\n\nTable 1 (8 rows \u00d7 3 columns):\n\n| No. | Nonproprietary Names                                               | SEM 1: Excipient: sodium thiosulfate; magnification: 100  ; voltage: 10 kV. | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------|---|---|---|\n| 1   | BP: Sodium Thiosulphate                                           |                                                                                | | | |\n|     | JP: Sodium Thiosulfate Hydrate                                    |                                                                                | | | |\n|     | PhEur: Sodium Thiosulfate                                         |                                                                                | | | |\n|     | USP-NF: Sodium Thiosulfate                                        |                                                                                | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 2   | Synonyms                                                          |                                                                                | | | |\n|     | Ametox; disodium thiosulfate; disodium thiosulfate pentahydrate; |                                                                                | | | |\n|     | natrii thiosulfas; natrium thiosulfuricum; sodium hyposulfite;  |                                                                                | | | |\n|     | sodium subsulfite; Sodothiol; Sulfothiorine; thiosulfuric acid   |                                                                                | | | |\n|     | disodium salt.                                                    |                                                                                | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 3   | Chemical Name and CAS Registry Number                             |                                                                                | | | |\n|     | Sodium thiosulfate anhydrous [7772-98-7]                         |                                                                                | | | |\n|     | Sodium thiosulfate pentahydrate [10102-17-7]                    |                                                                                | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 4   | Empirical Formula and Molecular Weight                            | 1000 \u03bcm                                                                       | | | |\n|     | Na\u2082S\u2082O\u2083                                                         | 158.11 (for anhydrous)                                                        | | | |\n|     | Na\u2082S\u2082O\u2083\u21025H\u2082O                                                    | 248.2 (for pentahydrate)                                                      | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 5   | Structural Formula                                                 | Test                       | JP XV           | PhEur 6.0        | USP32\u2013NF27 |\n|-----|-------------------------------------------------------------------|---------------------------|------------------|------------------|------------|\n|     | ONa                                                               | Identification             | \u00fe                | \u00fe                | \u00fe          |\n|     |                                                                   | Characters                 | \u2014                | \u00fe                | \u2014          |\n|     | s                                                                 | pH                         | 6.0\u20138.0         | 6.0\u20138.4          | \u2014          |\n|     |                                                                   | Appearance of solution     | \u00fe                | \u00fe                | \u2014          |\n|     | ONa                                                               | Water                      | \u2014                | \u2014                | 32.0\u201337%   |\n|     |                                                                   | Calcium                    | \u00fe                | \u2014                | \u00fe          |\n|     |                                                                   | Heavy metals               | 420 ppm         | 410 ppm          | 40.002%    |\n|     |                                                                   | Arsenic                    | 45 ppm          | \u2014                | \u2014          |\n|     |                                                                   | Loss on drying             | \u00fe                | \u2014                | \u2014          |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 6   | Functional Category                                                | Sulfides                   | \u2014                | \u00fe                | \u2014          |\n|     | Antioxidant.                                                      | Sulfates and sulfites      | \u2014                | 40.2%            | \u2014          |\n|     |                                                                   | Assay (dried basis)        | 99.0\u2013101.0%     | 99.0\u2013101.0%      | 99.0\u2013100.5%|\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 7   | Applications in Pharmaceutical Formulation or Technology         | Sodium thiosulfate is used as an antioxidant in pharmaceuticals (ophthalmic, intravenous, and oral preparations). It has also been used for its antifungal properties(1) and as a reagent in analytical chemistry. | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 8   | Description                                                       | Sodium thiosulfate occurs as odorless and colorless crystals, a crystalline powder or granules.", "mimetype": "text/plain", "start_char_idx": 72413, "end_char_idx": 79014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9689eb5f-06fd-4abc-b35c-6fe438aef1a0": {"__data__": {"id_": "9689eb5f-06fd-4abc-b35c-6fe438aef1a0", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49c9122-3aa8-4c8d-a5b9-7d5e5b52774f", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "beeffe5e1a5c207efa37e686f64d24f83adad7f6734fff4e342b503c7458b7aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac272538-d0bd-4b46-8f44-c6b46de700a3", "node_type": "1", "metadata": {}, "hash": "2f18598fccdc14bfe89b79c589af6026e93098831fcaecf9645f17b819a0f719", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Sulfates and sulfites      | \u2014                | 40.2%            | \u2014          |\n|     |                                                                   | Assay (dried basis)        | 99.0\u2013101.0%     | 99.0\u2013101.0%      | 99.0\u2013100.5%|\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 7   | Applications in Pharmaceutical Formulation or Technology         | Sodium thiosulfate is used as an antioxidant in pharmaceuticals (ophthalmic, intravenous, and oral preparations). It has also been used for its antifungal properties(1) and as a reagent in analytical chemistry. | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 8   | Description                                                       | Sodium thiosulfate occurs as odorless and colorless crystals, a crystalline powder or granules. It is efflorescent in dry air and deliquescent in moist air. | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 11  | Stability and Storage Conditions                                   | Sodium thiosulfate decomposes on heating. The bulk powder should be stored in a cool place, and the container should be kept tightly closed in a dry and well-ventilated place. It should not be stored near acids. | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 12  | Incompatibilities                                                  | Sodium thiosulfate is incompatible with iodine, with acids, and with lead, mercury, and silver salts. It may reduce the activity of some preservatives, including bronopol, phenylmercuric salts, and thimerosal.(1) | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 9   | Pharmacopeial Specifications                                       | See Table I.                                                                  | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 10  | Typical Properties                                                 | Acidity/alkalinity      Aqueous solution practically neutral at pH 6.5\u20138.0 (pentahydrate). | | | |\n|     | Density       1.69 g/cm\u00b3 (pentahydrate)                          |                                                                                | | | |\n|     | Hygroscopicity     Slightly deliquesces in moist air (pentahydrate). |                                                                                | | | |\n|     | Melting point   488C (pentahydrate)                              |                                                                                | | | |\n|     | Solubility      Soluble in water; practically insoluble in ethanol (95%). |                                                                                | | | |\n|-----|-------------------------------------------------------------------|--------------------------------------------------------------------------------| | | |\n| 14  | Safety                                                            | Sodium thiosulfate is used in ophthalmic, intravenous, and oral pharmaceutical preparations. Apart from osmotic disturbances, sodium thiosulfate is relatively nontoxic. It is moderately toxic by | | | |\n\n\n\n--- Page 12 ---\n\n672 Sorbic Acid\nthesubcutaneousrouteandmildlyirritatingtorespiratorytractand TheEINECSnumberforsodiumthiosulfateis231-867-5.The\nskin.Largeoraldoseshaveacatharticaction.(1) PubChemCompoundID(CID)forsodiumthiosulfatepentahydrate\nLD (IP,mouse)5.6g/kg(4) is516922.\n50\nLD (IV,mouse)2.4g/kg\n50 19 SpecificReferences\n15 HandlingPrecautions 1 Sweetman SC, ed. Martindale: The Complete Drug Reference, 36th\nedn. London,UK:PharmaceuticalPress,2009;1466.\nObservenormalprecautionsappropriatetothecircumstancesand\n2 Lowenheim FA, Moran MK, eds. Faith, Keyes & Clarks Industrial\nquantity of the material handled. Protective gloves are recom-\nChemicals,4thedn. NewYork:Wiley-Interscience,1975;769\u2013773.\nmendedforprolongedorrepeatedcontactuse.Hazardousproducts 3 Holleman AF, Wiberg E. Inorganic Chemistry. San Diego: Academic\n(sulfuroxides)areformedwhenheatedtodecomposition. Press,2001;1937.\n4 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\n16 RegulatoryStatus edn.", "mimetype": "text/plain", "start_char_idx": 77986, "end_char_idx": 82758, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ac272538-d0bd-4b46-8f44-c6b46de700a3": {"__data__": {"id_": "ac272538-d0bd-4b46-8f44-c6b46de700a3", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9689eb5f-06fd-4abc-b35c-6fe438aef1a0", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "a19e57054c8f17227d506c267ae7981e2a877fedbd23954ddb418938e92b08ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85327feb-7c9c-411c-abaf-59bc82db2369", "node_type": "1", "metadata": {}, "hash": "a2ba7519e4b32ba072c5a401f5f73c99c88f7c5c842650e829258b84caf11270", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Martindale: The Complete Drug Reference, 36th\nedn. London,UK:PharmaceuticalPress,2009;1466.\nObservenormalprecautionsappropriatetothecircumstancesand\n2 Lowenheim FA, Moran MK, eds. Faith, Keyes & Clarks Industrial\nquantity of the material handled. Protective gloves are recom-\nChemicals,4thedn. NewYork:Wiley-Interscience,1975;769\u2013773.\nmendedforprolongedorrepeatedcontactuse.Hazardousproducts 3 Holleman AF, Wiberg E. Inorganic Chemistry. San Diego: Academic\n(sulfuroxides)areformedwhenheatedtodecomposition. Press,2001;1937.\n4 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\n16 RegulatoryStatus edn. NewYork:Wiley,2004;3284\u20133285.\n5 FrankenbergL,So\u00a8rboB.Effectofcyanideantidotesonthemetabolic\nGRASlisted.IncludedintheFDAInactiveIngredientsDatabase(IV\nconversionofcyanidetothiocyanate.ArchToxicol1975;14:81\u201389.\nsolutions; ophthalmic solutions and suspensions; oral capsules,\n6 SylvesterDMetal.Effectsofthiosulfateoncyanidepharmacokinetics\nsolutions,andtablets).IncludedintheCanadianListofAcceptable indogs.ToxicolApplPharmacol1983;69:265\u2013271.\nNon-medicinalIngredients.\n7 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nPharmacoepeia,2008;914.\n17 RelatedSubstances\n\u2014 20 GeneralReferences\n\u2014\n18 Comments\nSodium thiosulfate has been used as an antidote to cyanide 21 Authors\npoisoning.(5,6)Thiosulfateactsasasulfurdonorfortheconversion\nJCHooton,NSandler.\nofcyanidetothiocyanate(whichcanthenbesafelyexcretedinthe\nurine),catalyzedbytheenzymerhodanase.\n22 DateofRevision\nThere is a specification for sodium thiosulfate in the Food\nChemicalsCodex(FCC).(7) 16February2009.\nSorbic Acid\n1 NonproprietaryNames 6 FunctionalCategory\nS\nBP:SorbicAcid Antimicrobialpreservative.\nPhEur:SorbicAcid\nUSP-NF:SorbicAcid 7 Applications in Pharmaceutical Formulation or\nTechnology\n2 Synonyms\nSorbicacidisanantimicrobialpreservative(1)withantibacterialand\nantifungal properties used in pharmaceuticals, foods, enteral\nAcidum sorbicum; E200; (2-butenylidene) acetic acid; crotylidene\npreparations,andcosmetics.Generally,itisusedatconcentrations\naceticacid;hexadienicacid;hexadienoicacid;2,4-hexadienoicacid;\nof 0.05\u20130.2% in oral and topical pharmaceutical formulations,\n1,3-pentadiene-1-carboxylic acid; 2-propenylacrylic acid; (E,E)-\nespeciallythosecontainingnonionicsurfactants.Sorbicacidisalso\nsorbicacid;SorbistatK.\nusedwithproteins,enzymes,gelatin,andvegetablegums.(2)Ithas\nbeen shown to be an effective preservative for promethazine\n3 ChemicalNameandCASRegistryNumber hydrochloridesolutionsinaconcentrationof1g/L.(3)\n(E,E)-Hexa-2,4-dienoicacid [22500-92-1] Sorbicacidhaslimitedstabilityandactivityagainstbacteriaand\nis thus frequently used in combination with other antimicrobial\npreservatives or glycols, when synergistic effects appear to occur;\n4 EmpiricalFormulaandMolecularWeight seeSection10.\nC H O 112.13\n6 8 2\n8 Description\n5 StructuralFormula Sorbicacidisatasteless,whitetoyellow-whitecrystallinepowder\nwithafaintcharacteristicodor.\n9 PharmacopeialSpecifications\nSeeTableI.\n\n\n\ud83d\udcca Tables on Page 12:", "mimetype": "text/plain", "start_char_idx": 82145, "end_char_idx": 85152, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "85327feb-7c9c-411c-abaf-59bc82db2369": {"__data__": {"id_": "85327feb-7c9c-411c-abaf-59bc82db2369", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac272538-d0bd-4b46-8f44-c6b46de700a3", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "896eeca0bfce00722c09841262072167fe0f4204865eb3774412492b80e9c257", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2", "node_type": "1", "metadata": {}, "hash": "0421efbc013e904d31312ae0c036cc0fee32bd8eda0d7f8628850f03a0c3c16d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "usedwithproteins,enzymes,gelatin,andvegetablegums.(2)Ithas\nbeen shown to be an effective preservative for promethazine\n3 ChemicalNameandCASRegistryNumber hydrochloridesolutionsinaconcentrationof1g/L.(3)\n(E,E)-Hexa-2,4-dienoicacid [22500-92-1] Sorbicacidhaslimitedstabilityandactivityagainstbacteriaand\nis thus frequently used in combination with other antimicrobial\npreservatives or glycols, when synergistic effects appear to occur;\n4 EmpiricalFormulaandMolecularWeight seeSection10.\nC H O 112.13\n6 8 2\n8 Description\n5 StructuralFormula Sorbicacidisatasteless,whitetoyellow-whitecrystallinepowder\nwithafaintcharacteristicodor.\n9 PharmacopeialSpecifications\nSeeTableI.\n\n\n\ud83d\udcca Tables on Page 12:\n\n\nTable 1 (1 rows \u00d7 3 columns):\n\n| Section | Title                                                                 | Content                                                                                                           |\n|---------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|\n| 1       | Nonproprietary Names                                                  | BP: Sorbic Acid\n\n\n\n--- Page 13 ---\n\nSEM1: Excipient:sorbicacid;manufacturer:PfizerLtd.;magnification: 1.0\n60(cid:3).\n0.0\n\u22121.7\nFlashpoint 1278C\nMeltingpoint 134.58C\nNIRspectra seeFigure1.\nSolubility see Table III. In syrup, the solubility of sorbic acid\ndecreaseswithincreasingsugarcontent.\nVaporpressure <1.3Pa(<0.01mmHg)at208C\nTableI: Pharmacopeialspecificationsforsorbicacid.\nTableIII: Solubilityofsorbicacid.\nTest PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe Solvent Solubilityat208Cunlessotherwisestated\nCharacters \u00fe \u2014\nAppearanceofsolution \u00fe \u2014 Acetone 1in11\nMeltingrange 132\u20131368C 132\u20131358C Chloroform 1in15\nWater 41.0% 40.5% Ethanol 1in8\nResidueonignition \u2014 40.2% Ethanol(95%) 1in10\nSulfatedash 40.2% \u2014 Ether 1in30\nHeavymetals 410ppm 40.001% Glycerin 1in320\nAldehyde(asC H O) 40.15% \u2014 Methanol 1in8\n2 4 Propyleneglycol 1in19\nAssay(anhydrousbasis) 99.0\u2013101.0% 99.0\u2013101.0% Water 1in400at308C\n1in26at1008C\n10 TypicalProperties\nAntimicrobial activity Sorbic acid is primarily used as an 11 StabilityandStorageConditions\nantifungalagent,althoughitalsopossessesantibacterialproper-\nSorbicacidissensitivetooxidation,particularlyinthepresenceof\nties. The optimum antibacterial activity is obtained at pH 4.5;\nlight;oxidationoccursmorereadilyinaqueoussolutionthaninthe\nand practically no activity is observed above pH 6.(4,5) The\nsolidform.Sorbicacidmaybestabilizedbyphenolicantioxidants\nefficacyofsorbicacidisenhancedwhenitisusedincombination\nsuchas0.02%propylgallate.(6)\nwithotherantimicrobialpreservativesorglycolssincesynergistic\neffects occur.(6) Reported minimum inhibitory concentrations Sorbicacidiscombustiblewhenexposedtoheatorflame.When\n(MICs)atpH6areshowninTableII.(7) heatedtodecomposition,itemitsacridsmokeandirritatingfumes.\nBoilingpoint 2288Cwithdecomposition. The bulk material should be stored in a well-closed container,\nDensity 1.20g/cm3 protectedfromlight,atatemperaturenotexceeding408C.\nDissociationconstant pK =4.76\na\n12 Incompatibilities\nSorbic acid is incompatible with bases, oxidizing agents, and\nreducing agents.", "mimetype": "text/plain", "start_char_idx": 84461, "end_char_idx": 87700, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2": {"__data__": {"id_": "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85327feb-7c9c-411c-abaf-59bc82db2369", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "9637df86278144bab7dad3ae72988fada3de0fa085f695745c26519f9642cbf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba", "node_type": "1", "metadata": {}, "hash": "27dd8f547c4f3f478ba1776efe64e29a93f7f0b203ef2eeaf849e4dab1ce015e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(6)\nwithotherantimicrobialpreservativesorglycolssincesynergistic\neffects occur.(6) Reported minimum inhibitory concentrations Sorbicacidiscombustiblewhenexposedtoheatorflame.When\n(MICs)atpH6areshowninTableII.(7) heatedtodecomposition,itemitsacridsmokeandirritatingfumes.\nBoilingpoint 2288Cwithdecomposition. The bulk material should be stored in a well-closed container,\nDensity 1.20g/cm3 protectedfromlight,atatemperaturenotexceeding408C.\nDissociationconstant pK =4.76\na\n12 Incompatibilities\nSorbic acid is incompatible with bases, oxidizing agents, and\nreducing agents. Some loss of antimicrobial activity occurs in the\npresence of nonionic surfactants and plastics. Oxidation is\ncatalyzed by heavy-metal salts. Sorbic acid will also react with\nsulfur-containing amino acids, although this can be prevented by\nthe addition of ascorbic acid, propyl gallate, or butylhydroxyto-\nluene.\nWhenstoredinglasscontainers,thesolutionbecomesverypH\nsensitive;therefore,preparationsusingsorbicacidasapreservative\nshouldbetestedfortheirmicrobialpurityafterprolongedperiods\nofstorage.\nAqueous solutions of sorbic acid without the addition of\nantioxidants are rapidly decomposed when stored in polypropy-\nlene,polyvinylchloride,andpolyethylenecontainers.\n])R/1(gol\n.vired\ndn2[\n\u00d7\n0001\n0.9\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\n)R/1(gol\nSorbic Acid 673\n1173 1714 23832419\n1755\n1678\n2370\n1738\n1189\n2316\n1156 1701\nFigure1: Near-infraredspectrumofsorbicacidmeasuredby\nreflectance.\nS\nTableII: Minimuminhibitoryconcentrations(MICs)ofsorbicacidat\npH6.\nMicroorganism MIC(mg/mL)\nAspergillusniger 200\u2013500\nCandidaalbicans 25\u201350\nClostridiumsporogenes 100\u2013500\nEscherichiacoli 50\u2013100\nKlebsiellapneumoniae 50\u2013100\nPenicilliumnotatum 200\u2013300\nPseudomonasaeruginosa 100\u2013300\nPseudomonascepacia 50\u2013100\nPseudomonasfluorescens 100\u2013300\nSaccharomycescerevisiae 200\u2013500\nStaphylococcusaureus 50\u2013100\n\n\n\ud83d\udcca Tables on Page 13:\n\n\nTable 1 (10 rows \u00d7 3 columns):\n\n| Test                           | PhEur 6.0           | USP32\u2013NF27         |\n|-------------------------------|---------------------|---------------------|\n| Identification                 | \u00fe                   | \u00fe                   |\n| Characters                     | \u00fe                   | \u2014                   |\n| Appearance of solution         | \u00fe                   | \u2014                   |\n| Melting range                  | 132\u20131368C           | 132\u20131358C           |\n| Water                          | 41.0%               | 40.5%               |\n| Residue on ignition            | \u2014                   | 40.2%               |\n| Sulfated ash                   | 40.2%               | \u2014                   |\n| Heavy metals        (H O)      | 410 ppm             | 40.001%             |\n| Aldehyde (as C\u2082      4         | 40.15%              | \u2014                   |\n| Assay (anhydrous basis)        | 99.0\u2013101.0%         | 99.0\u2013101.0%         |", "mimetype": "text/plain", "start_char_idx": 87129, "end_char_idx": 90008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba": {"__data__": {"id_": "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b378ae5-9b3f-4a5b-a78e-5e5b7c365fb2", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "257812803f8ecfe989921d53f8c3108026f76a3d59aaee0ae51846b128e2ce46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66", "node_type": "1", "metadata": {}, "hash": "09e45476b9682731e68a21d942f303bbc8013d70601c2e7a5092f95cd0e65b52", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 2 (9 rows \u00d7 2 columns):\n\n| Solvent                     | Solubility at 208C unless otherwise stated |\n|-----------------------------|--------------------------------------------|\n| Acetone                     | 1 in 11                                   |\n| Chloroform                  | 1 in 15                                   |\n| Ethanol                     | 1 in 8                                    |\n| Ethanol (95%)               | 1 in 10                                   |\n| Ether                       | 1 in 30                                   |\n| Glycerin                    | 1 in 320                                  |\n| Methanol                    | 1 in 8                                    |\n| Propylene glycol            | 1 in 19                                   |\n| Water                       | 1 in 400 at 308C                          |\n|                             | 1 in 26 at 1008C                          |\n\n\n\nTable 3 (11 rows \u00d7 2 columns):\n\n| Microorganism                                     | MIC (mg/mL)                      |\n|--------------------------------------------------|----------------------------------|\n| Aspergillus niger                                 | 200\u2013500                          |\n| Candida albicans                                  | 25\u201350                            |\n| Clostridium sporogenes                            | 100\u2013500                          |\n| Escherichia coli                                  | 50\u2013100                           |\n| Klebsiella pneumoniae                             | 50\u2013100                           |\n| Penicillium notatum                               | 200\u2013300                          |\n| Pseudomonas aeruginosa                            | 100\u2013300                          |\n| Pseudomonas cepacia                               | 50\u2013100                           |\n| Pseudomonas fluorescens                           | 100\u2013300                          |\n| Saccharomyces cerevisiae                          | 200\u2013500                          |\n| Staphylococcus aureus                             | 50\u2013100                           |\n\n\n\n--- Page 14 ---\n\n674 Sorbic Acid\n13 MethodofManufacture Sodiumsorbate\nEmpiricalformula C H O Na\nNaturally occurring sorbic acid may be extracted as the lactone 6 7 2\nSynonyms E201;sodium(E,E)-hexa-2,4-dienoate.\n(parasorbic acid) from the berries of the mountain ash Sorbus\nMolecularweight 134.12\naucuparia L. (Fam. Rosaceae). Synthetically, sorbic acid may be\nCASnumber [42788-83-0]\npreparedbythecondensationofcrotonaldehydeandketeneinthe\nAppearance Light,white,crystallinepowder.\npresence of boron trifluoride; by the condensation of crotonalde-\nSolubility Soluble1in3partsofwater.\nhyde and malonic acid in pyridine solution; or from 1,1,3,5-\nComments TheEINECSnumberforsodiumsorbateis231-819-\ntetraalkoxyhexane.Fermentationofsorbaldehydeorsorbitolwith\n3.\nbacteriainaculturemediumhasalsobeenused.\n18 Comments\n14 Safety\nThetrans,trans-isomerofsorbicacidisthecommercialproduct.A\nSorbic acid is used as an antimicrobial preservative in oral and\nspecification for sorbic acid is contained in the Food Chemicals\ntopicalpharmaceuticalformulationsandisgenerallyregardedasa Codex(FCC).(22)\nnontoxic material. However, adverse reactions to sorbic acid and\nThe EINECS number for sorbic acid is 203-768-7. The\npotassium sorbate, including irritant skin reactions(8\u201311) and PubChem Compound ID (CID) for sorbic acid includes 643460\nallergic hypersensitivity skin reactions (which are less frequent), and1550734.\nhavebeenreported.(12\u201314)\nOther adverse reactions that have been reported include\n19 SpecificReferences\nexfoliative dermatitis due to ointments that contain sorbic\nacid,(15)andallergicconjunctivitiscausedbycontactlenssolutions 1 Charvalos E et al. Controlled release of water-soluble polymeric\ncomplexes of sorbic acid with antifungal activities. Appl Microbiol\npreservedwithsorbicacid.(16)\nBiotechnol2001;57(5\u20136):770\u2013775.\nNo adverse reactions have been described after systemic 2 Weiner M, Bernstein IL.", "mimetype": "text/plain", "start_char_idx": 90012, "end_char_idx": 94055, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66": {"__data__": {"id_": "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ff8f144-96ba-4cbf-b764-0eaf38ecc5ba", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "cb5666ce488418ff8c48a07ece3cb4ea165b7e29df882af4f4a21ea821818278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b68bc1d-e0a4-4244-9550-766bee3d69b4", "node_type": "1", "metadata": {}, "hash": "479e6bfc2b075ab2d8609d91bf4855ce4517c601f93207292bf65dba212820c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The\npotassium sorbate, including irritant skin reactions(8\u201311) and PubChem Compound ID (CID) for sorbic acid includes 643460\nallergic hypersensitivity skin reactions (which are less frequent), and1550734.\nhavebeenreported.(12\u201314)\nOther adverse reactions that have been reported include\n19 SpecificReferences\nexfoliative dermatitis due to ointments that contain sorbic\nacid,(15)andallergicconjunctivitiscausedbycontactlenssolutions 1 Charvalos E et al. Controlled release of water-soluble polymeric\ncomplexes of sorbic acid with antifungal activities. Appl Microbiol\npreservedwithsorbicacid.(16)\nBiotechnol2001;57(5\u20136):770\u2013775.\nNo adverse reactions have been described after systemic 2 Weiner M, Bernstein IL. Adverse Reactions to Drug Formulation\nadministrationofsorbicacid,andithasbeenreportedthatitcan Agents:AHandbookofExcipients.NewYork:MarcelDekker,1989;\nbe ingested safely by patients who are allergic to sorbic acid.(17) 179.\nHowever,perioralcontacturticariahasbeenreported.(11) 3 Van-Doorne H, Leijen JB. Preservation of some oral liquid prepara-\nTheWHOhassetanestimatedtotalacceptabledailyintakefor tions:replacementofchloroformbyotherpreservatives.PharmWorld\nSci1994;16(Feb18):18\u201321.\nsorbic acid, calcium sorbate, potassium sorbate, and sodium\n4 GolightlyLKetal.Adverseeffectsassociatedwithinactiveingredients\nsorbate, expressed as sorbic acid, at up to 25mg/kg body- indrugproducts(partI).MedToxicol1988;3:128\u2013165.\nweight.(18,19)\n5 Eklund T. The antimicrobial effect of dissociated and undissociated\nAnimal toxicological studies have shown no mammalian sorbicacidatdifferentpHlevels.JApplBacteriol1983;54:383\u2013389.\ncarcinogenicity or teratogenicity for sorbic acid consumed at up 6 WoodfordR,AdamsE.Sorbicacid.AmPerfumCosmet1970;85(3):\nto10%ofthediet.(20) 25\u201330.\n7 Wallha\u00a8usser KH. Sorbic acid. Kabara JJ, ed. Cosmetic and Drug\nLD 50 (mouse,IP):2.82g/kg(21) PreservationPrinciplesandPractice.NewYork:MarcelDekker,1984;\nLD (mouse,oral):3.20g/kg 668\u2013670.\n50\n8 SoschinD,LeydenJJ.Sorbicacid-inducederythemaandedema.JAm\nLD 50 (mouse,SC):2.82g/kg AcadDermatol1986;14:234\u2013241.\nLD 50 (rat,oral):7.36g/kg 9 FisherAA.Erythemalimitedtothefaceduetosorbicacid.Cutis1987;\n40:395\u2013397.\n15 HandlingPrecautions 10 ClemmensenOJ,SchiodtM.Patchtestreactionofthebuccalmucosato\nsorbicacid.ContactDermatitis1982;8(5):341\u2013342.\nS Observenormalprecautionsappropriatetothecircumstancesand 11 ClemmensenO,HjorthN.Perioralcontacturticariafromsorbicacid\nquantityofmaterialhandled.Sorbicacidcanbeirritanttotheskin, andbenzoicacidinasaladdressing.ContactDermatitis1982;3:1\u20136.\neyes, and respiratory system. Eye protection, gloves, and a dust 12 Saihan EM, Harman RRM. Contact sensitivity to sorbic acid in\nmaskorrespiratorarerecommended. \u2018UnguentumMerck\u2019.BrJDermatol1978;99:583\u2013584.\n13 FisherAA.Cutaneousreactionstosorbicacidandpotassiumsorbate.\nCutis1980;25:350,352,423.", "mimetype": "text/plain", "start_char_idx": 93347, "end_char_idx": 96194, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b68bc1d-e0a4-4244-9550-766bee3d69b4": {"__data__": {"id_": "4b68bc1d-e0a4-4244-9550-766bee3d69b4", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af15fdfe-b7e5-46f0-9ce8-fd035d0e4d66", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "4c89c9edba09b0c169318708c05e3eb09691b129981e7b3be677c8543ae187de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01483c06-0398-4f52-8dfe-59afe118a6f8", "node_type": "1", "metadata": {}, "hash": "0e53c04c1653162ab3cec0b6e7a00f818ead8f4090697c8ed05468f509bdd71f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "S Observenormalprecautionsappropriatetothecircumstancesand 11 ClemmensenO,HjorthN.Perioralcontacturticariafromsorbicacid\nquantityofmaterialhandled.Sorbicacidcanbeirritanttotheskin, andbenzoicacidinasaladdressing.ContactDermatitis1982;3:1\u20136.\neyes, and respiratory system. Eye protection, gloves, and a dust 12 Saihan EM, Harman RRM. Contact sensitivity to sorbic acid in\nmaskorrespiratorarerecommended. \u2018UnguentumMerck\u2019.BrJDermatol1978;99:583\u2013584.\n13 FisherAA.Cutaneousreactionstosorbicacidandpotassiumsorbate.\nCutis1980;25:350,352,423.\n16 RegulatoryStatus\n14 FisherAA.Allergicreactionsto the preservatives in over-the-counter\nGRASlisted.AcceptedasafoodadditiveinEurope.Includedinthe hydrocortisonetopicalcreamsandlotions.Cutis1983;32:222,224,\nFDA Inactive Ingredients Database (ophthalmic solutions; oral 230.\ncapsules, solutions, syrups, tablets; topical and vaginal prepara- 15 CoyleHEetal.SorbicacidsensitivityfromUnguentumMerck.Contact\ntions). Included in nonparenteral medicines licensed in the UK.\nDermatitis1981;7:56\u201357.\n16 FisherAA.Allergicreactionstocontactlenssolutions.Cutis1985;36:\nIncluded in the Canadian List of Acceptable Non-medicinal\n209\u2013211.\nIngredients.\n17 KlaschkaF,BeiersdorffHU.Allergiceczematousreactionfromsorbic\nacidusedasapreservativeinexternalmedicaments.MunchMedWschr\n17 RelatedSubstances 1965;107:185\u2013187.\n18 FAO/WHO.Toxicologicalevaluationofcertainfoodadditiveswitha\nCalciumsorbate;potassiumsorbate;sodiumsorbate.\nreviewofgeneralprinciplesandofspecifications.Seventeenthreportof\nCalciumsorbate thejointFAO/WHOexpertcommitteeonfoodadditives.WorldHealth\nEmpiricalformula C H O Ca OrganTechRepSer 1974;No.539.\n12 14 4\nSynonyms E203 19 FAO/WHO. Evaluation of certain food additives and contaminants.\nMolecularweight 262.33 Twenty-ninthreportofthejointFAO/WHOexpertcommitteeonfood\nadditives.WorldHealthOrganTechRepSer 1986;No.733.\nCASnumber [7492-55-9]\n20 WalkerR.Toxicologyofsorbicacidandsorbates.FoodAdditContam\nAppearance White,odorless,tasteless,crystallinepowder. 1990;7(5):671\u2013676.\nSolubility Soluble1in83partsofwater;practicallyinsolublein\n21 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nfats. edn. NewYork:Wiley,2004;3291.\nComments TheEINECSnumberforcalciumsorbateis231-321- 22 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\n6. Pharmacopeia,2008;917.\n\n\n\ud83d\udcca Tables on Page 14:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Section | Content                                                                                                           |\n|---------|-------------------------------------------------------------------------------------------------------------------|\n| 13      | Method of Manufacture                                                                                             |\n|         | Naturally occurring sorbic acid may be extracted as the lactone (parasorbic acid) from the berries of the mountain ash Sorbus aucuparia L. (Fam. Rosaceae). Synthetically, sorbic acid may be prepared by the condensation of crotonaldehyde and ketene in the presence of boron trifluoride; by the condensation of crotonaldehyde and malonic acid in pyridine solution; or from 1,1,3,5-tetraalkoxyhexane. Fermentation of sorbaldehyde or sorbitol with bacteria in a culture medium has also been used.", "mimetype": "text/plain", "start_char_idx": 95659, "end_char_idx": 98917, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "01483c06-0398-4f52-8dfe-59afe118a6f8": {"__data__": {"id_": "01483c06-0398-4f52-8dfe-59afe118a6f8", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b68bc1d-e0a4-4244-9550-766bee3d69b4", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "1b3490e42a9b169932ce75717cb1b53cc03959de1f65530fd4b90a2bc89a554f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b48f408c-12e3-4277-b226-58db609fe7b5", "node_type": "1", "metadata": {}, "hash": "89ae222a62333a0c01de11e5bffb6cd6ee0e822cba4d8d0db13360ff3a8b2ecc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmacopeia,2008;917.\n\n\n\ud83d\udcca Tables on Page 14:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Section | Content                                                                                                           |\n|---------|-------------------------------------------------------------------------------------------------------------------|\n| 13      | Method of Manufacture                                                                                             |\n|         | Naturally occurring sorbic acid may be extracted as the lactone (parasorbic acid) from the berries of the mountain ash Sorbus aucuparia L. (Fam. Rosaceae). Synthetically, sorbic acid may be prepared by the condensation of crotonaldehyde and ketene in the presence of boron trifluoride; by the condensation of crotonaldehyde and malonic acid in pyridine solution; or from 1,1,3,5-tetraalkoxyhexane. Fermentation of sorbaldehyde or sorbitol with bacteria in a culture medium has also been used. |\n|         | Sodium sorbate                                                                                                   |\n|         | Empirical formula  C\u2086H\u2087O\u2082Na                                                                                    |\n|         | Synonyms    E201; sodium (E,E)-hexa-2,4-dienoate.                                                              |\n|         | Molecular weight   134.12                                                                                        |\n|         | CAS number     [42788-83-0]                                                                                     |\n|         | Appearance    Light, white, crystalline powder.                                                                  |\n|         | Solubility  Soluble 1 in 3 parts of water.                                                                       |\n|         | Comments      The EINECS number for sodium sorbate is 231-819-3.                                                |\n| 14      | Safety                                                                                                           |\n|         | Sorbic acid is used as an antimicrobial preservative in oral and topical pharmaceutical formulations and is generally regarded as a nontoxic material. However, adverse reactions to sorbic acid and potassium sorbate, including irritant skin reactions(8\u201311) and allergic hypersensitivity skin reactions (which are less frequent), have been reported.(12\u201314) |\n|         | Other adverse reactions that have been reported include exfoliative dermatitis due to ointments that contain sorbic acid,(15) and allergic conjunctivitis caused by contact lens solutions preserved with sorbic acid.(16) |\n|         | No adverse reactions have been described after systemic administration of sorbic acid, and it has been reported that it can be ingested safely by patients who are allergic to sorbic acid.(17) However, perioral contact urticaria has been reported.(11) |\n|         | The WHO has set an estimated total acceptable daily intake for sorbic acid, calcium sorbate, potassium sorbate, and sodium sorbate, expressed as sorbic acid, at up to 25 mg/kg body-weight.(18,19) |\n|         | Animal toxicological studies have shown no mammalian carcinogenicity or teratogenicity for sorbic acid consumed at up to 10% of the diet.(20) |\n|         | LD\u2085\u2080 (mouse, IP): 2.82 g/kg(21)                                                                                 |\n|         | LD\u2085\u2080 (mouse, oral): 3.20 g/kg                                                                                    |\n|         | LD\u2085\u2080 (mouse, SC): 2.82 g/kg                                                                                     |\n|         | LD\u2085\u2080 (rat, oral): 7.36 g/kg                                                                                     |\n| 15      | Handling Precautions                                                                                             |\n|         | Observe normal precautions appropriate to the circumstances and quantity of material handled. Sorbic acid can be irritant to the skin, eyes, and respiratory system. Eye protection, gloves, and a dust mask or respirator are recommended. |\n| 16      | Regulatory Status                                                                                                |\n|         | GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Database (ophthalmic solutions; oral capsules, solutions, syrups, tablets; topical and vaginal preparations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| 17      | Related Substances                                                                                               |\n|         | Calcium sorbate; potassium sorbate; sodium sorbate.", "mimetype": "text/plain", "start_char_idx": 97950, "end_char_idx": 102833, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b48f408c-12e3-4277-b226-58db609fe7b5": {"__data__": {"id_": "b48f408c-12e3-4277-b226-58db609fe7b5", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c56752-6519-446f-9e97-720e092e952c", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b5a8caa56a36ede6e6d92abd90183ef1daad1e1767ff5597ce49e56cfb786f28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01483c06-0398-4f52-8dfe-59afe118a6f8", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed p660_675.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d15cb4a14241b77875433a37b2803edf1ffdcfa89d3bf34de1ea12028c433343", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sorbic acid can be irritant to the skin, eyes, and respiratory system. Eye protection, gloves, and a dust mask or respirator are recommended. |\n| 16      | Regulatory Status                                                                                                |\n|         | GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Database (ophthalmic solutions; oral capsules, solutions, syrups, tablets; topical and vaginal preparations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| 17      | Related Substances                                                                                               |\n|         | Calcium sorbate; potassium sorbate; sodium sorbate.                                                              |\n|         | Calcium sorbate                                                                                                  |\n|         | Empirical formula        C\u2081\u2082H\u2081\u2084O\u2084Ca                                                                            |\n|         | Synonyms          E203                                                                                            |\n|         | Molecular weight          262.33                                                                                  |\n|         | CAS number        [7492-55-9]                                                                                   |\n|         | Appearance        White, odorless, tasteless, crystalline powder.                                                 |\n|         | Solubility             Soluble 1 in 83 parts of water; practically insoluble in fats.                             |\n|         | Comments                      The EINECS number for calcium sorbate is 231-321-6.                                   |", "mimetype": "text/plain", "start_char_idx": 102028, "end_char_idx": 103916, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "590deeb7-0acf-400b-82a5-514377ada131": {"__data__": {"id_": "590deeb7-0acf-400b-82a5-514377ada131", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71d6854e-62c7-458b-ab13-0a05c8479f25", "node_type": "1", "metadata": {}, "hash": "0623ec57cc171e6b71f7554272507267fd1d553efe89838baedbcb8d2734f7ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 1 ---\n\nSodium Borate 633\n40 Gilbert DL et al. Compatibility of ciprofloxacin lactate with sodium 20 GeneralReferences\nbicarbonateduringsimulatedY-siteadministration.AmJHealthSyst\nHannula A-M et al. Release of ibuprofen from hard gelatin capsule\nPharm1997;54:1193\u20131195.\nformulations:effectofsodiumbicarbonateasadisintegrant.ActaPharm\n41 TrisselLA.Concentration-dependentprecipitationofsodiumbicarbo-\nFenn1989;98:131\u2013134.\nnatewithciprofloxacinlactate[letter].AmJHealthSystPharm1996;\nSendallFEJetal.Effervescenttablets.PharmJ1983;230:289\u2013294.\n53:84\u201385.\n42 Korth-BradleyJMetal.Incompatibilityofamiodaronehydrochloride TraversDN,WhiteRC.Themixingofmicronizedsodiumbicarbonatewith\nand sodium bicarbonate injections [letter]. Am J Health Syst Pharm sucrosecrystals.JPharmPharmacol1971;23:260S\u2013261S.\n1995;52:2340.\n43 BaaskeDMetal.Stabilityofnicardipinehydrochlorideinintravenous\nsolutions.AmJHealthSystPharm1996;53:1701\u20131705.\n44 WilliamsNAetal.Stabilityoflevofloxacininintravenoussolutionsin 21 Author\npolyvinylchloridebags.AmJHealthSystPharm1996;53:2309\u20132313. CGCable.\n45 Panchmatia K, Jolobe OM. Contra-indications of Solpadol [letter].\nPharmJ1993;251:73.\n46 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;3233.\n22 DateofRevision\n47 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nPharmacopeia,2008;877. 16February2009.\nSodium Borate\n1 NonproprietaryNames applications;seeSection14.Sodiumborateisalsousedincosmetics\nBP:Borax suchasmoisturizers,deodorants,andshampoos.\nJP:SodiumBorate\nPhEur:Borax 8 Description\nUSP-NF:SodiumBorate Sodiumborateoccursaswhite,hardcrystals,granules,orcrystal-\nlinepowder.Itisodorlessandefflorescent.\n2 Synonyms\nBorax decahydrate; boric acid disodium salt; E285; natrii tetra-\n9 PharmacopeialSpecifications\nboras; sodium biborate decahydrate; sodium pyroborate deca-\nhydrate;sodiumtetraboratedecahydrate. SeeTableI.\n3 ChemicalNameandCASRegistryNumber TableI: Pharmacopeialspecificationsforsodiumborate.\nS\nDisodiumtetraboratedecahydrate [1303-96-4] Test JPXV PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe \u00fe\n4 EmpiricalFormulaandMolecularWeight Characters \u2014 \u00fe \u2014\nNa B O (cid:5)10H O 381.37 Carbonateand \u00fe \u2014 \u00fe\n2 4 7 2\nbicarbonate\nColorofsolution \u00fe \u00fe\u2014\n5 StructuralFormula\npH 9.1\u20139.6 9.0\u20139.6 \u2014\nSeeSection4. Heavymetals 420ppm 425ppm 40.002%\nArsenic 45ppm 45ppm \u2014\nCalcium \u2014 4100ppm \u2014\n6 FunctionalCategory Ammonium \u2014 410ppm \u2014\nAlkalizing agent; antimicrobial preservative; buffering agent; Sulfates \u2014 450ppm \u2014\ndisinfectant;emulsifyingagent;stabilizingagent. Assay 99.0\u2013103.0% 99.0\u2013103.0% 99.0\u2013105.0%\n7 Applications in Pharmaceutical Formulation or\nTechnology\n10 TypicalProperties\nSodium borate is used in pharmaceutical applications similarly to\nboric acid (see Boric Acid).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2740, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71d6854e-62c7-458b-ab13-0a05c8479f25": {"__data__": {"id_": "71d6854e-62c7-458b-ab13-0a05c8479f25", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "590deeb7-0acf-400b-82a5-514377ada131", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d4b3d23b6aedf415149697fc181a90f9c106dc2401ee252522354a72c3d766d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6798a5a-b6b7-4110-bf80-579549521320", "node_type": "1", "metadata": {}, "hash": "8f2937c5b519e3fded9da64fe0cdca3a4c884675efb98f933f8142f2422bb083", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Heavymetals 420ppm 425ppm 40.002%\nArsenic 45ppm 45ppm \u2014\nCalcium \u2014 4100ppm \u2014\n6 FunctionalCategory Ammonium \u2014 410ppm \u2014\nAlkalizing agent; antimicrobial preservative; buffering agent; Sulfates \u2014 450ppm \u2014\ndisinfectant;emulsifyingagent;stabilizingagent. Assay 99.0\u2013103.0% 99.0\u2013103.0% 99.0\u2013105.0%\n7 Applications in Pharmaceutical Formulation or\nTechnology\n10 TypicalProperties\nSodium borate is used in pharmaceutical applications similarly to\nboric acid (see Boric Acid). It has been used externally as a mild Acidity/alkalinity pH=9.0\u20139.6(4%w/vaqueoussolution)\nastringentandasanemulsifyingagentincreams.(1)Ithasalsobeen Density 1.73g/cm3\nusedinlozenges,mouthwashes,oticpreparations(0.3%w/v),and Meltingpoint 758Cwhenrapidlyheated.At1008Citloses5H 2 O;\nophthalmic solutions (0.03\u20131.0% w/v). Sodium borate has addi-\nat1508Citloses9H\n2\nO;andat3208Citbecomesanhydrous.At\ntionallybeeninvestigatedinthepreventionofcrystalformationin about 8808C the substance melts into a glassy state: \u2018borax\nfreeze-driedsolutions.(2) beads\u2019.\nPreparations of sodium borate in honey have historically been Solubility 1 in 1 of glycerin; 1 in 1 of boiling water; 1 in 16 of\nused as paints for the throat, tongue, and mouth, but such use is water;practicallyinsolubleinethanol(95%),ethanol(99.5%),\nnow inadvisable because of concerns about toxicity in such anddiethylether.\n\n\n\ud83d\udcca Tables on Page 1:\n\n\nTable 1 (11 rows \u00d7 4 columns):\n\n| Test                    | JP XV           | PhEur 6.0        | USP32\u2013NF27      |\n|------------------------|------------------|------------------|------------------|\n| Identification         | \u00fe                | \u00fe                | \u00fe                |\n| Characters             | \u2014                | \u00fe                | \u2014                |\n| Carbonate and         | \u00fe                | \u2014                | \u00fe                |\n| bicarbonate            |                  |                  |                  |\n| Color of solution      | \u00fe                | \u00fe                | \u2014                |\n| pH                     | 9.1\u20139.6         | 9.0\u20139.6         | \u2014                |\n| Heavy metals           | 420 ppm         | 425 ppm         | 40.002%          |\n| Arsenic                | 45 ppm          | 45 ppm          | \u2014                |\n| Calcium                | \u2014                | 4100 ppm        | \u2014                |\n| Ammonium               | \u2014                | 410 ppm         | \u2014                |\n| Sulfates               | \u2014                | 450 ppm         | \u2014                |\n| Assay                  | 99.0\u2013103.0%     | 99.0\u2013103.0%     | 99.0\u2013105.0%      |\n\n\n\n--- Page 2 ---\n\n634 Sodium Borate\n11 StabilityandStorageConditions Sodiumborateanhydrous\nSodiumborateshouldbestoredinawell-closedcontainerinacool, Synonyms Borax glass; disodium tetraborate anhydrous; fused\ndry,place.SeealsoSection18. borax; fused sodium borate; sodium pyroborate; sodium\ntetraborateanhydrous.\nEmpiricalformula Na B O\n12 Incompatibilities 2 4 7\nMolecularweight 201.2\nSodium borate is incompatible with acids and with metallic and CASnumber [1330-43-4]\nalkaloidalsalts. Boilingpoint 15758C(decomposes)\nMeltingpoint 7418C\n13 MethodofManufacture Solubility Slightly soluble in glycerin, and water; practically\nSodiumboratecanbepreparedfrommineralssuchasborosodium insolubleinethanol(95%).", "mimetype": "text/plain", "start_char_idx": 2276, "end_char_idx": 5543, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6798a5a-b6b7-4110-bf80-579549521320": {"__data__": {"id_": "d6798a5a-b6b7-4110-bf80-579549521320", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71d6854e-62c7-458b-ab13-0a05c8479f25", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "e4a66be1b202e8d7b01897231d902d5b1c943faa9a39ef01681d4ec73bd2806b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba", "node_type": "1", "metadata": {}, "hash": "9e4eafe1d8cf3c7c80e332a8fb2e5b9e73baa4b5d4b7f13afc59ed488250233c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "borax; fused sodium borate; sodium pyroborate; sodium\ntetraborateanhydrous.\nEmpiricalformula Na B O\n12 Incompatibilities 2 4 7\nMolecularweight 201.2\nSodium borate is incompatible with acids and with metallic and CASnumber [1330-43-4]\nalkaloidalsalts. Boilingpoint 15758C(decomposes)\nMeltingpoint 7418C\n13 MethodofManufacture Solubility Slightly soluble in glycerin, and water; practically\nSodiumboratecanbepreparedfrommineralssuchasborosodium insolubleinethanol(95%).\ncalcite,pandermite,ortinkal;thesearenaturalsodiumorcalcium Specificgravity 2.367\nborates. Treatment of the mineral with sodium carbonate and Comments TheEINECSnumberforsodiumborateanhydrousis\nsodium hydrogencarbonate yields the sodium borate decahydrate. 215-540-4.\nIn the USA, brine from salt lakes is also an important source of\nsodiumborate.(3)\n18 Comments\nCommercially available sodium borate decahydrate is usually\n14 Safety\npresent as monoclinic prismatic crystals that become opaque on\nSodium borate has weak bacteriostatic and astringent properties.\nthesurfaceindryair.Inadditiontothedecahydrate,apentahydrate\nHistorically,sodiumboratehasbeenusedasadisinfectantinskin\nexists; this is also known as \u2018jeweller\u2019s borax\u2019. The anhydrous\nlotions and eye-, nose-, and mouthwashes. However, boric acid is\nsubstanceisalsoavailableandiscalled\u2018pyroborax\u2019.\neasily absorbed via mucous membranes and damaged skin, and\nThe EINECS number for sodium borate is 271-536-2. The\nsevere toxicity has been observed, especially in babies and\nchildren.(4)Consequently,theuseofsodiumborateasadisinfectant PubChemCompoundID(CID)forsodiumborateis11954323.\nis now considered somewhat obsolete and careful use is recom-\nmended. The toxic effects of sodium borate include vomiting,\n19 SpecificReferences\ndiarrhea, erythema, CNS depression, and kidney damage. The\n1 Prince LM. Beeswax/borax reaction in cold creams. Cosmet Perfum\nlethal oral intake is approximately 20 g in adults and 5 g in\nchildren.(5) 1974;89(May):47\u201349.\n2 Izutsu K et al. Effects of sodium tetraborate and boric acid on\nLD (guineapig,oral):5.33g/kg(5,6) nonisothermalmannitolcrystallizationinfrozensolutionsandfreeze-\n50\nLD (mouse,IP):2.711g/kg driedsolids.IntJPharm2004;273(1):85\u201393.\n50\n3 Lyday PA. Boron.Mineral Yearbook., vol. 1: Washington, DC: US\nLD (mouse,IV):1.320g/kg\n50 DepartmentoftheInteriorUSGeologicalSurvey,1992;249.\nLD 50 (mouse,oral):2.0g/kg 4 GordonASetal.Seizuredisordersandanemiaassociatedwithchronic\nLD (rat,oral):2.66g/kg boraxintoxication.CanMedAssocJ1973;108:719\u2013721724.\n50\n5 LewisRJ.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11thedn.\nNewYork:Wiley,2004;3234.\n15 HandlingPrecautions\n6 SmythHFetal.Range-findingtoxicitydata:listVII.AmIndHygAssoc\nObservenormalprecautionsappropriatetothecircumstancesand J1969;30(5):470\u2013476.\nthequantityofmaterialhandled;donotcombinewithacids.\n20 GeneralReferences\n16 RegulatoryStatus\nS\n\u2014\nAcceptedforuseasafoodadditiveinEurope.IncludedintheFDA\nInactive Ingredients Database (otic preparations; ophthalmic\nsolutions and suspensions). Included in nonparenteral medicines 21 Author\nlicensedintheUK,Italy,France,Germany,andJapan.Includedin\nHJdeJong.", "mimetype": "text/plain", "start_char_idx": 5076, "end_char_idx": 8194, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba": {"__data__": {"id_": "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6798a5a-b6b7-4110-bf80-579549521320", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "3e2e7e865c08d4218ad3507bb2f9f6db47e1eb0f75ded0f1de62c6722226c6cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e4431a1-9c10-481e-80c5-4416fe248958", "node_type": "1", "metadata": {}, "hash": "14c120bb9efbe8b6bd60cb8ca467c5af99ecd6ebfa6c3ffecfaaa7c53b356ad9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "50\n5 LewisRJ.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11thedn.\nNewYork:Wiley,2004;3234.\n15 HandlingPrecautions\n6 SmythHFetal.Range-findingtoxicitydata:listVII.AmIndHygAssoc\nObservenormalprecautionsappropriatetothecircumstancesand J1969;30(5):470\u2013476.\nthequantityofmaterialhandled;donotcombinewithacids.\n20 GeneralReferences\n16 RegulatoryStatus\nS\n\u2014\nAcceptedforuseasafoodadditiveinEurope.IncludedintheFDA\nInactive Ingredients Database (otic preparations; ophthalmic\nsolutions and suspensions). Included in nonparenteral medicines 21 Author\nlicensedintheUK,Italy,France,Germany,andJapan.Includedin\nHJdeJong.\ntheCanadianListofAcceptableNon-medicinalIngredients.\n17 RelatedSubstances 22 DateofRevision\nBoricacid;sodiumborateanhydrous. 3February2009.\n\n\n\ud83d\udcca Tables on Page 2:\n\n\nTable 1 (11 rows \u00d7 3 columns):\n\n| Section | Title                                   | Details                                                                                          |\n|---------|-----------------------------------------|--------------------------------------------------------------------------------------------------|\n| 11      | Stability and Storage Conditions        | Sodium borate anhydrous. Sodium borate should be stored in a well-closed container in a cool, dry place. See also Section 18. |\n|         |                                         | Synonyms: Borax glass; disodium tetraborate anhydrous; fused borax; fused sodium borate; sodium pyroborate; sodium tetraborate anhydrous. |\n|         |                                         | Empirical formula: Na\u2082B\u2084O\u2087                                                                       |\n|         |                                         | Molecular weight: 201.2                                                                           |\n|         |                                         | CAS number: [1330-43-4]                                                                          |\n|         |                                         | Boiling point: 15758C (decomposes)                                                               |\n| 13      | Method of Manufacture                   | Sodium borate can be prepared from minerals such as borosodium calcite, pandermite, or tinkal; these are natural sodium or calcium borates. Treatment of the mineral with sodium carbonate and sodium hydrogencarbonate yields the sodium borate decahydrate. In the USA, brine from salt lakes is also an important source of sodium borate.(3) |\n|         |                                         | Melting point: 7418C                                                                             |\n|         |                                         | Solubility: Slightly soluble in glycerin, and water; practically insoluble in ethanol (95%).     |\n|         |                                         | Specific gravity: 2.367                                                                          |\n|         |                                         | Comments: The EINECS number for sodium borate anhydrous is 215-540-4.                           |\n| 14      | Safety                                  | Sodium borate has weak bacteriostatic and astringent properties. Historically, sodium borate has been used as a disinfectant in skin lotions and eye-, nose-, and mouthwashes. However, boric acid is easily absorbed via mucous membranes and damaged skin, and severe toxicity has been observed, especially in babies and children.(4) Consequently, the use of sodium borate as a disinfectant is now considered somewhat obsolete and careful use is recommended. The toxic effects of sodium borate include vomiting, diarrhea, erythema, CNS depression, and kidney damage. The lethal oral intake is approximately 20 g in adults and 5 g in children.(5) |\n|         |                                         | LD\u2085\u2080 (guinea pig, oral): 5.33 g/kg(5,6)                                                          |\n|         |                                         | LD\u2085\u2080 (mouse, IP): 2.711 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (mouse, IV): 1.320 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (mouse, oral): 2.0 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (rat, oral): 2.66 g/kg                                                                        |\n| 15      | Handling Precautions                    | Observe normal precautions appropriate to the circumstances and the quantity of material handled; do not combine with acids. |\n| 16      | Regulatory Status                       | Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (otic preparations; ophthalmic solutions and suspensions).", "mimetype": "text/plain", "start_char_idx": 7585, "end_char_idx": 12548, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e4431a1-9c10-481e-80c5-4416fe248958": {"__data__": {"id_": "5e4431a1-9c10-481e-80c5-4416fe248958", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c68e65c5-6ebc-4291-bdf2-3086b0bf38ba", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "0b931fcd654c1e1d44e51609b893395fc8e8ec0c1a2c1708075be8dce1b02f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "318c2bc6-844d-4b03-b7ff-9da9a3920d78", "node_type": "1", "metadata": {}, "hash": "857f658173e61b0c18801858d9b82ffa8f5e836058aee7ff9bba202f3093d359", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(5) |\n|         |                                         | LD\u2085\u2080 (guinea pig, oral): 5.33 g/kg(5,6)                                                          |\n|         |                                         | LD\u2085\u2080 (mouse, IP): 2.711 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (mouse, IV): 1.320 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (mouse, oral): 2.0 g/kg                                                                      |\n|         |                                         | LD\u2085\u2080 (rat, oral): 2.66 g/kg                                                                        |\n| 15      | Handling Precautions                    | Observe normal precautions appropriate to the circumstances and the quantity of material handled; do not combine with acids. |\n| 16      | Regulatory Status                       | Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (otic preparations; ophthalmic solutions and suspensions). Included in nonparenteral medicines licensed in the UK, Italy, France, Germany, and Japan. Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| 17      | Related Substances                      | Boric acid; sodium borate anhydrous.                                                             |\n| 18      | Comments                                | The EINECS number for sodium borate is 271-536-2. The PubChem Compound ID (CID) for sodium borate is 11954323. |\n| 19      | Specific References                     | 1. Prince LM. Beeswax/borax reaction in cold creams. Cosmet Perfum 1974; 89(May): 47\u201349.        |\n|         |                                         | 2. Izutsu K et al. Effects of sodium tetraborate and boric acid on nonisothermal mannitol crystallization in frozen solutions and freeze-dried solids. Int J Pharm 2004; 273(1): 85\u201393. |\n|         |                                         | 3. Lyday PA. Boron. Mineral Yearbook., vol. 1: Washington, DC: US Department of the Interior US Geological Survey, 1992; 249. |\n|         |                                         | 4. Gordon AS et al. Seizure disorders and anemia associated with chronic borax intoxication. Can Med Assoc J 1973; 108: 719\u2013721724. |\n|         |                                         | 5. Lewis RJ. Sax\u2019s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004; 3234. |\n|         |                                         | 6. Smyth HF et al. Range-finding toxicity data: list VII. Am Ind Hyg Assoc J 1969; 30(5): 470\u2013476. |\n| 20      | General References                      | \u2014                                                                                                |\n| 21      | Author                                  | HJ de Jong.                                                                                      |\n| 22      | Date of Revision                        | 3 February 2009.                                                                                |\n\n\n\n--- Page 3 ---\n\nSodium Carbonate\n1 NonproprietaryNames\nTableI: Pharmacopeialspecificationsforsodiumcarbonate.\nBP:AnhydrousSodiumCarbonate\nTest JPXV PhEur6.0 USP32\u2013NF27\nJP:DriedSodiumCarbonate\nPhEur:SodiumCarbonate,Anhydrous Identification \u00fe \u00fe \u00fe\nCharacters \u2014 \u00fe \u2014\nUSP-NF:SodiumCarbonate Appearanceofsolution \u00fe \u00fe \u2014\nAlkalihydroxidesand \u2014 \u00fe \u2014\nbicarbonates\n2 Synonyms Chlorides 40.071% 4125ppm \u2014\nBisodium carbonate; calcined soda; carbonic acid disodium salt; Sulfates \u2014 4250ppm \u2014\nArsenic 43.1ppm 45ppm \u2014\ncenzias de soda; crystol carbonate; disodium carbonate; E500; Iron \u2014 450ppm \u2014\nnatriicarbonasanhydricus;sodaash;sodacalcined.", "mimetype": "text/plain", "start_char_idx": 11382, "end_char_idx": 15194, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "318c2bc6-844d-4b03-b7ff-9da9a3920d78": {"__data__": {"id_": "318c2bc6-844d-4b03-b7ff-9da9a3920d78", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e4431a1-9c10-481e-80c5-4416fe248958", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "c5c692f76291d853f85861aa8ee508357b14382624479b85e1c5007036e7ab69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff", "node_type": "1", "metadata": {}, "hash": "04cf8ce6071abb3edb3de449751cd9c964ce8688ce4e6200967ddad72c94ea5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "BP:AnhydrousSodiumCarbonate\nTest JPXV PhEur6.0 USP32\u2013NF27\nJP:DriedSodiumCarbonate\nPhEur:SodiumCarbonate,Anhydrous Identification \u00fe \u00fe \u00fe\nCharacters \u2014 \u00fe \u2014\nUSP-NF:SodiumCarbonate Appearanceofsolution \u00fe \u00fe \u2014\nAlkalihydroxidesand \u2014 \u00fe \u2014\nbicarbonates\n2 Synonyms Chlorides 40.071% 4125ppm \u2014\nBisodium carbonate; calcined soda; carbonic acid disodium salt; Sulfates \u2014 4250ppm \u2014\nArsenic 43.1ppm 45ppm \u2014\ncenzias de soda; crystol carbonate; disodium carbonate; E500; Iron \u2014 450ppm \u2014\nnatriicarbonasanhydricus;sodaash;sodacalcined. Heavymetals 420ppm 450ppm 40.001%\nLossondrying 42.0% 41.0% \u2014\nWater \u2014 \u2014 40.5%\n3 ChemicalNameandCASRegistryNumber Assay(driedbasis) >99.0% 99.5\u2013100.5% 99.5\u2013100.5%\nSodiumcarbonateanhydrous [497-19-8]\nSodiumcarbonatemonohydrate [5968-11-6]\nSodiumcarbonatedecahydrate [6132-02-1]\n10 TypicalProperties\n4 EmpiricalFormulaandMolecularWeight Acidity/alkalinity Stronglyalkaline;pH=11.4(1%w/vaqueous\nNa CO 105.99\nsolutionat258C).(5)\n2 3\nNa CO (cid:5)H O 124.0 Hygroscopicity One mole of sodium carbonate will gradually\n2 3 2\nNa CO (cid:5)10H O 286.1 absorb1moleofwater(approximately15%)onexposuretoair.\n2 3 2 Meltingpoint 8518C\nRefractive index n20 = 1.3352 at 1.0% w/w solution; 1.3440 at\nD\n5 StructuralFormula 5.0%w/wsolution;1.3547for10.0%w/wsolution.(6)\nSolubility Freelysolubleinwater,withsolubilityinitiallyincreas-\nSeeSection4.\ning with temperature and then settling at 30.8% w/w above\n808C(5)(seeFigure1).Solubleinglycerin;practicallyinsolublein\n6 FunctionalCategory ethanol(95%).\nSpecificgravity 2.53\nAlkalizingagent;bufferingagent.\n7 Applications in Pharmaceutical Formulation or\nTechnology\n36\nSodium carbonate is used as an alkalizing agent in injectable,\nophthalmic,oral,andrectalformulations.\nIneffervescenttablets orgranules,sodiumcarbonateisusedin 32\ncombination with an acid, typically citric acid or tartaric acid.(1)\nWhenthetabletsorgranulescomeintocontactwithwater,anacid\u2013\n28\nbasereactionoccursinwhichcarbondioxidegasisproducedand\nthe product disintegrates.(2) Raw materials with low moisture\ncontents are required to prevent the early triggering of the 24\neffervescentreaction.(2)\nAs an alkalizing agent, concentrations of sodium carbonate 20\nbetween 2% and 5% w/w are used in compressed tablet\nformulations.(1,3) As an effervescent agent, concentrations of\nsodiumcarbonateupto10%w/wcanbeused.(2) 16\nTherapeutically, sodium carbonate is also used as an oral\nantacid.(4)\n12\n8 Description 8\nSodium carbonate is a white, almost white, or colorless inorganic\nsalt, produced as crystalline powder or granules. It is hygroscopic 4\nandodorlesswithanalkalinetaste. 0 20 40 60 80 100\nTemperature (\u00b0C)\n9 PharmacopeialSpecifications\nSeeTableI.\n)%\ntw(\nnoitulos\ndetarutas\nni\nOC\naN\n3\n2\nS\nFigure1: Solubilityofsodiumcarbonateinwater.(5)Adaptedwith\npermission.\n635\n\n\n\ud83d\udcca Tables on Page 3:", "mimetype": "text/plain", "start_char_idx": 14681, "end_char_idx": 17475, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff": {"__data__": {"id_": "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "318c2bc6-844d-4b03-b7ff-9da9a3920d78", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "423021629d936687af37ef8de9e51c08cdcab73caf351702f870be224a112e06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1", "node_type": "1", "metadata": {}, "hash": "b997f98adffaa9c25405d9e0f2020b74e1f6883f21cb090add684a2e2b52f10a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(1,3) As an effervescent agent, concentrations of\nsodiumcarbonateupto10%w/wcanbeused.(2) 16\nTherapeutically, sodium carbonate is also used as an oral\nantacid.(4)\n12\n8 Description 8\nSodium carbonate is a white, almost white, or colorless inorganic\nsalt, produced as crystalline powder or granules. It is hygroscopic 4\nandodorlesswithanalkalinetaste. 0 20 40 60 80 100\nTemperature (\u00b0C)\n9 PharmacopeialSpecifications\nSeeTableI.\n)%\ntw(\nnoitulos\ndetarutas\nni\nOC\naN\n3\n2\nS\nFigure1: Solubilityofsodiumcarbonateinwater.(5)Adaptedwith\npermission.\n635\n\n\n\ud83d\udcca Tables on Page 3:\n\n\nTable 1 (12 rows \u00d7 4 columns):\n\n| Test                          | JP XV        | PhEur 6.0        | USP32\u2013NF27   |\n|-------------------------------|--------------|------------------|--------------|\n| Identification                | \u00fe            | \u00fe                | \u00fe            |\n| Characters                    | \u2014            | \u00fe                | \u2014            |\n| Appearance of solution        | \u00fe            | \u00fe                | \u2014            |\n| Alkali hydroxides and         | \u2014            | \u00fe                | \u2014            |\n| bicarbonates                  |              |                  |              |\n| Chlorides                     | 40.071%      | 4125 ppm         | \u2014            |\n| Sulfates                      | \u2014            | 4250 ppm         | \u2014            |\n| Arsenic                       | 43.1 ppm     | 45 ppm           | \u2014            |\n| Iron                          | \u2014            | 450 ppm          | \u2014            |\n| Heavy metals                  | 420 ppm      | 450 ppm          | 40.001%      |\n| Loss on drying                | 42.0%        | 41.0%            | \u2014            |\n| Water                         | \u2014            | \u2014                | 40.5%        |\n| Assay (dried basis)           | >99.0%       | 99.5\u2013100.5%      | 99.5\u2013100.5%  |\n\n\n\nTable 2 (3 rows \u00d7 3 columns):\n\n| Compound                     | Empirical Formula | Molecular Weight |\n|------------------------------|-------------------|------------------|\n| Sodium carbonate anhydrous    | Na\u2082CO\u2083            | 105.99           |\n| Sodium carbonate monohydrate   | Na\u2082CO\u2083\u00b7C\u2081H\u2082O     | 124.0            |\n| Sodium carbonate decahydrate   | Na\u2082CO\u2083\u00b710H\u2082O     | 286.1            |\n\n\n\nTable 3 (6 rows \u00d7 2 columns):\n\n| Property                     | Value                                   |\n|------------------------------|-----------------------------------------|\n| Acidity/alkalinity           | Strongly alkaline; pH = 11.4 (1% w/v aqueous solution at 25\u00b0C). |\n| Hygroscopicity               | One mole of sodium carbonate will gradually absorb 1 mole of water (approximately 15%) on exposure to air. |\n| Melting point                | 851\u00b0C                                   |\n| Refractive index             | n\u00b2\u2070 = 1.3352 at 1.0% w/w solution; 1.3440 at 5.0% w/w solution; 1.3547 for 10.0% w/w solution. |\n| Solubility                   | Freely soluble in water, with solubility initially increasing with temperature and then settling at 30.8% w/w above 80\u00b0C. Soluble in glycerin; practically insoluble in ethanol (95%). |\n| Specific gravity             | 2.53                                    |\n\n\n\n--- Page 4 ---\n\n636 Sodium Carbonate\n11 StabilityandStorageConditions Comments Listed in PhEur 6.0 and JP XV. Used in alkaline\nbaths.(4)\nSodium carbonate converts to the monohydrate form when in\ncontact with water and produces heat. It begins to lose carbon Sodiumcarbonatemonohydrate\ndioxide at temperatures above 4008C(7) and decomposes before Empiricalformula Na CO (cid:5)H O\n2 3 2\nboiling.Storeinairtightcontainers.", "mimetype": "text/plain", "start_char_idx": 16913, "end_char_idx": 20498, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1": {"__data__": {"id_": "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e52bcfe-61ce-4a25-8c0c-12f28d5a12ff", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "a6893fb0a304678d68403d5b25b6ed336fb27b0640a3d60ce7d966b39b611268", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bbbf578-4489-452b-9efe-3361b95034ec", "node_type": "1", "metadata": {}, "hash": "09a4759fcabf8e8a1964719de4691fa32a38a3ec7b3f564acfbd667782760ca4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 4 ---\n\n636 Sodium Carbonate\n11 StabilityandStorageConditions Comments Listed in PhEur 6.0 and JP XV. Used in alkaline\nbaths.(4)\nSodium carbonate converts to the monohydrate form when in\ncontact with water and produces heat. It begins to lose carbon Sodiumcarbonatemonohydrate\ndioxide at temperatures above 4008C(7) and decomposes before Empiricalformula Na CO (cid:5)H O\n2 3 2\nboiling.Storeinairtightcontainers. Molecularweight 124.0\nCASnumber [5968-11-6]\n12 Incompatibilities Description Colorlessorwhitecrystalsorgranules.\nSodium carbonate decomposes when in contact with acids in the Solubility Soluble in 3 parts water, 1.8 parts boiling water, or 7\npartsglycerin.Practicallyinsolubleinethanol(95%).Driesout\npresence ofwater to produce carbon dioxide and effervescence. It\ninwarmdryairorabove508C,andconvertstoanhydrousform\nmay react violently with aluminum, phosphorous pentoxide,\nsulfuricacid,fluorine,andlithium.\nabove1008C.\nComments Listed in PhEur 6.0 and USP32\u2013NF27. Commonly\nusedinantacidpreparationsandasareagent.(4)\n13 MethodofManufacture\nSodiumcarbonateisproducedbytheammonia-sodaprocess,also\n18 Comments\nknownastheSolvayprocess.(7)\nSodiumcarbonateismorestableineffervescentformulationsthan\nsodiumbicarbonate,(3)butislesseffectiveasaneffervescentagent\n14 Safety\nand therefore sodium bicarbonate is most commonly used in\nSodium carbonate is used in injectable, oral, and rectal pharma- effervescent formulations.(2) Sodium carbonate can be added to\nceuticalformulations.Thepureformofsodiumcarbonateismildly these formulations as a stabilizing agent (up to 10% w/w) as it\ntoxic by ingestion, moderately toxic by inhalation and SC routes, absorbs moisture, preventing early effervescent reactions.(2) This\nandverytoxicbytheIProute.Itisirritatingtotheskinandeyes. effectisexploitedinEffer-Soda,inwhichasodiumbicarbonatecore\nDust and vapors of sodium carbonate may irritate mucous is protected by a surface layer of sodium carbonate, equivalent to\nmembranes,causingcoughingandshortnessofbreath.Italsohas 8\u201312%w/w.(9)\nexperimentalreproductiveeffects. The technical grade of sodium carbonate anhydrous (approxi-\nSodium carbonate can migrate to food from packaging mately99%purity)isknownassodaash.\nmaterials.Whenusedasanexcipientorantacid,sodiumcarbonate A specification for sodium carbonate is contained in the Food\nisgenerallyregardedasanontoxicandnonirritatingmaterial. ChemicalsCodex(FCC).(10)\nLD (mouse,IP):0.12g/kg(8) The EINECS number for sodium carbonate is 207-838-8. The\n50\nPubChemCompoundID(CID)forsodiumcarbonateis10340.\nLD (mouse,SC):2.21g/kg\n50\nLD (rat,oral):4.09g/kg\n50 19 SpecificReferences\n1 NiaziS.Compressedsoliddosageformulations.NiaziSK,ed.Hand-\n15 HandlingPrecautions\nbookofPharmaceuticalManufacturingFormulations,vol.1:PartII.\nObservenormalprecautionsappropriatetothecircumstancesand BocaRatonFL:CRCPress,2004.\nquantityofthematerialhandled.Whenheatedtodecompositionit 2 Bertuzzi D. Effervescent granulation. Parikh D, ed. Handbook of\nemits toxic fumes of sodium oxide. Eye protection and gloves are Pharmaceutical Granulation Technology, 2nd edn. Boca Raton FL:\nrecommended. Respiratory protection is also recommended if TaylorandFrancis,2005;365.\ninhalabledustispresent.", "mimetype": "text/plain", "start_char_idx": 20078, "end_char_idx": 23288, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7bbbf578-4489-452b-9efe-3361b95034ec": {"__data__": {"id_": "7bbbf578-4489-452b-9efe-3361b95034ec", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff98d6d6-5cd8-4663-ad4f-28ee8feffef1", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b54988023dc512e604152774ca8a904e5cbf178fc9a74789dd91d9c39e67fc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfe2b049-c05a-4433-aa7b-5efb24283018", "node_type": "1", "metadata": {}, "hash": "e41dd992efa583d3cffaa46d1fb44c37ed5fd7516851c6f8daadda20acf8f95a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Observenormalprecautionsappropriatetothecircumstancesand BocaRatonFL:CRCPress,2004.\nquantityofthematerialhandled.Whenheatedtodecompositionit 2 Bertuzzi D. Effervescent granulation. Parikh D, ed. Handbook of\nemits toxic fumes of sodium oxide. Eye protection and gloves are Pharmaceutical Granulation Technology, 2nd edn. Boca Raton FL:\nrecommended. Respiratory protection is also recommended if TaylorandFrancis,2005;365.\ninhalabledustispresent. 3 BadawySetal.Effectofprocessingandformulationvariablesonthe\nstabilityofasaltofaweaklybasicdrugcandidate.PharmDevTechnol\n2004;9:239\u2013245.\n16 RegulatoryStatus 4 SweetmanSC,ed.Martindale:theCompleteDrugReference,36thedn.\nS\nGRAS listed. Accepted for use as a food additive in Europe. London:PharmaceuticalPress,2009;2389.\nIncluded in the FDA Inactive Ingredients Database (injections; 5 EggemanT.Sodiumcarbonate.Kirk-OthmerEncyclopediaofChemical\nTechnology,5thedn,vol.22: NewYork:Wiley,2001;787\u2013797.\nophthalmicsolution;oralcapsulesandtablets;rectalsuspensions).\n6 Lide DR, ed. CRC Handbook of Chemistry and Physics, 88th edn.\nIncluded in the Canadian List of Acceptable Non-medicinal\nBocaRatonFL:CRCPress/TaylorandFrancis,2008;8\u201352.\nIngredients. Included in parenteral (powder for solution for 7 O\u2019NeilMJ,ed.MerckIndex:AnEncyclopediaofChemicals,Drugsand\ninjection) and nonparenteral medicines (oral effervescent tablets, Biologicals, 14th edn. Whitehouse Station NJ: Merck, 2006; 1480\u2013\nsoluble tablets, granules, lozenges, chewing gums) licensed in the 1481.\nUK. 8 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialChemicals,11th\nUSP32\u2013NF27 allowseither theanhydrousorthe monohydrate edn. NewYork:Wiley,2004;3236.\nform. 9 SPIPharma.TechnicalBulletinNo.117/0300:Effer-Soda,2007.\n10 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nPharmacopeia,2008;878.\n17 RelatedSubstances\nSodium bicarbonate; sodium carbonate decahydrate; sodium\n20 GeneralReferences\ncarbonatemonohydrate.\n\u2014\nSodiumcarbonatedecahydrate\nEmpiricalformula Na 2 CO 3 (cid:5)10H 2 O 21 Author\nMolecularweight 286.1\nKPHapgood.\nCASnumber [6132-02-1]\nDescription Colorless,transparent,orwhitecrystalsorpowder.\nSolubility Freelysolubleinwater;practicallyinsolubleinethanol 22 DateofRevision\n(95%). 3March2009.\n\n\n\ud83d\udcca Tables on Page 4:", "mimetype": "text/plain", "start_char_idx": 22844, "end_char_idx": 25081, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cfe2b049-c05a-4433-aa7b-5efb24283018": {"__data__": {"id_": "cfe2b049-c05a-4433-aa7b-5efb24283018", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bbbf578-4489-452b-9efe-3361b95034ec", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "544be8ba373a7e837c479b30adac24de59a0d184f08272b9d54515609948dbdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d22d03f-d41d-462e-9739-dcdd6733a071", "node_type": "1", "metadata": {}, "hash": "ae39d61fd9baf08ec0229b4ca432bd8dddde4e064550c92418a457fc88a70896", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3March2009.\n\n\n\ud83d\udcca Tables on Page 4:\n\n\nTable 1 (24 rows \u00d7 2 columns):\n\n| Section                          | Details                                                                                                           |\n|----------------------------------|-------------------------------------------------------------------------------------------------------------------|\n| **Sodium Carbonate**             |                                                                                                                   |\n| **Stability and Storage Conditions** | Sodium carbonate converts to the monohydrate form when in contact with water and produces heat. It begins to lose carbon dioxide at temperatures above 400\u00b0C(7) and decomposes before boiling. Store in airtight containers. |\n| **Incompatibilities**            | Sodium carbonate decomposes when in contact with acids in the presence of water to produce carbon dioxide and effervescence. It may react violently with aluminum, phosphorous pentoxide, sulfuric acid, fluorine, and lithium. |\n| **Method of Manufacture**        | Sodium carbonate is produced by the ammonia-soda process, also known as the Solvay process.(7) Comments Listed in PhEur 6.0 and JP XV. Used in alkaline baths.(4) |\n| **Sodium carbonate monohydrate** |                                                                                                                   |\n| Empirical formula                | Na\u2082CO\u2083\u00b7H\u2082O                                                                                                      |\n| Molecular weight                 | 124.0                                                                                                            |\n| CAS number                       | [5968-11-6]                                                                                                     |\n| Description                      | Colorless or white crystals or granules.                                                                         |\n| Solubility                       | Soluble in 3 parts water, 1.8 parts boiling water, or 7 parts glycerin. Practically insoluble in ethanol (95%). Dries out in warm dry air or above 50\u00b0C, and converts to anhydrous form above 100\u00b0C. |\n| Comments                         | Listed in PhEur 6.0 and USP32\u2013NF27. Commonly used in antacid preparations and as a reagent.(4)                   |\n| **Safety**                       | Sodium carbonate is used in injectable, oral, and rectal pharmaceutical formulations. The pure form of sodium carbonate is mildly toxic by ingestion, moderately toxic by inhalation and SC routes, and very toxic by the IP route. It is irritating to the skin and eyes. Dust and vapors of sodium carbonate may irritate mucous membranes, causing coughing and shortness of breath. It also has experimental reproductive effects. Sodium carbonate can migrate to food from packaging materials. When used as an excipient or antacid, sodium carbonate is generally regarded as a nontoxic and nonirritating material. |\n| LD\u2085\u2080 (mouse, IP)                | 0.12 g/kg(8)                                                                                                     |\n| LD\u2085\u2080 (mouse, SC)                | 2.21 g/kg                                                                                                        |\n| LD\u2085\u2080 (rat, oral)                | 4.09 g/kg                                                                                                        |\n| **Handling Precautions**         | Observe normal precautions appropriate to the circumstances and quantity of the material handled. When heated to decomposition it emits toxic fumes of sodium oxide. Eye protection and gloves are recommended. Respiratory protection is also recommended if inhalable dust is present. |\n| **Regulatory Status**            | GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (injections; ophthalmic solution; oral capsules and tablets; rectal suspensions). Included in the Canadian List of Acceptable Non-medicinal Ingredients. Included in parenteral (powder for solution for injection) and nonparenteral medicines (oral effervescent tablets, soluble tablets, granules, lozenges, chewing gums) licensed in the UK. USP32\u2013NF27 allows either the anhydrous or the monohydrate form. |\n| **Related Substances**           | Sodium bicarbonate; sodium carbonate decahydrate; sodium carbonate monohydrate.                                 |\n| **Sodium carbonate decahydrate** |                                                                                                                   |\n| Empirical formula                | Na\u2082CO\u2083\u00b710H\u2082O                                                                                                    |\n| Molecular weight                 | 286.1                                                                                                            |\n| CAS number                       | [6132-02-1]                                                                                                     |\n| Description                      | Colorless, transparent, or white crystals or powder.                                                            |\n| Solubility                       | Freely soluble in water; practically insoluble in ethanol (95%).                                                |\n| **General References**           | \u2014                                                                                                                |\n| **Author**                       | KP Hapgood.                                                                                                      |\n| **Date of Revision**             | 3 March 2009.                                                                                                   |", "mimetype": "text/plain", "start_char_idx": 25048, "end_char_idx": 30933, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d22d03f-d41d-462e-9739-dcdd6733a071": {"__data__": {"id_": "7d22d03f-d41d-462e-9739-dcdd6733a071", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfe2b049-c05a-4433-aa7b-5efb24283018", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "54c33c9a984e2f2dc88127426cecdb7ccbf48c6ef17894c9b07fa8b851c3dd5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91", "node_type": "1", "metadata": {}, "hash": "a191c8203455b772b347745c6c91be55ee48f72c300e2146e70434deca66f111", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 5 ---\n\nSodium Chloride\n1 NonproprietaryNames crystallization although, below 08C, salt may crystallize as a\nBP:SodiumChloride dihydrate.\nJP:SodiumChloride\nPhEur:SodiumChloride 9 PharmacopeialSpecifications\nUSP:SodiumChloride SeeTableII.SeealsoSection18.\n2 Synonyms\n10 TypicalProperties\nAlberger; chlorure de sodium; common salt; hopper salt; natrii\nAcidity/alkalinity pH=6.7\u20137.3(saturatedaqueoussolution)\nchloridum;naturalhalite;rocksalt;saline;salt;seasalt;tablesalt.\nAngleofrepose 388forcubiccrystals\nBoilingpoint 14138C\n3 ChemicalNameandCASRegistryNumber\nSodiumchloride [7647-14-5] SEM1: Excipient:sodiumchloride,powder;manufacturer:Mallinckrodt\nSpecialityChemicalsCo.;magnification:600(cid:2).\n4 EmpiricalFormulaandMolecularWeight\nNaCl 58.44\n5 StructuralFormula\nSeeSection4.\n6 FunctionalCategory\nTabletandcapsulediluent;tonicityagent.\n7 Applications in Pharmaceutical Formulation or\nTechnology\nSodium chloride is widely used in a variety of parenteral and\nnonparenteralpharmaceuticalformulations,wheretheprimaryuse\nistoproduceisotonicsolutions.\nSodium chloride has been used as a lubricant and diluent in\ncapsulesanddirect-compressiontabletformulationsinthepast,(1\u20135)\nalthough this practice is no longer common. Sodium chloride has\nalsobeenusedasachannelingagent(6,7)andasanosmoticagent(8,9)\nin the cores of controlled-release tablets. It has been used as a\nporositymodifierintabletcoatings,(10)andtocontroldrugrelease S\nfrommicrocapsules.(11,12)\nThe addition of sodium chloride to aqueous spray-coating\nSEM2: Excipient:sodiumchloride,granular;manufacturer:VanWaters\nsolutions containing hydroxypropyl cellulose or hypromellose &Rogers,Inc.;magnification:120(cid:2).\nsuppresses the agglomeration of crystalline cellulose particles.(13)\nSodium chloride can also be used to modify drug release from\ngels(14) and from emulsions.(15) It can be used to control micelle\nsize,(16\u201318) and to adjust the viscosity of polymer dispersions by\nalteringtheioniccharacterofaformulation.(19,20)\nSeeTableI.\nTableI: Usesofsodiumchloride.\nUse Concentration(%)\nCapsulediluent 10\u201380\nControlledflocculationofsuspensions 41\nDirectcompressiontabletdiluent 10\u201380\nToproduceisotonicsolutionsinintravenousor 40.9\nophthalmicpreparations\nWater-solubletabletlubricant 5\u201320\n8 Description\nSodium chloride occurs as a white crystalline powder or colorless\ncrystals; it has a saline taste. The crystal lattice is a face-centered\ncubic structure. Solid sodium chloride contains no water of\n637\n\n\n\ud83d\udcca Tables on Page 5:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Use                                                 | Concentration (%) |\n|-----------------------------------------------------|-------------------|\n| Capsule diluent                                     | 10\u201380             |\n| Controlled flocculation of suspensions              | 41                |\n| Direct compression tablet diluent                   | 10\u201380             |\n| To produce isotonic solutions in intravenous or     | 40.9              |\n| ophthalmic preparations                              |                   |\n| Water-soluble tablet lubricant                      | 5\u201320              |\n\n\n\n--- Page 6 ---\n\nSEM3: Excipient:sodiumchloride,granular;manufacturer:VanWaters\n&Rogers,Inc.;magnification:600(cid:2). TableIII: Freezingpointdepressionvaluesofaqueoussodium\nchloride.\nAqueoussodiumchloridesolution(%w/v) Freezingpointdepression(8C)\n11.69 6.90\n17.53 10.82\n23.38 15.14\n30.39 21.12\nHardness(Mohs) 2\u20132.5\nHygroscopicity Hygroscopicabove75%relativehumidity.", "mimetype": "text/plain", "start_char_idx": 30937, "end_char_idx": 34441, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91": {"__data__": {"id_": "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d22d03f-d41d-462e-9739-dcdd6733a071", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "29244e9f40e128452c23e034c5ebb38ec46b5bc166f610aedf49650b64fde7ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5237f296-7c75-445c-96a7-b6d718c7eee6", "node_type": "1", "metadata": {}, "hash": "3b55386b498eb4394a8edbcd4f3cee532905b0d3ceedd701ab7c993cb811d62d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 6 ---\n\nSEM3: Excipient:sodiumchloride,granular;manufacturer:VanWaters\n&Rogers,Inc.;magnification:600(cid:2). TableIII: Freezingpointdepressionvaluesofaqueoussodium\nchloride.\nAqueoussodiumchloridesolution(%w/v) Freezingpointdepression(8C)\n11.69 6.90\n17.53 10.82\n23.38 15.14\n30.39 21.12\nHardness(Mohs) 2\u20132.5\nHygroscopicity Hygroscopicabove75%relativehumidity.\nMeltingpoint 8048C\nNIRspectra seeFigure2.\nOsmolarity A 0.9% w/v aqueous solution is iso-osmotic with\nserum.\nRefractiveindex n20=1.343fora1Maqueoussolution.\nD\nSolubility seeTableIV.\nThermalconductivity 1.15Wm/Kat273K\nSpecificheatcapacity 854J/kg/K\nTableII: Pharmacopeialspecificationsforsodiumchloride.\nTest JPXV PhEur6.0 USP32\nIdentification \u00fe \u00fe \u00fe\nCharacters \u00fe \u00fe \u2014\nAppearanceof \u00fe \u00fe \u00fe\nsolution\nAcidityoralkalinity \u00fe \u00fe \u00fe\nLossondrying 40.5% 40.5% 40.5%\nArsenic 42ppm 41ppm 41mg/g\nBromides \u00fe 4100ppm 40.01%\nChloride \u2014 \u2014 \u00fe 120\nBarium \u00fe \u00fe \u00fe\nNitrites \u2014 \u00fe \u00fe 80\nAluminum \u2014 40.2ppm(a) 40.2mg/g(a)\nMagnesiumand \u00fe 4100ppm 40.01% 40\nalkalineearth\nmetals 0\nIodide \u00fe \u00fe \u00fe 0 20 40 60 80 100 120 140 160 180 200\nIron \u00fe 42ppm 42mg/g Compression pressure (MPa)\nSulfate \u00fe 4200ppm 40.02%\nFerrocyanides \u00fe \u00fe \u00fe\nHeavymetals 43ppm 45ppm 45ppm\nPhosphate \u00fe 425ppm 40.0025%\nPotassium \u2014 4500ppm(a)(b) 40.05%(a)(b) Sterility \u2014 \u2014 \u00fe\nBacterial \u2014 45IU/g(b) \u00fe\nendotoxins\nAssay(driedbasis) 99.0\u2013100.5% 99.0\u2013100.5% 99.0\u2013100.5%\n(a)Ifforuseinperitonealdialysis,hemodialysisorhemofiltrationsolutions.\n(b)Ifforparenteraluse.\nCompressibility Withsodiumchloridepowderoflessthan30mm\nparticle size, tablets are formed by plastic deformation; above\nthis size, both plastic deformation and fracture occur.(1,3,4) See\nalsoFigure1.\nDensity\n2.17g/cm3;\n1.20g/cm3forsaturatedaqueoussolution.\nDensity(bulk) 0.93g/cm3\nDensity(tapped) 1.09g/cm3\nDielectricconstant 5.9at1MHz\nFreezingpointdepression seeTableIII.\n)N(\nhtgnerts\ngnikaerb\ntelbaT\n400\n360\n320\n280\n240\n200\n160\nFigure1: Compressioncharacteristicsofsodiumchloride(cubic\ncrystals).(3)Tabletdiameter=12mm.\n2.0\n0.0\n\u22122.0\n)R/1(gol\n.vired\ndn2[\n\u00d7\n00001\n0.0\n1882\n2312 2372\n1382\n1415 1716 2209 2326\n1910\n)R/1(gol\n638 Sodium Chloride\nS\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\nFigure2: Near-infraredspectrumofsodiumchloridemeasuredby\nreflectance.Sodiumchloridedoesnotabsorbinthenear-infraredregion;\nhowever,itwillgenerallyshowsomepeaksduetotracesofmoisture\n(approx.1450nmand1950nm).", "mimetype": "text/plain", "start_char_idx": 34075, "end_char_idx": 36431, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5237f296-7c75-445c-96a7-b6d718c7eee6": {"__data__": {"id_": "5237f296-7c75-445c-96a7-b6d718c7eee6", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a1945f1-0522-4c9b-a9a1-c4b82d01bc91", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "733a5bd56eb284e272ada6118db9788260209c8244ec72cb9a49e4487a5519eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd", "node_type": "1", "metadata": {}, "hash": "a685fbbe98f48c80fadcedb90cfb7dfb94c32aadc14785663615b4f5a88a4d9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2.0\n0.0\n\u22122.0\n)R/1(gol\n.vired\ndn2[\n\u00d7\n00001\n0.0\n1882\n2312 2372\n1382\n1415 1716 2209 2326\n1910\n)R/1(gol\n638 Sodium Chloride\nS\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\nFigure2: Near-infraredspectrumofsodiumchloridemeasuredby\nreflectance.Sodiumchloridedoesnotabsorbinthenear-infraredregion;\nhowever,itwillgenerallyshowsomepeaksduetotracesofmoisture\n(approx.1450nmand1950nm).\n\n--- Page 7 ---\n\nSodium Chloride 639\n15 HandlingPrecautions\nTableIV: Solubilityofsodiumchloride.\nObservenormalprecautionsappropriatetothecircumstancesand\nSolvent Solubilityat208Cunlessotherwisestated\nquantity of material handled. If heated to high temperatures,\nEthanol Slightlysoluble sodiumchlorideevolvesavaporirritatingtotheeyes.\nEthanol(95%) 1in250\nGlycerin 1in10 16 RegulatoryStatus\nWater 1in2.8\n1in2.6at1008C GRAS listed. Included in the FDA Inactive Ingredients Database\n(injections; inhalations; nasal, ophthalmic, oral, otic, rectal, and\ntopical preparations). Included in nonparenteral and parenteral\nVaporpressure medicines licensed in the UK. Included in the Canadian List of\n133.3Paat8658Cforsolid; AcceptableNon-medicinalIngredients.\n1759.6Paat208Cforasaturatedaqueoussolution(equivalent\nto75.3%relativehumidity). 17 RelatedSubstances\nViscosity A 10% w/v solution has a viscosity of 1.19mPas Potassiumchloride.\n(1.19cP).\n18 Comments\n11 StabilityandStorageConditions Sodiumchlorideisoneofthematerialsthathavebeenselectedfor\nAqueous sodium chloride solutions are stable but may cause the harmonizationbythePharmacopeialDiscussionGroup.Forfurther\ninformation see the General Information Chapter <1196> in the\nseparationofglassparticlesfromcertaintypesofglasscontainers.\nUSP32\u2013NF27,theGeneralChapter5.8inPhEur6.0,alongwiththe\nAqueous solutions may be sterilized by autoclaving or filtration.\n\u2018Stateof Work\u2019 document onthe PhEurEDQM website, and also\nThe solid material is stable and should be stored in a well-closed\ntheGeneralInformationChapter8intheJPXV.\ncontainer,inacool,dryplace.\nDomestictablesaltmaycontainsodiumiodide(asaprophylac-\nIt has been shown that the compaction characteristics and the\ntic substance against goiter) and agents such as magnesium\nmechanical properties of tablets are influenced by the relative\ncarbonate, calcium phosphate, or starch, which reduce the\nhumidity of the storage conditions under which sodium chloride\nhygroscopiccharacteristicsofthesaltandmaintainthepowderin\nwaskept.(21,22)\nafree-flowingstate.\nFood-grade dendritic salt, which is porous, can be used as an\n12 Incompatibilities absorbentforliquidmedications,andasatabletdiluentinspecific\nformulations.\nAqueoussodiumchloridesolutionsarecorrosivetoiron.Theyalso\nEach gram of sodium chloride represents approximately\nreacttoformprecipitateswithsilver,lead,andmercurysalts.Strong\n17.1mmolofsodiumand17.1mmolofchloride;2.54gofsodium\noxidizingagentsliberatechlorinefromacidifiedsolutionsofsodium\nchlorideisapproximatelyequivalentto1gofsodium.\nchloride. The solubility of the antimicrobial preservative methyl-\nparabenisdecreasedinaqueoussodiumchloridesolutions(23)and A saturated solution of sodium chloride can be used as a\nconstant-humiditysolution;at258C,arelativehumidityof75%is\nthe viscosity of carbomer gels and solutions of hydroxyethyl\nproduced.", "mimetype": "text/plain", "start_char_idx": 36045, "end_char_idx": 39284, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd": {"__data__": {"id_": "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5237f296-7c75-445c-96a7-b6d718c7eee6", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "c8893945d6bee6123a85d00b639a6fe1f647a3566c4b2cf08787debecfed8c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad", "node_type": "1", "metadata": {}, "hash": "039e8e3fe6f7a3b96b14c640de56da1323ed64b8eba6c2fb586190f8e547e2ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Aqueoussodiumchloridesolutionsarecorrosivetoiron.Theyalso\nEach gram of sodium chloride represents approximately\nreacttoformprecipitateswithsilver,lead,andmercurysalts.Strong\n17.1mmolofsodiumand17.1mmolofchloride;2.54gofsodium\noxidizingagentsliberatechlorinefromacidifiedsolutionsofsodium\nchlorideisapproximatelyequivalentto1gofsodium.\nchloride. The solubility of the antimicrobial preservative methyl-\nparabenisdecreasedinaqueoussodiumchloridesolutions(23)and A saturated solution of sodium chloride can be used as a\nconstant-humiditysolution;at258C,arelativehumidityof75%is\nthe viscosity of carbomer gels and solutions of hydroxyethyl\nproduced. A specification for sodium chloride is contained in the\ncellulose or hydroxypropyl cellulose is reduced by the addition of\nFoodChemicalsCodex(FCC).(26)\nsodiumchloride.\nThe EINECS number for sodium chloride is 231-598-3. The\nPubChemCompoundID(CID)forsodiumchlorideis5234.\n13 MethodofManufacture\nS\nSodium chloride occurs naturally as the mineral halite. Commer- 19 SpecificReferences\ncially,itisobtainedbythesolarevaporationofseawater,bymining, 1 Leigh S et al. Compression characteristics of some pharmaceutical\norbytheevaporationofbrinefromundergroundsaltdeposits. materials.JPharmSci1967;56:888\u2013892.\n2 ReesJE,ShottonE.Someobservationsontheageingofsodiumchloride\ncompacts.JPharmPharmacol1970;22:17S\u201323S.\n14 Safety 3 ShottonE,ObiorahBA.Theeffectofparticleshapeandcrystalhabiton\nSodium chloride is the most important salt in the body for thepropertiesofsodiumchloride.JPharmPharmacol1973;25:37P\u2013\n43P.\nmaintaining the osmotic tension of blood and tissues. About\n4 RobertsRJetal.Brittle-ductiletransitionsindiecompactionofsodium\n5\u201312g of sodium chloride is consumed daily, in the normal adult\nchloride.ChemEngSci1989;44:1647\u20131651.\ndiet, and a corresponding amount is excreted in the urine. As an\n5 Hammouda Y et al. The use of sodium chloride as a directly\nexcipient, sodium chloride may be regarded as an essentially compressible filler. Part III: Drug-to-filler ratio. Pharm Ind 1978;\nnontoxicandnonirritantmaterial.However,toxiceffectsfollowing 40(9):987\u2013992.\ntheoralingestionof0.5\u20131.0g/kgbody-weightinadultsmayoccur. 6 Gonza\u00b4lez-RodriguezMLetal.Designandevaluationofanewcentral\nThe oral ingestion of larger quantities of sodium chloride, e.g. corematrixtablet.IntJPharm1997;146:175\u2013180.\n1000gin600mLofwater,(24)isharmfulandcaninduceirritation 7 Korsatko-Wabnegg B. [Development of press-coated tablets with\nof the gastrointestinal tract, vomiting, hypernatremia, respiratory\ncontrolled release effect using poly-D-(\u2013)-3-hydroxybutyric acid.]\nPharmazie1990;45:842\u2013844[inGerman].\ndistress,convulsions,ordeath.\n8 Moussa IS, Cartilier LH. Evaluation of crosslinked amylose press-\nIn rats, the minimum lethal intravenous dose is 2.5g/kg body- coatedtabletsforsustaineddrugdelivery.IntJPharm1997;149:139\u2013\nweight. 149.\nLD (mouse,IP):6.61g/kg(25) 9 O\u00a8zdemir N, Sahin J. Design of a controlled release osmotic pump\n50 systemofibuprofen.IntJPharm1997;158:91\u201397.\nLD 50 (mouse,IV):0.65g/kg 10 ShivanandP,SprockelOL.Acontrolledporositydrugdeliverysystem.\nLD (mouse,oral):4.0g/kg IntJPharm1998;167:83\u201396.", "mimetype": "text/plain", "start_char_idx": 38639, "end_char_idx": 41775, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad": {"__data__": {"id_": "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2a4688-fbb7-4370-9f4f-a0ddeec9eccd", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "eea1023689722ffba1fae15d83dc555f7dd2992bbb4c0c096830587506f284a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b03ed8e-0d46-411f-852f-160572c0feff", "node_type": "1", "metadata": {}, "hash": "bb1a31d7099b9f3d9af3abebab3f9c4312bab5408edf36684c8ad4b80d412fb5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmazie1990;45:842\u2013844[inGerman].\ndistress,convulsions,ordeath.\n8 Moussa IS, Cartilier LH. Evaluation of crosslinked amylose press-\nIn rats, the minimum lethal intravenous dose is 2.5g/kg body- coatedtabletsforsustaineddrugdelivery.IntJPharm1997;149:139\u2013\nweight. 149.\nLD (mouse,IP):6.61g/kg(25) 9 O\u00a8zdemir N, Sahin J. Design of a controlled release osmotic pump\n50 systemofibuprofen.IntJPharm1997;158:91\u201397.\nLD 50 (mouse,IV):0.65g/kg 10 ShivanandP,SprockelOL.Acontrolledporositydrugdeliverysystem.\nLD (mouse,oral):4.0g/kg IntJPharm1998;167:83\u201396.\n50\n11 TirkkonenS,ParonenP.Enhancementofdrugreleasefromethylcellu-\nLD (mouse,SC):3.0g/kg\n50 losemicrocapsulesusingsolidsodiumchlorideinthewall.IntJPharm\nLD (rat,oral):3.0g/kg 1992;88:39\u201351.\n50\n\n\n\ud83d\udcca Tables on Page 7:\n\n\nTable 1 (4 rows \u00d7 2 columns):\n\n| Solvent              | Solubility at 20\u00b0C unless otherwise stated |\n|----------------------|--------------------------------------------|\n| Ethanol              | Slightly soluble                           |\n| Ethanol (95%)        | 1 in 250                                  |\n| Glycerin             | 1 in 10                                   |\n| Water                | 1 in 2.8                                  |\n|                      | 1 in 2.6 at 100\u00b0C                         |\n\n\n\n--- Page 8 ---\n\n640 Sodium Citrate Dihydrate\n12 Tirkkonen S, Paronen P. Release of indomethacin from tabletted 23 McDonald C, Lindstrom RE. The effect of urea on the solubility of\nethylcellulosemicrocapsules.IntJPharm1993;92:55\u201362. methyl p-hydroxybenzoate in aqueous sodium chloride solution. J\n13 YuasaHetal.SuppressionofagglomerationinfluidizedbedcoatingI. PharmPharmacol1974;26:39\u201345.\nSuppressionofagglomerationbyaddingsodiumchloride.IntJPharm 24 Calam J et al. Extensive gastrointestinal damage following a saline\n1997;158:195\u2013201. emetic.DigDisSci1982;27:936\u2013940.\n14 Pandit NK, Wang D. Salt effects on the diffusion and release rate of 25 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\npropranololfrompoloxamer407gels.IntJPharm1998;167:183\u2013 edn. NewYork:Wiley,2004;3238\u20133239.\n189.\n26 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\n15 MishraB,PanditJK.Multiplewater-oil-wateremulsionsasprolonged\nPharmacopeia,2008;879.\nreleaseformulationsofpentazocine.JControlRelease1990;14:53\u201360.\n16 Shah D et al. Coacervate formation by inorganic salts with benzalk-\noniumchloride.JPharmSci1973;62:1741\u20131742. 20 GeneralReferences\n17 Richard AJ. Ultracentrifugal study of effect of sodium chloride on\nmicellesizeoffusidatesodium.JPharmSci1975;64:873\u2013875. European Directorate for the Quality of Medicines and Healthcare\n18 McDonaldC,RichardsonC.Theeffectofaddedsaltsonsolubilization (EDQM).EuropeanPharmacopoeia\u2013StateOfWorkOfInternational\nbyanon-ionicsurfactant.JPharmPharmacol1981;33:38\u201339. Harmonisation. Pharmeuropa 2009; 21(1): 142\u2013143. http://www.edq-\n19 MatthaAG.RheologicalstudiesonPlantagoalbicans(Psyllium)seed m.eu/site/-614.html(accessed3February2009).", "mimetype": "text/plain", "start_char_idx": 41227, "end_char_idx": 44192, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b03ed8e-0d46-411f-852f-160572c0feff": {"__data__": {"id_": "7b03ed8e-0d46-411f-852f-160572c0feff", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a7ed4e-a950-40eb-b9c6-e508a3d6aaad", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "cbef49d547dfe528ba5482ea0059c218dd20a418b7b3bc2cc272c902a92190a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3514730-c98a-4e1b-93e9-e9d37fb768b5", "node_type": "1", "metadata": {}, "hash": "b282c0bc9c4bd67045887375b154444282712f0887eb1a63ae59fffed38906cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "20 GeneralReferences\n17 Richard AJ. Ultracentrifugal study of effect of sodium chloride on\nmicellesizeoffusidatesodium.JPharmSci1975;64:873\u2013875. European Directorate for the Quality of Medicines and Healthcare\n18 McDonaldC,RichardsonC.Theeffectofaddedsaltsonsolubilization (EDQM).EuropeanPharmacopoeia\u2013StateOfWorkOfInternational\nbyanon-ionicsurfactant.JPharmPharmacol1981;33:38\u201339. Harmonisation. Pharmeuropa 2009; 21(1): 142\u2013143. http://www.edq-\n19 MatthaAG.RheologicalstudiesonPlantagoalbicans(Psyllium)seed m.eu/site/-614.html(accessed3February2009).\ngumdispersionsII:effectofsomepharmaceuticaladditives.PharmActa HengPWetal.Influenceofosmoticagentsindiffusionlayerondrugrelease\nHelv1977;52:214\u2013217. frommultilayercoatedpellets.DrugDevIndPharm2004;30(2):213\u2013\n20 OkorRS.Theeffectofphenolontheelectrolyteflocculationofcertain 220.\npolymericdispersionstothixotropicgels.PharmRes1993;10:220\u2013\n222.\n21 ElaminAAetal.Theeffectofpre-compactionprocessingandstorage 21 Author\nconditionson powderandcompactionproperties of somecrystalline\nJSMaximilien.\nmaterials.IntJPharm1994;108:213\u2013224.\n22 Ahlneck C, Alderborn G. Moisure adsorptionand tabletting. II. The\neffectontensilestrengthandairpermeabilityoftherelativehumidity\n22 DateofRevision\nduringstorageoftabletsof3crystallinematerials.IntJPharm1989;\n56:143\u2013150. 3February2009.\nSodium Citrate Dihydrate\n1 NonproprietaryNames 5 StructuralFormula\nBP:SodiumCitrate\nJP:SodiumCitrateHydrate\nS PhEur:SodiumCitrate\nUSP:SodiumCitrate\n2 Synonyms\nCitricacidtrisodiumsalt;E331;natriicitras;sodiumcitratetertiary;\ntrisodiumcitrate.\n6 FunctionalCategory\nAlkalizing agent; buffering agent; emulsifying agent; sequestering\nagent.\n3 ChemicalNameandCASRegistryNumber\nTrisodium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate 7 Applications in Pharmaceutical Formulation or\n[6132-04-3] Technology\nSodium citrate, as either the dihydrate or anhydrous material, is\nwidelyusedinpharmaceuticalformulations;seeTableI.\nIt is used in food products, primarily to adjust the pH of\nsolutions. It is also used as a sequestering agent. The anhydrous\nmaterialisusedineffervescenttabletformulations.(1)Sodiumcitrate\n4 EmpiricalFormulaandMolecularWeight is additionally used as a blood anticoagulant either alone or in\nC H Na O (cid:5)2H O 294.10 combinationwithothercitratessuchasdisodiumhydrogencitrate.\n6 5 3 7 2\n\n\n\ud83d\udcca Tables on Page 8:", "mimetype": "text/plain", "start_char_idx": 43639, "end_char_idx": 45984, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e3514730-c98a-4e1b-93e9-e9d37fb768b5": {"__data__": {"id_": "e3514730-c98a-4e1b-93e9-e9d37fb768b5", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b03ed8e-0d46-411f-852f-160572c0feff", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "3cef5278d015e812fa31d227e3c863cdcd26681585b41f6517b2dd229ec45514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f", "node_type": "1", "metadata": {}, "hash": "4290773b7aeb93e292270a37c3016a148dac9bbc69e98403181c2f8c40c672ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is used in food products, primarily to adjust the pH of\nsolutions. It is also used as a sequestering agent. The anhydrous\nmaterialisusedineffervescenttabletformulations.(1)Sodiumcitrate\n4 EmpiricalFormulaandMolecularWeight is additionally used as a blood anticoagulant either alone or in\nC H Na O (cid:5)2H O 294.10 combinationwithothercitratessuchasdisodiumhydrogencitrate.\n6 5 3 7 2\n\n\n\ud83d\udcca Tables on Page 8:\n\n\nTable 1 (32 rows \u00d7 1 columns):\n\n| **Sodium Citrate Dihydrate**                                                                 |\n|------------------------------------------------------------------------------------------------|\n| **1. Nonproprietary Names**                                                                    |\n| BP: Sodium Citrate                                                                              |\n| JP: Sodium Citrate Hydrate                                                                      |\n| PhEur: Sodium Citrate                                                                           |\n| USP: Sodium Citrate                                                                              |\n|                                                                                                |\n| **2. Synonyms**                                                                                 |\n| Citric acid trisodium salt; E331; natrii citras; sodium citrate tertiary; trisodium citrate.   |\n|                                                                                                |\n| **3. Chemical Name and CAS Registry Number**                                                   |\n| Trisodium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate [6132-04-3]                        |\n|                                                                                                |\n| **4. Empirical Formula and Molecular Weight**                                                  |\n| C\u2086H\u2085Na\u2083O\u2087\u00b72H\u2082O  294.10                                                                        |\n|                                                                                                |\n| **5. Structural Formula**                                                                        |\n| NaO.                                                                                           |\n|                                                                                                 |\n|                                                                                                 |\n| **6. Functional Category**                                                                       |\n| Alkalizing agent; buffering agent; emulsifying agent; sequestering agent.                      |\n|                                                                                                |\n| **7. Applications in Pharmaceutical Formulation or Technology**                                 |\n| Sodium citrate, as either the dihydrate or anhydrous material, is widely used in pharmaceutical |\n| formulations; see Table I. It is used in food products, primarily to adjust the pH of         |\n| solutions. It is also used as a sequestering agent. The anhydrous material is used in          |\n| effervescent tablet formulations.(1) Sodium citrate is additionally used as a blood           |\n| anticoagulant either alone or in combination with other citrates such as disodium hydrogen     |\n| citrate.                                                                                       |\n|                                                                                                |\n| **20. General References**                                                                      |\n| European Directorate for the Quality of Medicines and Healthcare (EDQM).                      |\n| European Pharmacopoeia \u2013 State Of Work Of International Harmonisation.                        |\n| Pharmeuropa 2009; 21(1): 142\u2013143. http://www.edqm.eu/site/-614.html (accessed 3 February 2009).|\n| Heng PW et al. Influence of osmotic agents in diffusion layer on drug release from multilayer   |\n| coated pellets. Drug Dev Ind Pharm 2004; 30(2): 213\u2013220.                                      |\n|                                                                                                |\n| **21. Author**                                                                                 |\n| JS Maximilien.                                                                                 |\n|                                                                                                |\n| **22. Date of Revision**                                                                        |\n| 3 February 2009.                                                                               |\n\n\n\n--- Page 9 ---\n\nSodium Citrate Dihydrate 641\nTherapeutically, sodium citrate is used to relieve the painful SEM1: Excipient:sodiumcitratedihydrate(granular);manufacturer:\nirritation caused by cystitis, and also to treat dehydration and\nPfizerLtd;magnification:60(cid:2).\nacidosisduetodiarrhea;seeSection14.\nTableI: Usesofsodiumcitratedihydrate.\nUse Concentration(%)\nBufferingagent 0.3\u20132.0\nInjections 0.02\u20134.0\nOphthalmicsolutions 0.1\u20132.0\nSequesteringagent 0.3\u20132.0\n8 Description\nSodiumcitratedihydrateconsistsofodorless,colorless,monoclinic\ncrystals,orawhitecrystallinepowderwithacooling,salinetaste.It\nis slightly deliquescent in moist air, and in warm dry air it is\nefflorescent.", "mimetype": "text/plain", "start_char_idx": 45575, "end_char_idx": 51064, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f": {"__data__": {"id_": "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3514730-c98a-4e1b-93e9-e9d37fb768b5", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "cc38ff71d412f8c3fa8c9f672dc3fd8a04769f5d476622f0f3e4578cbdcd834e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3a183c-4bfa-4f68-9df2-bd4a908e273f", "node_type": "1", "metadata": {}, "hash": "b925fe41c5ac59110536bac094e19c55e8c161a1bba30505d15c7e86a4ac6eab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "acidosisduetodiarrhea;seeSection14.\nTableI: Usesofsodiumcitratedihydrate.\nUse Concentration(%)\nBufferingagent 0.3\u20132.0\nInjections 0.02\u20134.0\nOphthalmicsolutions 0.1\u20132.0\nSequesteringagent 0.3\u20132.0\n8 Description\nSodiumcitratedihydrateconsistsofodorless,colorless,monoclinic\ncrystals,orawhitecrystallinepowderwithacooling,salinetaste.It\nis slightly deliquescent in moist air, and in warm dry air it is\nefflorescent. Although most pharmacopeias specify that sodium\ncitrateisthedihydrate,theUSP32statesthatsodiumcitratemaybe\neitherthedihydrateoranhydrousmaterial.\n9 PharmacopeialSpecifications\nSeeTableII.\nSEM2: Excipient:sodiumcitratedihydrate(granular);manufacturer:\nTableII: Pharmacopeialspecificationsforsodiumcitratedihydrate. PfizerLtd;magnification:600(cid:2).\nTest JPXV PhEur6.0 USP32\nIdentification \u00fe \u00fe \u00fe\nCharacters \u2014 \u00fe \u2014\npH 7.5\u20138.5 \u2014 \u2014\nAppearanceofsolution \u00fe \u00fe\u2014\nAcidityoralkalinity \u2014 \u00fe \u00fe\nLossondrying 10.0\u201313.0% \u2014 \u2014\nWater \u2014 11.0\u201313.0% 10.0\u201313.0%\nOxalate \u00fe 4300ppm \u2014\nSulfate 40.048% 4150ppm \u2014\nHeavymetals 410ppm 410ppm 40.001%\nArsenic 42ppm \u2014 \u2014\nChloride 40.015% 450ppm \u2014\nTartrate \u00fe \u2014 \u00fe\nReadilycarbonizable \u00fe \u00fe\u2014\nsubstances\nPyrogens \u2014 \u00fe(a) \u2014 S\nAssay(anhydrous 99.0\u2013101.0% 99.0\u2013101.0% 99.0\u2013100.5%\nbasis)\n(a)Ifintendedforuseinlarge-volumepreparationsforparenteraluse,compliancewith\natestforpyrogensmayberequired.\n10 TypicalProperties\nAcidity/alkalinity pH=7.0\u20139.0(5%w/vaqueoussolution) may cause the separation of small, solid particles from glass\nDensity(bulk) 1.12g/cm3 containers.\nDensity(tapped) 0.99g/cm3 Thebulkmaterialshouldbestoredinanairtightcontainerina\nDensity(true) 1.19g/cm3 cool,dryplace.\nMeltingpoint Convertstotheanhydrousformat1508C.\nNIRspectra seeFigure1.\n12 Incompatibilities\nOsmolarity A 3.02% w/v aqueous solution is iso-osmotic with\nAqueous solutions are slightly alkaline and will react with acidic\nserum.\nParticle size distribution Various grades of sodium citrate substances.Alkaloidalsaltsmaybeprecipitatedfromtheiraqueous\ndihydrate with different particle sizes are commercially avail- orhydro-alcoholsolutions.Calciumandstrontiumsaltswillcause\nable. precipitationofthecorrespondingcitrates.Otherincompatibilities\nSolubility Soluble 1 in 1.5 of water, 1 in 0.6 of boiling water; includebases,reducingagents,andoxidizingagents.\npracticallyinsolubleinethanol(95%).\n13 MethodofManufacture\n11 StabilityandStorageConditions Sodium citrate is prepared by adding sodium carbonate to a\nSodium citrate dihydrate is a stable material. Aqueous solutions solution of citric acid until effervescence ceases. The resulting\nmay be sterilized by autoclaving. On storage, aqueous solutions solutionisfilteredandevaporatedtodryness.\n\n--- Page 10 ---\n\n1.5 preparations).Includedinnonparenteralandparenteralmedicines\nlicensed in the UK. Included in the Canadian List of Acceptable\nNon-medicinalIngredients.\n17 RelatedSubstances\n0.0\nAnhydroussodiumcitrate;citricacidmonohydrate.", "mimetype": "text/plain", "start_char_idx": 50656, "end_char_idx": 53536, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b3a183c-4bfa-4f68-9df2-bd4a908e273f": {"__data__": {"id_": "5b3a183c-4bfa-4f68-9df2-bd4a908e273f", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c58279e-a9a6-40d2-b4f6-dd43d34c3a1f", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "dc21b902e57ff24e5a1b1e3ddd3a7899dd5d72b75be3b6b94a191b0f3d53396b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "395ae58a-093d-44d1-83fc-c87bffa547ad", "node_type": "1", "metadata": {}, "hash": "dca835727b2b0f8f7695a797d32cb58607a6bd6e76a4eed4256fabafc571565b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "practicallyinsolubleinethanol(95%).\n13 MethodofManufacture\n11 StabilityandStorageConditions Sodium citrate is prepared by adding sodium carbonate to a\nSodium citrate dihydrate is a stable material. Aqueous solutions solution of citric acid until effervescence ceases. The resulting\nmay be sterilized by autoclaving. On storage, aqueous solutions solutionisfilteredandevaporatedtodryness.\n\n--- Page 10 ---\n\n1.5 preparations).Includedinnonparenteralandparenteralmedicines\nlicensed in the UK. Included in the Canadian List of Acceptable\nNon-medicinalIngredients.\n17 RelatedSubstances\n0.0\nAnhydroussodiumcitrate;citricacidmonohydrate.\nAnhydroussodiumcitrate\nEmpiricalformula C H Na O\n6 5 3 7\nMolecularweight 258.07\nCASnumber [68-04-2]\nSynonyms anhydroustrisodium citrate;citric acidtrisodium salt\nanhydrous; trisodium 2-hydroxy-1,2,3-propanetricarboxylic\n\u22122.5\nacid.\nAppearance Colorlesscrystalsorawhitecrystallinepowder.\nSafety\nLD (mouse,IP):1.36g/kg(3)\n50\nLD (mouse,IV):0.17g/kg\n50\nLD (rabbit,IV):0.45g/kg\n50\nLD (rat,IP):1.55g/kg\n14 Safety 50\nAfter ingestion, sodium citrate is absorbed and metabolized to\n18 Comments\nbicarbonate. Although it is generally regarded as a nontoxic and\nnonirritant excipient, excessive consumption may cause gastro- Each gram of sodium citrate dihydrate represents approximately\nintestinal discomfort or diarrhea. Therapeutically, in adults, up to 10.2mmol of sodium and 3.4mmol of citrate. Each gram of\n15gdailyofsodiumcitratedihydratemaybeadministeredorally,in anhydrous sodium citrate represents approximately 11.6mmol of\ndivideddoses,asanaqueoussolutiontorelievethepainfulirritation sodiumand3.9mmolofcitrate.\ncausedbycystitis. The EINECS number for sodium citrate is 200-675-3. The\nCitratesandcitricacidenhanceintestinalaluminumabsorption PubChem Compound ID (CID) for sodium citrate dihydrate is\nin renal patients, which may lead to increased, harmful serum 71474.\naluminumlevels.Ithasthereforebeensuggestedthatpatientswith\nrenal failure taking aluminum compounds to control phosphate 19 SpecificReferences\nabsorptionshouldnotbeprescribedcitrate-orcitricacid-contain- 1 Anderson NR et al. Quantitative evaluation of pharmaceutical\ningproducts.(2)\neffervescentsystemsII:stabilitymonitoringofreactivityandporosity\nSee Section 17 for anhydrous sodium citrate animal toxicity measurements.JPharmSci1982;71:7\u201313.\ndata. 2 MainJ,WardMK.Potentiationofaluminumabsorptionbyefferves-\ncentanalgesictabletsinahaemodialysispatient.BrMedJ1992;304:\n1686.\n15 HandlingPrecautions\n3 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nObservenormalprecautionsappropriatetothecircumstancesand edn. NewYork:Wiley,2004;2572.\nquantityofmaterialhandled.Sodiumcitratedihydratedustmaybe\nirritanttotheeyesandrespiratorytract.Eyeprotectionandgloves 20 GeneralReferences\nare recommended. Sodium citrate should be handled in a well-\n\u2014\nventilatedenvironmentoradustmaskshouldbeworn.\n21 Author\n16 RegulatoryStatus\nGEAmidon.\nGRAS listed. Accepted for use as a food additive in Europe.\nIncluded in the FDA Inactive Ingredients Database (inhalations;\ninjections;ophthalmicproducts;oralsolutions,suspensions,syrups 22 DateofRevision\nand tablets; nasal, otic, rectal, topical, transdermal, and vaginal 6February2009.", "mimetype": "text/plain", "start_char_idx": 52906, "end_char_idx": 56127, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "395ae58a-093d-44d1-83fc-c87bffa547ad": {"__data__": {"id_": "395ae58a-093d-44d1-83fc-c87bffa547ad", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3a183c-4bfa-4f68-9df2-bd4a908e273f", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "74f4cdbaeff1e3b02122c96ea4552b29eb2e415d8a3fef6f90c1690f54adce10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fe8fe5e-e8f8-47dd-b75a-46469c361c47", "node_type": "1", "metadata": {}, "hash": "bc2df57b049642f5eb8427884edd8ec22593fbe9ee1ece3984abb8b5b8c65f92", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NewYork:Wiley,2004;2572.\nquantityofmaterialhandled.Sodiumcitratedihydratedustmaybe\nirritanttotheeyesandrespiratorytract.Eyeprotectionandgloves 20 GeneralReferences\nare recommended. Sodium citrate should be handled in a well-\n\u2014\nventilatedenvironmentoradustmaskshouldbeworn.\n21 Author\n16 RegulatoryStatus\nGEAmidon.\nGRAS listed. Accepted for use as a food additive in Europe.\nIncluded in the FDA Inactive Ingredients Database (inhalations;\ninjections;ophthalmicproducts;oralsolutions,suspensions,syrups 22 DateofRevision\nand tablets; nasal, otic, rectal, topical, transdermal, and vaginal 6February2009.\n)R/1(gol\n.vired\ndn2[\n\u00d7\n0001\n0.8\n2286 2331\n2263\n1708\n1684\n1176\n1744 2275\n1696\n1953 2318\n2297\n)R/1(gol\n642 Sodium Citrate Dihydrate\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\nFigure1: Near-infraredspectrumofsodiumcitratedihydratemeasured\nbyreflectance.\nS\n\n\n\ud83d\udcca Tables on Page 10:", "mimetype": "text/plain", "start_char_idx": 55527, "end_char_idx": 56419, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3fe8fe5e-e8f8-47dd-b75a-46469c361c47": {"__data__": {"id_": "3fe8fe5e-e8f8-47dd-b75a-46469c361c47", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "395ae58a-093d-44d1-83fc-c87bffa547ad", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "373bae676365989f64f8d979d245530b7f51d248b3602417bbbc9391c51a8702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af20ba09-5d3d-4b95-9195-4dbf3954ad39", "node_type": "1", "metadata": {}, "hash": "6607f78ce7a0e55b3601a44768dde0343b22c72f87beaf6c5c9fe0fab2798a8a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "S\n\n\n\ud83d\udcca Tables on Page 10:\n\n\nTable 1 (23 rows \u00d7 2 columns):\n\n| **Parameter**                          | **Value**                          |\n|----------------------------------------|------------------------------------|\n| Sodium Citrate Dihydrate              |                                    |\n| 1.5                                    | 2286                               |\n| 2331                                   | 0.8                                |\n| [2nd deriv. log(1/R)                  | 2263                               |\n|                                        |                                    |\n| Non-medicinal Ingredients              |                                    |\n|                                        |                                    |\n| Anhydrous sodium citrate; citric acid monohydrate. |                        |\n|                                        |                                    |\n| 1176                                   | 1744                               |\n| 2275                                   |                                    |\n| Anhydrous sodium citrate               |                                    |\n|                                        |                                    |\n| Empirical formula                      | C\u2086H\u2085Na\u2083O\u2087                         |\n| Molecular weight                       | 258.07                             |\n| CAS number                             | [68-04-2]                          |\n| Synonyms                               | anhydrous trisodium citrate; citric acid trisodium salt |\n|                                        |                                    |\n| Wavelength/nm                          |                                    |\n| \u22122.5                                   | 2297                               |\n| \u22120.2                                   |                                    |\n| 1100                                   | 1300                               |\n| 1500                                   | 1700                               |\n| 1900                                   | 2100                               |\n| 2300                                   | 2500                               |\n|                                        |                                    |\n| Appearance                             | Colorless crystals or a white crystalline powder. |\n|                                        |                                    |\n| Safety                                 |                                    |\n| LD\u2085\u2080 (mouse, IP)                      | 1.36 g/kg(3)                       |\n| LD\u2085\u2080 (mouse, IV)                      | 0.17 g/kg                          |\n| LD\u2085\u2080 (rabbit, IV)                     | 0.45 g/kg                          |\n| LD\u2085\u2080 (rat, IP)                        | 1.55 g/kg                          |\n|                                        |                                    |\n| Comments                               |                                    |\n| Each gram of sodium citrate dihydrate represents approximately 10.2 mmol of sodium and 3.4 mmol of citrate. Each gram of anhydrous sodium citrate represents approximately 11.6 mmol of sodium and 3.9 mmol of citrate. | |\n| The EINECS number for sodium citrate is 200-675-3. The PubChem Compound ID (CID) for sodium citrate dihydrate is 71474. | |\n|                                        |                                    |\n| Specific References                    |                                    |\n| 1  Anderson NR et al.                 | Quantitative evaluation of pharmaceutical effervescent systems II: stability monitoring of reactivity and porosity measurements. J Pharm Sci 1982; 71: 7\u201313. |\n| 2  Main J, Ward MK.                   | Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J 1992; 304: 1686. |\n| 3  Lewis RJ, ed.                      | Sax\u2019s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004; 2572. |\n|                                        |                                    |\n| Handling Precautions                   |                                    |\n| Observe normal precautions appropriate to the circumstances and quantity of material handled. Sodium citrate dihydrate dust may be irritant to the eyes and respiratory tract. Eye protection and gloves are recommended. Sodium citrate should be handled in a well-ventilated environment or a dust mask should be worn. | |\n|                                        |                                    |\n| Regulatory Status                      |                                    |\n| GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (inhalations; injections; ophthalmic products; oral solutions, suspensions, syrups and tablets; nasal, otic, rectal, topical, transdermal, and vaginal). | |\n|                                        |                                    |\n| Author                                 | GE Amidon.                        |\n| Date of Revision                       | 6 February 2009.                  |", "mimetype": "text/plain", "start_char_idx": 56395, "end_char_idx": 61602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af20ba09-5d3d-4b95-9195-4dbf3954ad39": {"__data__": {"id_": "af20ba09-5d3d-4b95-9195-4dbf3954ad39", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fe8fe5e-e8f8-47dd-b75a-46469c361c47", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "953fc9343c27ca2d4b78b837fcb3361b931c0240bb5f42be7b741c7f2f065f1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb24da0-d3a7-428e-8790-6481c542a5f5", "node_type": "1", "metadata": {}, "hash": "a98bbcc2db3a89ffba4cf422e6d280acf22f0b23aa8e38abd178e8e388590a60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 11 ---\n\nSodium Cyclamate\n1 NonproprietaryNames\nTableI: Pharmacopeialspecificationsforsodiumcyclamate.\nBP:SodiumCyclamate\nTest PhEur6.0\nPhEur:SodiumCyclamate\nIdentification \u00fe\nCharacters \u00fe\nAppearanceofsolution \u00fe\n2 Synonyms pH(10%w/vaqueoussolution) 5.5\u20137.5\nAbsorbanceat270nm 40.10\nCyclamate sodium; cyclohexylsulfamic acid monosodium salt; Sulfamicacid \u00fe\nE952;natriicyclamas;sodiumcyclohexanesulfamate. Aniline 41ppm\nCyclohexylamine 410ppm\nDicyclohexylamine 41ppm\nSulfates 40.1%\n3 ChemicalNameandCASRegistryNumber Heavymetals 410ppm\nLossondrying 41.0%\nSodiumN-cyclohexylsulfamate [139-05-9] Assay(driedbasis) 98.5\u2013101.0%\n4 EmpiricalFormulaandMolecularWeight\n10 TypicalProperties\nC 6 H 12 NNaO 3 S 201.22 Acidity/alkalinity pH=5.5\u20137.5fora10%w/vaqueoussolution.\nNIRspectra seeFigure1.\nSolubility seeTableII.\n5 StructuralFormula\nTableII: Solubilityofsodiumcyclamate.\nSolvent Solubilityat208Cunlessotherwisestated\nBenzene Practicallyinsoluble\nChloroform Practicallyinsoluble\nEthanol(95%) 1in250\nEther Practicallyinsoluble\nPropyleneglycol 1in25\nWater 1in5\n1in2at458C\n6 FunctionalCategory\nSweeteningagent.\n11 StabilityandStorageConditions\nSodium cyclamate is hydrolyzed by sulfuric acid and cyclohex-\n7 Applications in Pharmaceutical Formulation or ylamineataveryslowratethatisproportionaltothehydrogenion\nTechnology concentration.Therefore,forallpracticalconsiderations,itcanbe\nSodium cyclamate is used as an intense sweetening agent in regarded as stable. Solutions are also stable to heat, light, and air\npharmaceutical formulations, foods, beverages, and table-top overawidepHrange.\nsweeteners. In dilute solution, up to about 0.17% w/v, the\nsweetening power is approximately 30 times that of sucrose. 3.0\nHowever, at higher concentrations this is reduced and at a\nconcentration of 0.5% w/v a bitter taste becomes noticeable.\nSodiumcyclamateenhancesflavorsystemsandcanbeusedtomask\n0.0\nsomeunpleasanttastecharacteristics.Inmostapplications,sodium\ncyclamateisusedincombinationwithsaccharin,ofteninaratioof\n10:1.(1)\n8 Description\nSodium cyclamate occurs as white, odorless or almost odorless\ncrystals,orasacrystallinepowderwithanintenselysweettaste. \u22127.0\n9 PharmacopeialSpecifications\nSeeTableI.\n)R/1(gol\n.vired\ndn2[\n\u00d7\n0001\n0.8\n1578 1592 2107 2137 2327 2363\n1208\n1605 2310\n2210 2346\n1564\n2122\n)R/1(gol\nS\n\u22120.2\n1100 1300 1500 1700 1900 2100 2300 2500\nWavelength/nm\nFigure1: Near-infraredspectrumofsodiumcyclamatemeasuredby\nreflectance.\n643\n\n\n\ud83d\udcca Tables on Page 11:", "mimetype": "text/plain", "start_char_idx": 61606, "end_char_idx": 64068, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cbb24da0-d3a7-428e-8790-6481c542a5f5": {"__data__": {"id_": "cbb24da0-d3a7-428e-8790-6481c542a5f5", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af20ba09-5d3d-4b95-9195-4dbf3954ad39", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "2860a6adf3fce1582930051af0d06f30336253acb17042dd6d6ac9d66ce7a1b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "123e9725-4ccd-4122-900d-71d141b2d346", "node_type": "1", "metadata": {}, "hash": "e3c53421cda9eaa55eaf757f7ea23eee74f13e802e5cae28115322910ef0900c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\ud83d\udcca Tables on Page 11:\n\n\nTable 1 (13 rows \u00d7 2 columns):\n\n| Test                              | PhEur 6.0      |\n|-----------------------------------|-----------------|\n| Identification                    | \u00fe               |\n| Characters                        | \u00fe               |\n| Appearance of solution            | \u00fe               |\n| pH (10% w/v aqueous solution)     | 5.5\u20137.5        |\n| Absorbance at 270 nm              | 40.10          |\n| Sulfamic acid                     | \u00fe               |\n| Aniline                           | 41 ppm         |\n| Cyclohexylamine                   | 410 ppm        |\n| Dicyclohexylamine                 | 41 ppm         |\n| Sulfates                          | 40.1%          |\n| Heavy metals                      | 410 ppm        |\n| Loss on drying                    | 41.0%          |\n| Assay (dried basis)               | 98.5\u2013101.0%    |\n\n\n\nTable 2 (6 rows \u00d7 2 columns):\n\n| Solvent               | Solubility at 20\u00b0C unless otherwise stated |\n|----------------------|--------------------------------------------|\n| Benzene              | Practically insoluble                      |\n| Chloroform           | Practically insoluble                      |\n| Ethanol (95%)        | 1 in 250                                  |\n| Ether                | Practically insoluble                      |\n| Propylene glycol     | 1 in 25                                   |\n| Water                | 1 in 5                                    |\n|                      | 1 in 2 at 45\u00b0C                            |\n\n\n\n--- Page 12 ---\n\n644 Sodium Cyclamate\nSamples of tablets containing sodium cyclamate and saccharin cyclohexylamine. However, this is no longer the case, and\nhaveshownnolossinsweeteningpowerfollowingstorageforupto cyclamatesarenowpermittedforuseasafoodadditiveinEurope.\n20years. IncludedintheFDAInactiveIngredientsDatabase(oralpowder,\nThebulkmaterialshouldbestoredinawell-closedcontainerina solutions,chewabletablets,andsuspensions).Includedinnonpar-\ncool,dryplace. enteralmedicineslicensedintheUK.IncludedintheCanadianList\nofAcceptableNon-medicinalIngredients.\n12 Incompatibilities\n\u2014 17 RelatedSubstances\nAlitame;calciumcyclamate;cyclamicacid.\n13 MethodofManufacture\nCalciumcyclamate\nCyclamatesarepreparedbythesulfonationofcyclohexylaminein Empiricalformula C H CaN O S (cid:5)2H O\nthe presence of a base. Commercially, the sulfonation can involve 12 24 2 6 2 2\nMolecularweight 432.57\nsulfamicacid,asulfatesalt,orsulfurtrioxide.Tertiarybasessuchas\nCASnumber\ntriethylamine or trimethylamine may be used as the condensing\nagent.Theaminesaltsofcyclamatethatareproducedareconverted [5897-16-5]forthedihydrate;\ntothesodium,calcium,potassium,ormagnesiumsaltbytreatment [139-06-0]fortheanhydrousform.\nwiththeappropriatemetaloxide. Synonyms Calcium N-cyclohexylsulfamate dihydrate; Cyclan;\ncyclohexanesulfamic acid calcium salt; cyclohexylsulfamic acid\n14 Safety calciumsalt;E952;Sucarylcalcium.\nAppearance White, odorless or almost odorless crystals or a\nThere has been considerable controversy concerning the safety of\ncrystallinepowderwithanintenselysweettaste.\ncyclamatefollowingtheFDAdecisionin1970tobanitsuseinthe\nUSA.(2\u20134) This decision resulted from a feeding study in rats that Acidity/alkalinity pH=5.5\u20137.5fora10%w/vaqueoussolution.\nSolubility Freely soluble in water; practically insoluble in\nsuggested that cyclamate could cause an unusual form of bladder\nbenzene,chloroform,ethanol(95%),andether.\ncancer.However,thatstudyhasbeencriticizedbecauseitinvolved\nvery high doses of cyclamate administered with saccharin, which Cyclamicacid\nhasitselfbeenthesubjectofcontroversyconcerningitssafety;see Empiricalformula C H NO S\n6 13 3\nSaccharin.", "mimetype": "text/plain", "start_char_idx": 64048, "end_char_idx": 67738, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "123e9725-4ccd-4122-900d-71d141b2d346": {"__data__": {"id_": "123e9725-4ccd-4122-900d-71d141b2d346", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb24da0-d3a7-428e-8790-6481c542a5f5", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "877585a1b4de7ab861504a1a741f581b1cb04b1b7d4add18b0617cc852c0a00d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce2633fb-05e6-4b10-b363-b8441b2742d7", "node_type": "1", "metadata": {}, "hash": "8351e3e7833c53ef7123ba019ec7c9b7b87ab69bc7f420a0fc5bb703349ad5da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "cyclamatefollowingtheFDAdecisionin1970tobanitsuseinthe\nUSA.(2\u20134) This decision resulted from a feeding study in rats that Acidity/alkalinity pH=5.5\u20137.5fora10%w/vaqueoussolution.\nSolubility Freely soluble in water; practically insoluble in\nsuggested that cyclamate could cause an unusual form of bladder\nbenzene,chloroform,ethanol(95%),andether.\ncancer.However,thatstudyhasbeencriticizedbecauseitinvolved\nvery high doses of cyclamate administered with saccharin, which Cyclamicacid\nhasitselfbeenthesubjectofcontroversyconcerningitssafety;see Empiricalformula C H NO S\n6 13 3\nSaccharin. Although excreted almost entirely unchanged in the Molecularweight 179.23\nurine, a potentially harmful metabolite of sodium cyclamate, CASnumber [100-88-9]\ncyclohexylamine,hasbeendetectedinhumans.(5)Inaddition,there\nSynonyms Cyclamate; cyclohexanesulfamic acid; N-cyclohexyl-\nisevidencetosuggestcyclamateismetabolizedtocyclohexylamine sulfamicacid;E952;hexamicacid;Sucaryl.\nby the microflora in the large intestine of some individuals Appearance White, odorless or almost odorless crystals or a\n(approximately 25% of the population with higher precedence in crystallinepowderwithanintenselysweettaste.\nJapanesethan EuropeansorNorthAmericans). Cyclohexylamine, Meltingpoint 169\u20131708C\nfollowing absorption, is metabolized to an extent of 1-2% to Solubility Slightlysolubleinwater.\ncyclohexanol and cyclohexane-1,2-diol. Established no-observed-\neffect level (NOEL) and acceptable daily intake (ADI) values are\nbasedoncyclohexylaminelevelsofhighcyclamateconverters.(6,7) 18 Comments\nExtensivelong-termanimalfeedingstudiesandepidemiological The perceived intensity of sweeteners relative to sucrose depends\nstudiesinhumanshavefailedtoshowanyevidencethatcyclamate upontheir concentration, temperature of tasting, and pH, and on\nis carcinogenic or mutagenic.(8,9) As a result, sodium cyclamate is theflavorandtextureoftheproductconcerned.\nnow accepted in many countries for use in foods and pharmaceu- Intensesweeteningagentswillnotreplacethebulk,textural,or\nS\nticalformulations.SeealsoSection16. preservativecharacteristicsofsucroseifsucroseisremovedfroma\nFew adverse reactions to cyclamate have been reported, formulation.\nalthoughitsusehasbeenassociatedwithinstancesofphotosensitive Synergistic effects for combinations of sweeteners have been\ndermatitis.(10)\nreported, e.g. sodium cyclamate with saccharin sodium or\nThe WHO has set an estimated acceptable daily intake for\nacesulfamepotassium.\nsodiumandcalciumcyclamate,expressedascyclamicacid,atupto\nSodiumcyclamatehasalsobeenusedtoincreasethesolubilityof\n11mg/kgbody-weight.(11)InEurope,atemporaryacceptabledaily\nneohesperidindihydrochalconeinsweetenerblends.(13)\nintake for sodium and calcium cyclamate, expressed as cyclamic\nThe PubChem Compound ID (CID) for sodium cyclamate is\nacid,hasbeensetatupto1.5mg/kgbody-weight.\n23665706.\nLD (mouse,IP):1.15g/kg(12)\n50\nLD 50 (mouse,IV):4.8g/kg 19 SpecificReferences\nLD (mouse,oral):17g/kg\n50 1 Bernryma GH et al. A case for safety of cyclamate and cyclamate-\nLD 50 (rat,IP):1.35g/kg saccharincombinations.AmJClinNutr1968;21(6):673\u2013687.\nLD (rat,IV):3.5g/kg 2 Nabors LO, Miller WT. Cyclamate: a toxicological review. Commen\n50\nToxicol1989;3(4):307\u2013315.", "mimetype": "text/plain", "start_char_idx": 67154, "end_char_idx": 70383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce2633fb-05e6-4b10-b363-b8441b2742d7": {"__data__": {"id_": "ce2633fb-05e6-4b10-b363-b8441b2742d7", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "123e9725-4ccd-4122-900d-71d141b2d346", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "fcf09b0e135badaefee62c0f6d84fe00f50256e05352b22ae2f43b4975f090a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce24f24-3e71-4dd4-b6e0-20f07028ab68", "node_type": "1", "metadata": {}, "hash": "0f86817b13ed0e7055cbd2643d912cda92c234e8beb48ac75d410d292b29811d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "23665706.\nLD (mouse,IP):1.15g/kg(12)\n50\nLD 50 (mouse,IV):4.8g/kg 19 SpecificReferences\nLD (mouse,oral):17g/kg\n50 1 Bernryma GH et al. A case for safety of cyclamate and cyclamate-\nLD 50 (rat,IP):1.35g/kg saccharincombinations.AmJClinNutr1968;21(6):673\u2013687.\nLD (rat,IV):3.5g/kg 2 Nabors LO, Miller WT. Cyclamate: a toxicological review. Commen\n50\nToxicol1989;3(4):307\u2013315.\nLD (rat,oral):15.25g/kg\n50 3 Lecos C. The sweet and sour history of saccharin, cyclamate and\naspartame.FDAConsumer1981;15(7):8\u201311.\n15 HandlingPrecautions 4 Anonymous. Cyclamate alone not a carcinogen. Am Pharm 1985;\nObservenormalprecautionsappropriatetothecircumstancesand NS25(9):11.\nquantityofmaterialhandled.Eyeprotectionisrecommended. 5 KojimaS, Ichibagase H.Studieson synthetic sweetening agents VIII.\nCyclohexylamine,ametaboliteofsodiumcyclamate.ChemPharmBull\n1966;14:971\u2013974.\n16 RegulatoryStatus\n6 MitchellH,ed.SweetenersandSugarAlternativesinFoodTechnology.\nTheuseofcyclamatesasartificialsweetnersinfood,softdrinks,and Oxford:BlackwellScientific,2006;123.\nartificial sweetening tablets was at one time prohibited in the UK 7 BoppB,PriceP.AlternativeSweeteners,3rdedn. NewYork:Marcel\nand some other countries owing to concern about the metabolite Dekker,Inc.,2001;63\u201385.\n\n\n\ud83d\udcca Tables on Page 12:\n\n\nTable 1 (2 rows \u00d7 3 columns):\n\n| Section | Title                                   | Details                                                                                          |\n|---------|-----------------------------------------|--------------------------------------------------------------------------------------------------|\n| 12      | Incompatibilities                       | cyclohexylamine. However, this is no longer the case, and cyclamates are now permitted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Database (oral powder, solutions, chewable tablets, and suspensions). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| 17      | Related Substances                     | Alitame; calcium cyclamate; cyclamic acid. Cyclamates are prepared by the sulfonation of cyclohexylamine in the presence of a base. Commercially, the sulfonation can involve sulfamic acid, a sulfate salt, or sulfur trioxide. Tertiary bases such as triethylamine or trimethylamine may be used as the condensing agent. The amine salts of cyclamate that are produced are converted to the sodium, calcium, potassium, or magnesium salt by treatment with the appropriate metal oxide. |\n|         | Calcium cyclamate                      | Empirical formula: C\u2081\u2082H\u2082\u2084CaN\u2082O\u2086S\u2082\u21022H\u2082O\n\n\n\n--- Page 13 ---\n\nSodium Formaldehyde Sulfoxylate 645\n8 D\u2019ArcyPF.Adversereactionstoexcipientsinpharmaceuticalformula- 20 GeneralReferences\ntions. Florence AT, Salole EG, eds. Formulation Factors in Adverse\nAnonymous.Saccharinissafe.ChemBr2001;37(4):18.\nReactions.London:Wright,1990;1\u201322.\nSchiffman SS et al. Effect of temperature, pH, and ions on sweet taste.\n9 Schma\u00a8hl D, Habs M. Investigations on the carcinogenicity of the\nPhysiolBehav2000;68(4):469\u2013481.\nartificialsweetenerssodiumcyclamateandsodiumsaccharininratsina\ntwo-generationexperiment.Arzneimittelforschung1984;34:604\u2013606.\n10 YongJM,SandersonKV. Photosensitive dermatitisandrenaltubular\nacidosisafteringestionof calciumcyclamate. Lancet1969;ii: 1273\u2013\n1274. 21 Author\n11 FAO/WHO.", "mimetype": "text/plain", "start_char_idx": 70012, "end_char_idx": 73410, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bce24f24-3e71-4dd4-b6e0-20f07028ab68": {"__data__": {"id_": "bce24f24-3e71-4dd4-b6e0-20f07028ab68", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce2633fb-05e6-4b10-b363-b8441b2742d7", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "c18e4cc81ba9a3909a1897414309aa0d43ea33f1f7bbd82f2737e458b3132fae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "386aca1d-221f-4bed-8f0b-a93bfd4bde2b", "node_type": "1", "metadata": {}, "hash": "913b7bf5a13efeff562da7e4c215c202e55e4fc92c03ddaff62b4a4d524d3214", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Formulation Factors in Adverse\nAnonymous.Saccharinissafe.ChemBr2001;37(4):18.\nReactions.London:Wright,1990;1\u201322.\nSchiffman SS et al. Effect of temperature, pH, and ions on sweet taste.\n9 Schma\u00a8hl D, Habs M. Investigations on the carcinogenicity of the\nPhysiolBehav2000;68(4):469\u2013481.\nartificialsweetenerssodiumcyclamateandsodiumsaccharininratsina\ntwo-generationexperiment.Arzneimittelforschung1984;34:604\u2013606.\n10 YongJM,SandersonKV. Photosensitive dermatitisandrenaltubular\nacidosisafteringestionof calciumcyclamate. Lancet1969;ii: 1273\u2013\n1274. 21 Author\n11 FAO/WHO. Evaluation of certain food additives and contaminants.\nTwenty-sixthreportofthejointFAO/WHOexpertcommitteeonfood PLGoggin.\nadditives.WorldHealthOrganTechRepSer1982;No.683.\n12 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;3243.\n13 Benavente-GarciaOetal.Improvedwatersolubilityofneohesperidin\n22 DateofRevision\ndihydrochalconeinsweetenerblends.JAgricFoodChem2001;49(1):\n189\u2013191. 12December2008.\nSodium Formaldehyde Sulfoxylate\n1 NonproprietaryNames 8 Description\nUSP-NF:SodiumFormaldehydeSulfoxylate Whenfreshlyprepared,sodiumformaldehydesulfoxylateoccursas\nwhite, odorless crystals, which quickly develop a characteristic\n2 Synonyms garlicodoronstanding.\nFormaldehyde hydrosulfite; formaldehyde sodium sulfoxylate;\nformaldehydesulfoxylic acid sodium salt; methanesulfinic acid, 9 PharmacopeialSpecifications\nhydroxy-, monosodium salt; monosodium hydroxymethane sulfi-\nSeeTableI.\nnate;Rongalite;sodiumhydroxymethanesulfinate;sodiumhydro-\nxymethylsulfinate; sodium methanalsulfoxylate; sodium\nTableI: Pharmacopeialspecificationsforsodiumformaldehyde\nsulfinomethanolate.\nsulfoxylate.\n3 ChemicalNameandCASRegistryNumber Test USP32\u2013NF27\nSodiumformaldehydesulfoxylate [149-44-0] Identification \u00fe\nSodiumformaldehydesulfoxylatedihydrate [6035-47-8] Clarityandcolorofsolution \u00fe\nAlkalinity \u00fe S\npH(1in50solution) 9.5\u201310.5\n4 EmpiricalFormulaandMolecularWeight Lossondrying 427.0%\nCH NaO S 118.09 Sulfide \u00fe\n3 3\nCH NaO S(cid:5)2H O 154.11 Iron \u00fe\n3 3 2 Sodiumsulfite 45.0%\nAssay(assulfurdioxide) 45.5\u201354.5%\n5 StructuralFormula\nNote:USP32\u2013NF27alsostatesthatsodiumformaldehydesulfoxylatemaycontaina\nsuitablestabilizersuchassodiumcarbonate.\n10 TypicalProperties\nAcidity/alkalinity pH=9.5\u201310.5(2%w/vaqueoussolution)\nMeltingpoint 64\u2013688C(dihydrate)\nSolubility Freely soluble in water; slightly soluble in ethanol,\nchloroform,etherandbenzene.\n6 FunctionalCategory\nAntioxidant. 11 StabilityandStorageConditions\nStore in well-closed, light-resistant containers at controlled room\n7 Applications in Pharmaceutical Formulation or temperature(15\u2013308C).\nTechnology\nSodium formaldehyde sulfoxylate is a water-soluble antioxidant\n12 Incompatibilities\nandisgenerallyusedasthedihydrate.Itisusedintheformulation\nof injection products at a level of up to 0.1% w/v in the final Sodium formaldehyde sulfoxylate is incompatible with strong\npreparationadministeredtothepatient. oxidizingagents;itisdecomposedbydiluteacid.", "mimetype": "text/plain", "start_char_idx": 72845, "end_char_idx": 75833, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "386aca1d-221f-4bed-8f0b-a93bfd4bde2b": {"__data__": {"id_": "386aca1d-221f-4bed-8f0b-a93bfd4bde2b", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce24f24-3e71-4dd4-b6e0-20f07028ab68", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d380fbd3428e66a3c50922b4091d4ee9471bc7e21a7a8385c33c55a37630a689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ad2ca9f-da1b-4f66-9c77-4263a95aca32", "node_type": "1", "metadata": {}, "hash": "b0e57419448ae21b2ebefd483a578ce39eb4a6cb0605e38578fd2069cd1e47e7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6 FunctionalCategory\nAntioxidant. 11 StabilityandStorageConditions\nStore in well-closed, light-resistant containers at controlled room\n7 Applications in Pharmaceutical Formulation or temperature(15\u2013308C).\nTechnology\nSodium formaldehyde sulfoxylate is a water-soluble antioxidant\n12 Incompatibilities\nandisgenerallyusedasthedihydrate.Itisusedintheformulation\nof injection products at a level of up to 0.1% w/v in the final Sodium formaldehyde sulfoxylate is incompatible with strong\npreparationadministeredtothepatient. oxidizingagents;itisdecomposedbydiluteacid.\n\n--- Page 14 ---\n\n646 Sodium Hyaluronate\n13 MethodofManufacture Comments Used as an additive in polymers and textiles. The\nSodium formaldehyde sulfoxylate is manufactured from sodium EINECSnumberis246-515-6.\ndithionateandformaldehydeinwater.\n18 Comments\n14 Safety Sodium formaldehyde sulfoxylate has been investigated as an\nThe toxicological properties of sodium formaldehyde sulfoxylate antidotetomercurypoisoning,butisconsideredlesseffectivethan\nhave not been fully investigated. However, it is used in the dimercaprol(Britishanti-lewisite(BAL))andothertreatments.(3,4)It\nformulation of injection products at a level to 0.1% w/v in the isalsousedasanindustrialbleach.Itisusedinchemicalsynthesisas\nfinalpreparationadministeredtothepatient. a nucleophilic agent in the preparation of sulfones. The empirical\nSodium formaldehyde sulfoxylate is moderately toxic by formula and molecular weight are also given as CH O SNa and\n4 3\ningestion, and when heated to decomposition it emits toxic fumes 119.1,respectively.(1)\nofsulfurdioxideandsodiumoxide.(1)\nThe EINECS number for sodium formaldehyde sulfoxylate is\nLD (mouse,oral):4g/kg(1,2) 205-739-4.ThePubChemCompoundIDforsodiumformaldehyde\n50\nLD (rat,IP):>2g/kg(2) sulfoxylateis23725019.\n50\nLD (rat,oral):>2g/kg(2)\n50 19 SpecificReferences\n1 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\n15 HandlingPrecautions\nedn. NewYork:Wiley,2004;1815.\nObservenormalprecautionsappropriatetothecircumstancesand 2 Sigma-Aldrich. Material safety data sheet: Sodium formaldehyde\nquantityofthematerialhandled.Maycauseirritationoftheeyes, sulfoxylate,Australia,2004.\nskin,respiratorytractanddigestivetract;theuseofeyeprotection,a 3 Stocken LA. British anti-lewisite as an antidote for acute mercury\nrespiratorandglovesisstronglyrecommended. poisoning.BiochemJ1947;41:358\u2013360.\n4 Lehotzky K. Protection by spironolactone and different antidotes\n16 RegulatoryStatus against acute organic mercury poisoning of rats. Int Arch Occup\nEnvironHealth1974;33:329\u2013334.\nIncluded in the FDA Inactive Ingredients Database (parenteral\nproductsupto0.1%viatheIM,IV,andSCroutes).Includedinthe\n20 GeneralReferences\nCanadianListofAcceptableNon-medicinalIngredients.\n\u2014\n17 RelatedSubstances\n21 Author\nZincformaldehydesulfoxylate.\nRCMoreton.\nZincformaldehydesulfoxylate\nEmpiricalformula C H O S Zn\n2 6 6 2 22 DateofRevision\nMolecularweight 256.5\nCASnumber [24887-06-7] 3March2009.\nS Sodium Hyaluronate\n1 NonproprietaryNames 5 StructuralFormula\nBP:SodiumHyaluronate\nPhEur:SodiumHyaluronate\n2 Synonyms\nHyaluronan;hyaluronatesodium;natriihyaluronas;RITAHAC-\n1-C.", "mimetype": "text/plain", "start_char_idx": 75271, "end_char_idx": 78412, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ad2ca9f-da1b-4f66-9c77-4263a95aca32": {"__data__": {"id_": "3ad2ca9f-da1b-4f66-9c77-4263a95aca32", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "386aca1d-221f-4bed-8f0b-a93bfd4bde2b", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d7b795f04b572a2a46f3683029676bba78e533f677698ac18b4d87dc353a8dd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78d39aa9-54e6-4103-b06a-385cb429b7f9", "node_type": "1", "metadata": {}, "hash": "777737fdf0158418e40f0d84cc5f83785782d9e0aef5a475d9bdca8563185513", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Included in the FDA Inactive Ingredients Database (parenteral\nproductsupto0.1%viatheIM,IV,andSCroutes).Includedinthe\n20 GeneralReferences\nCanadianListofAcceptableNon-medicinalIngredients.\n\u2014\n17 RelatedSubstances\n21 Author\nZincformaldehydesulfoxylate.\nRCMoreton.\nZincformaldehydesulfoxylate\nEmpiricalformula C H O S Zn\n2 6 6 2 22 DateofRevision\nMolecularweight 256.5\nCASnumber [24887-06-7] 3March2009.\nS Sodium Hyaluronate\n1 NonproprietaryNames 5 StructuralFormula\nBP:SodiumHyaluronate\nPhEur:SodiumHyaluronate\n2 Synonyms\nHyaluronan;hyaluronatesodium;natriihyaluronas;RITAHAC-\n1-C.\n3 ChemicalNameandCASRegistryNumber\nSodiumhyaluronate [9067-32-7]\n4 EmpiricalFormulaandMolecularWeight 6 FunctionalCategory\n(C H NO Na) (401.3) Humectant;lubricant;sustained-releaseagent.\n14 20 11 n n\n\n\n\ud83d\udcca Tables on Page 14:", "mimetype": "text/plain", "start_char_idx": 77834, "end_char_idx": 78635, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "78d39aa9-54e6-4103-b06a-385cb429b7f9": {"__data__": {"id_": "78d39aa9-54e6-4103-b06a-385cb429b7f9", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ad2ca9f-da1b-4f66-9c77-4263a95aca32", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "b78424b2f7d4dad9e22f1984146951afccf42ffaf4712a70b8c5aa8bc7ee55c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ef186b-e83c-45e8-9df8-27b4f9aab5e7", "node_type": "1", "metadata": {}, "hash": "049bdddfe6031bb9eebe4dc40dccc21eff0ae7f5ae4f67a2721a145223199c67", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "14 20 11 n n\n\n\n\ud83d\udcca Tables on Page 14:\n\n\nTable 1 (12 rows \u00d7 3 columns):\n\n| Section | Title                                      | Content                                                                                     |\n|---------|--------------------------------------------|---------------------------------------------------------------------------------------------|\n| 6       | Sodium Hyaluronate                         |                                                                                             |\n| 13      | Method of Manufacture                      | Sodium formaldehyde sulfoxylate is manufactured from sodium dithionate and formaldehyde in water. |\n| 14      | Safety                                     | The toxicological properties of sodium formaldehyde sulfoxylate have not been fully investigated. However, it is used in the formulation of injection products at a level to 0.1% w/v in the final preparation administered to the patient. Sodium formaldehyde sulfoxylate is moderately toxic by ingestion, and when heated to decomposition it emits toxic fumes of sulfur dioxide and sodium oxide.(1) |\n|         |                                            | LD\u2085\u2080 (mouse, oral): 4 g/kg(1,2)                                                            |\n|         |                                            | LD\u2085\u2080 (rat, IP): >2 g/kg(2)                                                                  |\n|         |                                            | LD\u2085\u2080 (rat, oral): >2 g/kg(2)                                                                |\n|         | Comments                                   | Used as an additive in polymers and textiles. The EINECS number is 246-515-6.               |\n| 18      | Comments                                   | Sodium formaldehyde sulfoxylate has been investigated as an antidote to mercury poisoning, but is considered less effective than dimercaprol (British anti-lewisite (BAL)) and other treatments.(3,4) It is also used as an industrial bleach. It is used in chemical synthesis as a nucleophilic agent in the preparation of sulfones. The empirical formula and molecular weight are also given as CH\u2084O\u2083SNa and 119.1, respectively.(1) The EINECS number for sodium formaldehyde sulfoxylate is 205-739-4. The PubChem Compound ID for sodium formaldehyde sulfoxylate is 23725019. |\n| 19      | Specific References                        |                                                                                             |\n|         | 15 Handling Precautions                    | 1 Lewis RJ, ed. Sax\u2019s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004; 1815. |\n|         |                                            | Sigma-Aldrich. Material safety data sheet: Sodium formaldehyde sulfoxylate, Australia, 2004. |\n|         |                                            | 3 Stocken LA. British anti-lewisite as an antidote for acute mercury poisoning. Biochem J 1947; 41: 358\u2013360. |\n|         |                                            | 4 Lehotzky K. Protection by spironolactone and different antidotes against acute organic mercury poisoning of rats. Int Arch Occup Environ Health 1974; 33: 329\u2013334. |\n| 16      | Regulatory Status                          | Included in the FDA Inactive Ingredients Database (parenteral products up to 0.1% via the IM, IV, and SC routes). Included in the Canadian List of Acceptable Non-medicinal Ingredients. |\n| 17      | Related Substances                         | Zinc formaldehyde sulfoxylate.                                                              |\n|         |                                            | Zinc formaldehyde sulfoxylate                                                                |\n|         |                                            | Empirical formula C\u2082H\u2086O\u2086S\u2082Zn                                                               |\n|         |                                            | Molecular weight 256.5                                                                      |\n|         |                                            | CAS number [24887-06-7]                                                                     |\n| S       | Sodium Hyaluronate                         |                                                                                             |\n| 1       | Nonproprietary Names                       | BP: Sodium Hyaluronate                                                                       |\n|         |                                            | PhEur: Sodium Hyaluronate                                                                    |\n| 2       | Synonyms                                   | Hyaluronan; hyaluronate sodium; natrii hyaluronas; RITA HA C-1-C.                          |\n| 3       | Chemical Name and CAS Registry Number      | Sodium hyaluronate [9067-32-7]                                                              |\n| 4       | Empirical Formula and Molecular Weight     | (C\u2081\u2084H\u2082\u2080NO\u2081\u2081Na)\u2099  (401.3)\u2099                                                                  |\n| 6       | Functional Category                        | Humectant; lubricant; sustained-release agent.                                               |\n| 21      | Author                                     | RC Moreton.                                                                                 |\n| 22      | Date of Revision                           | 3 March 2009.                                                                               |", "mimetype": "text/plain", "start_char_idx": 78600, "end_char_idx": 84182, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53ef186b-e83c-45e8-9df8-27b4f9aab5e7": {"__data__": {"id_": "53ef186b-e83c-45e8-9df8-27b4f9aab5e7", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78d39aa9-54e6-4103-b06a-385cb429b7f9", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "d8858ebc939363076d77b0fd6e86663476f36307315788b84639f789d48a03d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32bf73e7-7816-409a-97b9-6f60f27777f0", "node_type": "1", "metadata": {}, "hash": "3cac7981096eba69ac370826dfbb4873061f7ee81a26ddfe4e0ba240e5076eda", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "--- Page 15 ---\n\nSodium Hyaluronate 647\n7 Applications in Pharmaceutical Formulation or 12 Incompatibilities\nTechnology \u2014\nSodiumhyaluronateisthepredominantformofhyaluronicacidat\nphysiological pH. The name hyaluronan is used when the 13 MethodofManufacture\npolysaccharideismentionedingeneralterms,andintheliterature\nSodium hyaluronate occurs naturally in vitreous humor, serum,\nthe terms hyaluronic acid and sodium hyaluronate are used\nchicken combs, shark skin, and whale cartilage; it is usually\ninterchangeably.\nextracted and purified from chicken combs. It may also be\nHyaluronanisusedtherapeuticallytotreatosteoarthritisinthe\nmanufacturedbyfermentationofselectedStreptococcuszooepide-\nknee,andisaneffectivetreatmentforarthriticpain.(1)Crosslinked\nmicus bacterial strains; sodium hyaluronate is removed from the\nhyaluronangelsareusedasdrugdeliverysystems.(2)\nfermentationmediumbyfiltrationandpurifiedbyultrafiltration.It\nHyaluronanisthemostcommonnegativelychargedglycosami-\nisthenprecipitatedwithanorganicsolventanddried.\nnoglycan in the human vitreous humor, and is known to interact\nwith polymeric and liposomal DNA complexes,(3) where hyalur-\n14 Safety\nonansolutionshavebeenshowntodecreasethecellularuptakeof\ncomplexes.(4) This is useful for enhancing the availability and Sodiumhyaluronateisusedincosmeticsandintopical,parenteral,\nretentiontimeofdrugsadministeredtotheeye.Itisimmunoneutral, and ophthalmic pharmaceutical formulations. It is generally\nwhichmakesitusefulfortheattachmentofbiomaterialsforusein regardedasarelativelynontoxicandnonirritantmaterial.Sodium\ntissueengineeringanddrugdeliverysystems;(5)italsohasimportant hyaluronatehasbeenreportedtobeanexperimentalteratogen.(8)\napplications in the fields of vascosurgery and vascosupplementa- LD (mouse,IP):1.5g/kg(8)\ntion.(6) 50\nLD (rabbit,IP):1.82g/kg\n50\nLD (rat,IP):1.77g/kg\n50\n8 Description\nThePhEur6.3describessodiumhyaluronateasthesodiumsaltof 15 HandlingPrecautions\nhyaluronic acid, a glycosaminoglycan consisting of D-glucuronic\nObservenormalprecautionsappropriatetothecircumstancesand\nacidandN-acetyl-D-glucosaminedisaccharideunits.\nquantity of material handled. When heated to decomposition,\nSodium hyaluronate occurs as white to off-white powder or\nsodiumhyaluronateemitstoxicfumesofNa O.\ngranules.Itisveryhygroscopic. 2\n16 RegulatoryStatus\n9 PharmacopeialSpecifications\nIncluded in the FDA Inactive Ingredients Database (topical gel\nSeeTableI. preparation).\nTableI: Pharmacopeialspecificationforsodiumhyaluronate. 17 RelatedSubstances\nTest PhEur6.3 Hyaluronicacid.\nCharacters \u00fe Hyaluronicacid\nIdentification \u00fe Molecular weight Hyaluronic acid molecules have a molecular\nAppearanceofsolution \u00fe weightof300\u20132000kDaasthenumberofrepeatingdisacchar-\npH 5.0\u20138.5\nide units in each molecule is variable. In its natural form,\nIntrinsicviscosity \u00fe\nSulfatedglycosaminoglycans 41% hyaluronic acid exists as a high-molecular-weight polymer of\nNucleicacids 40.5 106\u2013107 Da. S\nProtein 40.3%(a) CASnumber [9067-32-7]\nChlorides 40.5% Appearance Hyaluronic acid appears as a white to off-white\nIron 480ppm powderorgranules.", "mimetype": "text/plain", "start_char_idx": 84186, "end_char_idx": 87269, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32bf73e7-7816-409a-97b9-6f60f27777f0": {"__data__": {"id_": "32bf73e7-7816-409a-97b9-6f60f27777f0", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ef186b-e83c-45e8-9df8-27b4f9aab5e7", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6af0c804d71815f8553e07b17056ba1258ef5d55266281f8e258ce9e17327df2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dee1374-936f-4ec9-b3cf-8724a44390dc", "node_type": "1", "metadata": {}, "hash": "37836b967bfc616f6fb0f90b4365f2f8b54cd55a57deee7396822c647a38ada4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "17 RelatedSubstances\nTest PhEur6.3 Hyaluronicacid.\nCharacters \u00fe Hyaluronicacid\nIdentification \u00fe Molecular weight Hyaluronic acid molecules have a molecular\nAppearanceofsolution \u00fe weightof300\u20132000kDaasthenumberofrepeatingdisacchar-\npH 5.0\u20138.5\nide units in each molecule is variable. In its natural form,\nIntrinsicviscosity \u00fe\nSulfatedglycosaminoglycans 41% hyaluronic acid exists as a high-molecular-weight polymer of\nNucleicacids 40.5 106\u2013107 Da. S\nProtein 40.3%(a) CASnumber [9067-32-7]\nChlorides 40.5% Appearance Hyaluronic acid appears as a white to off-white\nIron 480ppm powderorgranules.\nHeavymetals 420ppm(b) Comments Hyaluronicacidisusedasanadjuvantforophthalmic\nLossondrying 420.0% drugdelivery,(9)andhasbeenfoundtoenhancetheabsorptionof\nMicrobialcontamination 4102cfu/g\nBacterialendotoxins <0.5IU/mg(c) drugsandproteinsviamucosaltissue.(10)It hasalso beenused\nAssay 95.0\u2013105.0% experimentally in controlled-release films that are suitable for\napplication to surgical sites for the prevention of adhesion\n(a)<0.1%forparenteraldosageforms. formation,(11)andinmatrixformulationsusedingenedelivery\n(\n(\nb\nc)\n)\n4\n4\n0\n1\n.\n0\n5\np\nIU\np\n/\nm\nm\nf\ng\nor\nfo\np\nr\na\np\nre\na\nn\nr\nt\ne\ne\nn\nra\nte\nl\nra\np\nl\nre\nd\np\no\na\ns\nr\na\na\ng\nti\ne\non\nfo\ns\nr\n.\nms.\nsystems.(12)TheEINECSnumberforhyaluronicacidis232-678-\n0.\n10 TypicalProperties\n18 Comments\nAcidity/alkalinity pH=5.0\u20138.5(0.5%w/vaqueoussolution)\nMicrospherespreparedfromhyaluronanestershavebeenevaluated\nSolubility Solubleinwater,althoughspeedofdissolutiondepends\nfor the vaginal administration of calcitonin in the treatment of\nuponmolecularweight(highermolecularweightsareslowerto\npostmenopausal osteoporosis.(13) Microspheres prepared from\ndissolve, although this process can be increased by gentle\nhyaluronan esters have also been used experimentally as delivery\nagitation).Slightlysolubleinmixturesoforganicsolventswith\nwater.(7)\ndevicesfornervegrowthfactors,(14)andasanasaldeliverysystem\nforinsulin.(15)\nAn N-(2-hydroxypropyl)methacrylamide (HPMA)\u2013hyaluronan\n11 StabilityandStorageConditions polymeric drug delivery system has been used for the targeted\nSodiumhyaluronateshouldbestoredinacool,dryplaceintightly delivery of doxorubicin to cancer cells. This copolymer exhibited\nsealed containers. The powder is stable for 3 years if stored in increased toxicity due to hyaluronan receptor-mediated uptake of\nunopenedcontainers. themacromoleculardrug.(16)\n\n\n\ud83d\udcca Tables on Page 15:", "mimetype": "text/plain", "start_char_idx": 86678, "end_char_idx": 89091, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8dee1374-936f-4ec9-b3cf-8724a44390dc": {"__data__": {"id_": "8dee1374-936f-4ec9-b3cf-8724a44390dc", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32bf73e7-7816-409a-97b9-6f60f27777f0", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "db58d01a0145bf3627c49d6b55535c92c5d4d1dbc57cb56a4780c237531b68ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7fdd3cd-2f66-42c1-8e39-e49927043022", "node_type": "1", "metadata": {}, "hash": "9278618b3cae2b48713d8d9db497d81ed744b13f4f8a593d028a01f571a2db27", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(7)\ndevicesfornervegrowthfactors,(14)andasanasaldeliverysystem\nforinsulin.(15)\nAn N-(2-hydroxypropyl)methacrylamide (HPMA)\u2013hyaluronan\n11 StabilityandStorageConditions polymeric drug delivery system has been used for the targeted\nSodiumhyaluronateshouldbestoredinacool,dryplaceintightly delivery of doxorubicin to cancer cells. This copolymer exhibited\nsealed containers. The powder is stable for 3 years if stored in increased toxicity due to hyaluronan receptor-mediated uptake of\nunopenedcontainers. themacromoleculardrug.(16)\n\n\n\ud83d\udcca Tables on Page 15:\n\n\nTable 1 (15 rows \u00d7 2 columns):\n\n| Test                                           | PhEur 6.3                            |\n|------------------------------------------------|--------------------------------------|\n| Characters                                     | \u00fe                                    |\n| Identification                                 | \u00fe                                    |\n| Appearance of solution                         | \u00fe                                    |\n| pH                                            | 5.0\u20138.5                              |\n| Intrinsic viscosity                            | \u00fe                                    |\n| Sulfated glycosaminoglycans                    | 41%                                  |\n| Nucleic acids                                  | 40.5 (a)                             |\n| Protein                                        | 40.3%                                |\n| Chlorides                                      | 40.5%                                |\n| Iron                                           | 480 ppm(b)                           |\n| Heavy metals                                   | 420 ppm                              |\n| Loss on drying                                 | 420.0%                               |\n| Microbial contamination                        | 410\u00b2cfu/g(c)                         |\n| Bacterial endotoxins                           | &#x3C;0.5 IU/mg                           |\n| Assay                                          | 95.0\u2013105.0%                          |\n| (a) &#x3C;0.1% for parenteral dosage forms.        |                                      |\n| (b) 410 ppm for parenteral preparations.      |                                      |\n| (c) 40.5 IU/mg for parenteral dosage forms.   |                                      |\n\n\n\n--- Page 16 ---\n\n648 Sodium Hydroxide\nTheEINECSnumberforsodiumhyaluronateis232-678-0.The 10 ChoKYetal.Releaseofciprofloxacinfrompolymer-graft-hyaluronic\nPubChem Compound ID (CID) for sodium hyaluronate is acidhydrogelsinvitro.IntJPharm2003;260(1):83\u201391.\n3084049. 11 JacksonJKetal.Paclitaxel-loadedcrosslinkedhyaluronicacidfilmsfor\nthepreventionofpostsurgicaladhesions.PharmRes2002;19(4):411\u2013\n417.\n19 SpecificReferences 12 KimAetal.CharacterizationofDNA-hyaluronanmatrixforsustained\n1 Castellacci E, Polieri T. Antalgesic effect and clinical tolerability of genetransfer.JControlRelease2003;90(1):81\u201375.\nhyaluronicacidinpatientswithdegenerativediseasesofkneecartilage: 13 Rochira M et al. Novel vaginal delivery systems for calcitonin II.\nanoutpatienttreatmentsurvey.DrugsExpClinRes2004;30(2):67\u2013 Preparation and characterisation of HYAFF microspheres containing\n73. calcitonin.IntJPharm1996;144:19\u201326.\n2 DehayzaP,ChengL.Sodiumhyaluronatemicrospheres.USPatentNo. 14 GhezzoEetal.HyaluronanderivativemicrospheresasNGFdelivery\n2,004,127,459;2004. devices:preparationmethodsandinvitroreleasecharacterization.IntJ\n3 Pitka\u00a8nen L et al. Vitreous is a barrier in nonviral gene transfer by Pharm1992;29:133\u2013141.\ncationiclipidsandpolymers.PharmRes2003;20(4):576\u2013583. 15 Illum L et al. Hyaluronic acid ester microspheres as a nasal delivery\n4 Ruponen M et al. Interactions of polymeric and liposomal gene systemforinsulin.JControlRelease1994;29:133\u2013141.", "mimetype": "text/plain", "start_char_idx": 88540, "end_char_idx": 92376, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b7fdd3cd-2f66-42c1-8e39-e49927043022": {"__data__": {"id_": "b7fdd3cd-2f66-42c1-8e39-e49927043022", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dee1374-936f-4ec9-b3cf-8724a44390dc", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "603d27339b80d8c7883447a4e4eea4d655b50b689b6b2b622607bf8eec3dc311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b793a20-f7e0-4f35-b5fe-c7167e69c66b", "node_type": "1", "metadata": {}, "hash": "57a8b723dc21ac75eb0c42530f7f5ea7ec1ff30ab907eba62d716e359e0abc29", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2 DehayzaP,ChengL.Sodiumhyaluronatemicrospheres.USPatentNo. 14 GhezzoEetal.HyaluronanderivativemicrospheresasNGFdelivery\n2,004,127,459;2004. devices:preparationmethodsandinvitroreleasecharacterization.IntJ\n3 Pitka\u00a8nen L et al. Vitreous is a barrier in nonviral gene transfer by Pharm1992;29:133\u2013141.\ncationiclipidsandpolymers.PharmRes2003;20(4):576\u2013583. 15 Illum L et al. Hyaluronic acid ester microspheres as a nasal delivery\n4 Ruponen M et al. Interactions of polymeric and liposomal gene systemforinsulin.JControlRelease1994;29:133\u2013141.\ndeliverysystemswithextracellularglycosaminoglycans:physicochem- 16 LuoYetal.TargetteddeliveryofdoxorubicinbyHPMAcopolymer\u2013\nicalandtransfectionstudies.BiochimBiophysActa1999;1415:331\u2013 hyaluronanbioconjugates.PharmRes2002;19(4):396\u2013402.\n341.\n5 VercruysseKP,PrestwichGD.Hyaluronatederivativesindrugdelivery. 20 GeneralReferences\nCritRevTherCarrierSyst1998;15:513\u2013555.\n\u2014\n6 BalazsEA.etal Clinicalusesofhyaluronan.EveredD,WhelanJ,eds.\nTheBiologyofHyaluronan.Chichester:Wiley,1989;265\u2013280.\n7 ContiproCa.s.Sodiumhyaluronate.http://www.contipro.cz(accessed 21 Authors\n7January2009). MEQuinn,PJSheskey.\n8 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nedn. NewYork:Wiley,2004;1970.\n22 DateofRevision\n9 Saettone MF et al. Mucoadhesive ophthalmic vehicles: evaluation of\npolymericlow-viscosityformulations.JOculPharm1994;10:83\u201392. 7January2009.\nSodium Hydroxide\n1 NonproprietaryNames 8 Description\nBP:SodiumHydroxide Sodiumhydroxideoccursasawhiteornearlywhitefusedmass.Itis\nJP:SodiumHydroxide availableinsmallpellets,flakes,sticks,andothershapesorforms.It\nis hard and brittle and shows a crystalline fracture. Sodium\nPhEur:SodiumHydroxide\nS hydroxide is very deliquescent and on exposure to air it rapidly\nUSP-NF:SodiumHydroxide\nabsorbscarbondioxideandwater.\n2 Synonyms\nCaustic soda; E524; lye; natrii hydroxidum; soda lye; sodium\nhydrate.\n9 PharmacopeialSpecifications\n3 ChemicalNameandCASRegistryNumber SeeTableI.\nSodiumhydroxide [1310-73-2]\n4 EmpiricalFormulaandMolecularWeight TableI: Pharmacopeialspecificationsforsodiumhydroxide.\nNaOH 40.00 Test JPXV PhEur6.0 USP32\u2013NF27\nIdentification \u00fe \u00fe \u00fe\n5 StructuralFormula Characters \u2014 \u00fe \u2014\nSeeSection4. Appearanceofsolution \u00fe \u00fe\u2014\nInsolublesubstances \u2014 \u2014\u00fe\nandorganicmatter\n6 FunctionalCategory Sodiumcarbonate 42.0% 42.0% \u2014\nAlkalizingagent;bufferingagent. Sulfates \u2014 450ppm \u2014\nChlorides 40.05% 450ppm \u2014\nIron \u2014 410ppm \u2014\n7 Applications in Pharmaceutical Formulation or Mercury \u00fe \u2014 \u2014\nTechnology Heavymetals 430ppm 420ppm 40.003%\nSodiumhydroxideiswidelyusedinpharmaceuticalformulationsto Potassium \u00fe \u2014 \u00fe\nadjustthepHofsolutions.(1)Itcanalsobeusedtoreactwithweak Assay(totalalkali 595.0% 97.0\u2013100.5% 95.0\u2013100.5%\nacidstoformsalts. calculatedasNaOH)\n\n\n\ud83d\udcca Tables on Page 16:", "mimetype": "text/plain", "start_char_idx": 91837, "end_char_idx": 94586, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b793a20-f7e0-4f35-b5fe-c7167e69c66b": {"__data__": {"id_": "7b793a20-f7e0-4f35-b5fe-c7167e69c66b", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7fdd3cd-2f66-42c1-8e39-e49927043022", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "ac28c511de5e91fb6897567d2fea13d734e4634689358c9eb64ad4d8be97f03a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20", "node_type": "1", "metadata": {}, "hash": "f125fce1bcfb3314f2419c99614cf8347792f3dad8baf17d72fe9e7d93c29f89", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Sulfates \u2014 450ppm \u2014\nChlorides 40.05% 450ppm \u2014\nIron \u2014 410ppm \u2014\n7 Applications in Pharmaceutical Formulation or Mercury \u00fe \u2014 \u2014\nTechnology Heavymetals 430ppm 420ppm 40.003%\nSodiumhydroxideiswidelyusedinpharmaceuticalformulationsto Potassium \u00fe \u2014 \u00fe\nadjustthepHofsolutions.(1)Itcanalsobeusedtoreactwithweak Assay(totalalkali 595.0% 97.0\u2013100.5% 95.0\u2013100.5%\nacidstoformsalts. calculatedasNaOH)\n\n\n\ud83d\udcca Tables on Page 16:\n\n\nTable 1 (12 rows \u00d7 4 columns):\n\n| Test                       | JP XV        | PhEur 6.0    | USP32\u2013NF27   |\n|---------------------------|--------------|--------------|--------------|\n| Identification            | \u00fe            | \u00fe            | \u00fe            |\n| Characters                 | \u2014            | \u00fe            | \u2014            |\n| Appearance of solution     | \u00fe            | \u00fe            | \u2014            |\n| Insoluble substances       | \u2014            | \u2014            | \u00fe            |\n| and organic matter        |              |              |              |\n| Sodium carbonate           | 42.0%       | 42.0%        | \u2014            |\n| Sulfates                   | \u2014            | 450 ppm      | \u2014            |\n| Chlorides                  | 40.05%      | 450 ppm      | \u2014            |\n| Iron                       | \u2014            | 410 ppm      | \u2014            |\n| Mercury                    | \u00fe            | \u2014            | \u2014            |\n| Heavy metals               | 430 ppm      | 420 ppm      | 40.003%      |\n| Potassium                  | \u00fe            | \u2014            | \u00fe            |\n| Assay (total alkali       | 595.0%      | 97.0\u2013100.5%  | 95.0\u2013100.5%  |\n| calculated as NaOH)       |              |              |              |\n\n\n\n--- Page 17 ---\n\nSodium Hydroxide 649\n10 TypicalProperties 15 HandlingPrecautions\nAcidity/alkalinity Observe normal handling precautions appropriate to the quantity\npH(cid:6)12(0.05%w/waqueoussolution); and concentration of material handled. Gloves, eye protection, a\npH(cid:6)13(0.5%w/waqueoussolution); respirator,andotherprotectiveclothingshouldbeworn.\nSodium hydroxide is a corrosive irritant to the skin, eyes, and\npH(cid:6)14(5%w/waqueoussolution).\nmucous membranes. The solid and solutions cause burns, often\nMeltingpoint 3188C with deep ulceration. It is moderately toxic on ingestion and\nSolubility seeTableII. harmfuloninhalation.\nIntheUK,theworkplaceexposurelimit forsodiumhydroxide\nTableII: Solubilityofsodiumhydroxide. hasbeensetat2mg/m3short-term.(3)\nSolvent Solubilityat208Cunlessotherwisestated\n16 RegulatoryStatus\nEthanol 1in7.2\nGRAS listed. Accepted for use as a food additive in Europe.\nEther Practicallyinsoluble\nIncluded in the FDA Inactive Ingredients Database (dental\nGlycerin Soluble\npreparations; injections; inhalations; nasal, ophthalmic, oral, otic,\nMethanol 1in4.2\nWater 1in0.9 rectal,topical,andvaginalpreparations).Includedinnonparenteral\n1in0.3at1008C and parenteral medicines licensed in the UK. Included in the\nCanadianListofAcceptableNon-medicinalIngredients.\n17 RelatedSubstances\n11 StabilityandStorageConditions\nPotassiumhydroxide.\nSodium hydroxide should be stored in an airtight nonmetallic\ncontainer in a cool, dry place. When exposed to air, sodium\n18 Comments\nhydroxiderapidlyabsorbsmoistureandliquefies,butsubsequently\nSodium hydroxide is most commonly used in solutions of fixed\nbecomes solid again owing to absorption of carbon dioxide and\nconcentration. Sodium hydroxide has some antibacterial and\nformationofsodiumcarbonate.", "mimetype": "text/plain", "start_char_idx": 94179, "end_char_idx": 97603, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20": {"__data__": {"id_": "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b793a20-f7e0-4f35-b5fe-c7167e69c66b", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "8ea573abce901a71ae803a7040883494c87ac29706663374f1f45dfa8ac94b0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba", "node_type": "1", "metadata": {}, "hash": "1a3c6c4b50a074bc0c6c279542b92dceb3823f19381c6e61d5b98d827497517c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Included in the\nCanadianListofAcceptableNon-medicinalIngredients.\n17 RelatedSubstances\n11 StabilityandStorageConditions\nPotassiumhydroxide.\nSodium hydroxide should be stored in an airtight nonmetallic\ncontainer in a cool, dry place. When exposed to air, sodium\n18 Comments\nhydroxiderapidlyabsorbsmoistureandliquefies,butsubsequently\nSodium hydroxide is most commonly used in solutions of fixed\nbecomes solid again owing to absorption of carbon dioxide and\nconcentration. Sodium hydroxide has some antibacterial and\nformationofsodiumcarbonate.\nantiviral properties and is used as a disinfectant in some\napplications.(4\u20136)\n12 Incompatibilities A specification for sodium hydroxide is contained in the Food\nSodium hydroxide is a strong base and is incompatible with any\nChemicalsCodex(FCC).(7)\nThe EINECS number for sodium hydroxide is 215-185-5. The\ncompound that readily undergoes hydrolysis or oxidation. It will\nPubChemCompoundID(CID)forsodiumhydroxideis14798.\nreactwithacids,esters,andethers,especiallyinaqueoussolution.\n19 SpecificReferences\n13 MethodofManufacture\n1 Zhan X et al. Improved stability of 25% vitamin C parenteral\nSodium hydroxide is manufactured by electrolysis of brine using formulation.IntJPharm1998;173:43\u201349.\ninert electrodes. Chlorine is evolved as a gas at the anode and 2 LewisRJ,ed.Sax\u2019sDangerousPropertiesofIndustrialMaterials,11th\nhydrogenisevolvedasagasatthecathode.Theremovalofchloride edn. NewYork:Wiley,2004;3254\u20133255.\nand hydrogen ions leaves sodium and hydroxide ions in solution. 3 HealthandSafetyExecutive.EH40/2005:WorkplaceExposureLimits.\nSudbury: HSE Books, 2005 (updated 2007). http://www.hse.gov.uk/\nThesolutionisdriedtoproducethesolidsodiumhydroxide.\ncoshh/table1.pdf(accessed5February2009).\nAsecondmethodusestheKellner\u2013Solvaycell.Saturatedsodium\n4 Brown P et al. Sodium hydroxide decontamination of Creutzfeldt\u2013\nchloride solution is electrolyzed between a carbon anode and a Jakobdiseasevirus.NEnglJMed1984;320:727. S\nflowingmercurycathode.Inthiscasethesodiumisproducedatthe 5 GasserG.Creutzfeldt\u2013Jakobdisease[letter].BrMedJ1990;300:1523.\ncathode rather than the hydrogen because of the readiness of 6 Perkowski CA. Operational aspects of bioreactor contamination\nsodiumtodissolveinthemercury.Thesodium\u2013mercuryamalgamis control.JParenterSciTechnol1990;44:113\u2013117.\n7 Food Chemicals Codex, 6th edn. Bethesda, MD: United States\nthen exposed to water and a sodium hydroxide solution is\nPharmacopeia,2008;888.\nproduced.\n20 GeneralReferences\n14 Safety \u2014\nSodium hydroxide is widely used in the pharmaceutical and food\nindustries and is generally regarded as a nontoxic material at low 21 Author\nconcentrations. At high concentrations it is a corrosive irritant to\nAHKibbe.\ntheskin,eyes,andmucousmembranes.\nLD (mouse,IP):0.04g/kg(2) 22 DateofRevision\n50\nLD (rabbit,oral):0.5g/kg 5February2009.\n50\n\n\n\ud83d\udcca Tables on Page 17:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Solvent            | Solubility at 20\u00b0C unless otherwise stated |\n|--------------------|--------------------------------------------|\n| Ethanol            | 1 in 7.2                                  |\n| Ether              | Practically insoluble                     |\n| Glycerin           | Soluble                                   |\n| Methanol           | 1 in 4.2                                  |\n| Water              | 1 in 0.9                                  |\n|                    | 1 in 0.3 at 100\u00b0C                         |", "mimetype": "text/plain", "start_char_idx": 97061, "end_char_idx": 100487, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba": {"__data__": {"id_": "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e806d9-d5e6-4181-bc8d-8b3f9cb09f20", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "178a0967c84b7e23de33a27bf1373e37c4b49019e32ccc5724846d05ddd39e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a23d6423-fd1f-497c-8338-05285e3980f3", "node_type": "1", "metadata": {}, "hash": "7306136b332dc149e5f653093afce99346ddb46cb1f3072edb4d2e5a44b4cdd8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "At high concentrations it is a corrosive irritant to\nAHKibbe.\ntheskin,eyes,andmucousmembranes.\nLD (mouse,IP):0.04g/kg(2) 22 DateofRevision\n50\nLD (rabbit,oral):0.5g/kg 5February2009.\n50\n\n\n\ud83d\udcca Tables on Page 17:\n\n\nTable 1 (5 rows \u00d7 2 columns):\n\n| Solvent            | Solubility at 20\u00b0C unless otherwise stated |\n|--------------------|--------------------------------------------|\n| Ethanol            | 1 in 7.2                                  |\n| Ether              | Practically insoluble                     |\n| Glycerin           | Soluble                                   |\n| Methanol           | 1 in 4.2                                  |\n| Water              | 1 in 0.9                                  |\n|                    | 1 in 0.3 at 100\u00b0C                         |\n\n\n\n--- Page 18 ---\n\nSodium Lactate\n1 NonproprietaryNames\nTableI: Pharmacopeialspecificationsforsodiumlactate.\nBP:SodiumLactateSolution\nTest PhEur6.0 USP32\nPhEur:SodiumLactateSolution\nUSP:SodiumLactateSolution Characters \u00fe \u2014\nIdentification \u00fe \u00fe\nAppearanceofsolution \u00fe \u2014\npH 6.5\u20139.0 5.0\u20139.0\nReducingsugarsandsucrose \u00fe \u00fe\n2 Synonyms Methanol 450ppm(a) \u00fe\nE325; 2-hydroxypropanoic acid monosodium salt; Lacolin; lactic Chlorides 450ppm 40.05%\nOxalatesandphosphates \u00fe \u00fe\nacidmonosodiumsalt;lacticacidsodiumsalt;natriilactatissolutio;\nSulfates 4100ppm \u00fe\nPatlac;Purasal;RitalacNAL;sodiuma-hydroxypropionate.\nAluminum 40.1ppm(a) \u2014\nBarium \u00fe \u2014\nIron 410ppm \u2014\nHeavymetals 410ppm 40.001%\n3 ChemicalNameandCASRegistryNumber Bacterialendotoxins \u00fe(b) \u2014\nAssay 96.0\u2013104.0% 98.0\u2013102.0%\nSodiumlactate [72-17-3]\n(a)Ifintendedforuseinthemanufactureofparenteraldosageforms,hemodialysis,or\nhemofiltrationsolutions.\n(b)Ifintendedforuseinthemanufactureofparenteraldosageformswithoutafurther\nappropriateprocedurefortheremovalofbacterialendotoxins.\n4 EmpiricalFormulaandMolecularWeight\nC H NaO 112.06\n3 5 3 10 TypicalProperties\nAcidity/alkalinity pH=7foranaqueoussolution.\nBoilingpoint 1128C\nHygroscopicity Veryhygroscopic.\n5 StructuralFormula\nMeltingpoint 178Cwithdecompositionat1408C.\nThe PhEur 6.0 and USP 32 describe sodium lactate solution as a\nSolubility Misciblewithethanol(95%),andwithwater.\nmixture of the enantiomers of sodium 2-hydroxypropanoate in Specificgravity 1.31(cid:3)1.34\napproximatelyequalproportions.\n11 StabilityandStorageConditions\nSodiumlactateshouldbestoredinawell-closedcontainerinacool,\n6 FunctionalCategory dry, place. Sodium lactate is combustible and decomposes upon\nheating.\nAntimicrobial preservative; buffering agent; emulsifying agent;\nflavoringagent;humectant.\nS 12 Incompatibilities\nSeeLacticAcid.\n7 Applications in Pharmaceutical Formulation or 13 MethodofManufacture\nTechnology\nSeeLacticAcid.\nSodium lactate is widely used in cosmetics,(1,2) food products and\npharmaceutical applications including parenteral and topical 14 Safety\nformulations.\nSodium lactate occurs naturally in the body and is involved in\nTherapeutically, sodium lactate is used in infusions as a\nphysiological processes.", "mimetype": "text/plain", "start_char_idx": 99709, "end_char_idx": 102684, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a23d6423-fd1f-497c-8338-05285e3980f3": {"__data__": {"id_": "a23d6423-fd1f-497c-8338-05285e3980f3", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e9f2c5-f1a2-4ded-bf16-fb62be6653ba", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "5a4667bfc32305d8db5ea9b65f723af30a09b89094d8d91083fd53b9713f8e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2cb7ffa-3cf6-46a1-ab26-316a3531efc2", "node_type": "1", "metadata": {}, "hash": "e7f5e50af5fc2b9ca91c4fe871beff8c10d82465ece1d420fc4002ea2f6a0860", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11 StabilityandStorageConditions\nSodiumlactateshouldbestoredinawell-closedcontainerinacool,\n6 FunctionalCategory dry, place. Sodium lactate is combustible and decomposes upon\nheating.\nAntimicrobial preservative; buffering agent; emulsifying agent;\nflavoringagent;humectant.\nS 12 Incompatibilities\nSeeLacticAcid.\n7 Applications in Pharmaceutical Formulation or 13 MethodofManufacture\nTechnology\nSeeLacticAcid.\nSodium lactate is widely used in cosmetics,(1,2) food products and\npharmaceutical applications including parenteral and topical 14 Safety\nformulations.\nSodium lactate occurs naturally in the body and is involved in\nTherapeutically, sodium lactate is used in infusions as a\nphysiological processes. It is generally regarded as a relatively\ncomponentofRinger-lactatesolution;asanalternativeforsodium\nnontoxicandnonirritantmaterialwhenusedasanexcipient.Low\nhydrogencarbonateinlightacidosis;asarehydratingagent;andas\nconcentrationsarewelltoleratedbyskinandeyemucosa,although\na carrier for electrolyte concentrates or medicines in perfusion/ higherconcentrationsshouldbeavoided.\ninfusionsolutions.\nLD (rat,IP):2g/kg(3)\n50\n15 HandlingPrecautions\n8 Description Observenormalprecautionsappropriatetothecircumstancesand\nSodiumlactateoccursasaclear,colorless,slightlysyrupyliquid.It quantity of material handled. Sodium lactate may cause eye\nisodorless,orhasaslightodorwithacharacteristicsalinetaste.Itis irritation. When heated to decomposition, sodium lactate emits\nhygroscopic. toxicfumesofNa 2 O.(3)\n16 RegulatoryStatus\nGRASlisted(notforinfantformulas).IncludedintheFDAInactive\n9 PharmacopeialSpecifications\nIngredient Database (epidural, IM, IV, and SC injections; oral\nSeeTableI. suspensions;topicalgelsandsolutions).Includedinnonparenteral\n650\n\n\n\ud83d\udcca Tables on Page 18:\n\n\nTable 1 (15 rows \u00d7 2 columns):\n\n| Nonproprietary Names                                                      | Table I:      Pharmacopeial specifications for sodium lactate. | | |\n|--------------------------------------------------------------------------|---------------------------------------------------------------|---|---|\n| BP: Sodium Lactate Solution                                              | Test                                | PhEur 6.0                 | USP 32 |\n| PhEur: Sodium Lactate Solution                                           | Characters                          | \u00fe                         | \u2014      |\n| USP: Sodium Lactate Solution                                             | Identification                      | \u00fe                         | \u00fe      |\n|                                                                          | Appearance of solution              | \u00fe                         | \u2014      |\n|                                                                          | pH                                  | 6.5\u20139.0                   | 5.0\u20139.0 |\n| Synonyms                                                                | Reducing sugars and sucrose         | \u00fe            (a)          | \u00fe      |\n|                                                                          | Methanol                            | 450 ppm                   | \u00fe      |\n| E325; 2-hydroxypropanoic acid monosodium salt; Lacolin; lactic         | Chlorides                           | 450 ppm                   | 40.05% |\n| acid monosodium salt; lactic acid sodium salt; natrii lactatis solutio; | Oxalates and phosphates             | \u00fe                         | \u00fe      |\n| Patlac; Purasal; Ritalac NAL; sodium a-hydroxypropionate.              | Sulfates                            | 4100 ppm                  | \u00fe      |\n|                                                                          | Aluminum                            | 40.1 ppm(a)               | \u2014      |\n|                                                                          | Barium                              | \u00fe                         | \u2014      |\n|                                                                          | Iron                                | 410 ppm                   | \u2014      |\n|                                                                          | Heavy metals                        | 410 ppm                   | 40.001% |\n| Chemical Name and CAS Registry Number                                    | Bacterial endotoxins                | \u00fe(b)                      | \u2014      |\n| Sodium lactate [72-17-3]                                               | Assay                               | 96.0\u2013104.0%               | 98.0\u2013102.0% |\n|                                                                          | (a) If intended for use in the manufacture of parenteral dosage forms, hemodialysis, or hemofiltration solutions.", "mimetype": "text/plain", "start_char_idx": 101978, "end_char_idx": 106702, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f2cb7ffa-3cf6-46a1-ab26-316a3531efc2": {"__data__": {"id_": "f2cb7ffa-3cf6-46a1-ab26-316a3531efc2", "embedding": null, "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19e61bd9-9ada-4585-92ba-ea7057a3177d", "node_type": "4", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "6e88e74db62f41ae0df6b235046058db20d049ce6aac08fab4420f311ff30b17", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a23d6423-fd1f-497c-8338-05285e3980f3", "node_type": "1", "metadata": {"file_name": "handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "file_path": "data\\handbook-of-pharmaceutical-excipients-6th-ed-part-2.pdf", "table_count": 18, "parser": "llamaparse", "structured_tables": true}, "hash": "332c38dbd30fce62482cc04611c414a48601525d7fbb32337c1a527fbe55bcab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Sulfates                            | 4100 ppm                  | \u00fe      |\n|                                                                          | Aluminum                            | 40.1 ppm(a)               | \u2014      |\n|                                                                          | Barium                              | \u00fe                         | \u2014      |\n|                                                                          | Iron                                | 410 ppm                   | \u2014      |\n|                                                                          | Heavy metals                        | 410 ppm                   | 40.001% |\n| Chemical Name and CAS Registry Number                                    | Bacterial endotoxins                | \u00fe(b)                      | \u2014      |\n| Sodium lactate [72-17-3]                                               | Assay                               | 96.0\u2013104.0%               | 98.0\u2013102.0% |\n|                                                                          | (a) If intended for use in the manufacture of parenteral dosage forms, hemodialysis, or hemofiltration solutions. | | |\n|                                                                          | (b) If intended for use in the manufacture of parenteral dosage forms without a further appropriate procedure for the removal of bacterial endotoxins. | | |\n| Empirical Formula and Molecular Weight                                   | C\u2083H\u2085NaO\u2083         | 112.06                     |       |\n|                                                                          | 10       Typical Properties                                          |                               | |\n|                                                                          | Acidity/alkalinity       | pH = 7 for an aqueous solution. | |\n|                                                                          | Boiling point     | 1128C                        |       |\n| Structural Formula                                                       | Hygroscopicity    | Very hygroscopic.          |       |\n| The PhEur 6.0 and USP 32 describe sodium lactate solution as a         | Melting point     | 178C with decomposition at 1408C. | |\n| mixture of the enantiomers of sodium 2-hydroxypropanoate in            | Solubility        | Miscible with ethanol (95%), and with water. | |\n| approximately equal proportions.                                         | Specific gravity  | 1.31     1.34              |       |\n|                                                                          | 11       Stability and Storage Conditions                          |                               | |\n|                                                                          | Sodium lactate should be stored in a well-closed container in a cool, dry, place. Sodium lactate is combustible and decomposes upon heating. | | |\n| Functional Category                                                      | 12       Incompatibilities                                      |                               | |\n| Antimicrobial    preservative; buffering agent; emulsifying  agent;     | See Lactic Acid.                                          |                               | |\n| flavoring agent; humectant.                                             | 13       Method of Manufacture                               |                               | |\n| Applications in Pharmaceutical Formulation or Technology                | See Lactic Acid.                                          |                               | |\n| Sodium lactate is widely used in cosmetics, food products and          | 14       Safety                                           |                               | |\n| pharmaceutical applications including parenteral and topical           | Sodium lactate occurs naturally in the body and is involved in physiological processes. It is generally regarded as a relatively nontoxic and nonirritant material when used as an excipient. Low concentrations are well tolerated by skin and eye mucosa, although higher concentrations should be avoided. | | |\n| formulations.                                                           | LD\u2085\u2080 (rat, IP): 2 g/kg(3)                               |                               | |\n| Description                                                             | 8     Description                                        |                               | |\n| Sodium lactate occurs as a clear, colorless, slightly syrupy liquid. It | is odorless, or has a slight odor with a characteristic saline taste. It is hygroscopic. | | |\n| Handling Precautions                                                    | 15       Handling Precautions                              |                               | |\n| Observe normal precautions appropriate to the circumstances and         | quantity      of  material handled. Sodium  lactate           | may cause eye irritation. When heated to decomposition, sodium lactate emits toxic fumes of Na\u2082O.(3) | |\n| Regulatory Status                                                       | 16       Regulatory Status                                  |                               | |\n| Pharmacopeial Specifications                                             | GRAS listed (not for infant formulas). Included in the FDA Inactive Ingredient Database (epidural, IM, IV, and SC injections; oral suspensions; topical gels and solutions). Included in nonparenteral | | |\n| See Table I.                                                            | 6 50                                                  |                               | |", "mimetype": "text/plain", "start_char_idx": 105519, "end_char_idx": 111268, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}}